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Abstract
Glaucoma is the leading cause of irreversible blindness worldwide, and is characterized
by elevated intraocular pressure (IOP) caused by increased resistance to aqueous humor outflow.
The majority of outflow resistance is generated near the inner wall endothelium of Schlemm’s canal
(SC). The inner wall experiences a basal-to-apical directed flow as aqueous humor crosses the
outflow pathway. As IOP increases, the outflow pathway responds in a pressure-dependent manner,
resulting in the expansion of the trabecular meshwork (TM) and the collapse of SC. This effectively
reduces the cross-sectional area of the SC lumen and increases the shear stress experienced by
SC cells, reaching levels known to activate endothelial nitric oxide synthase (eNOS) in vascular
endothelia.
Our central hypothesis examines the role of eNOS as part of a dynamic mechano-regulatory
feedback system to regulate the outflow resistance sites through nitric oxide (NO) production to
maintain IOP homeostasis. We firstly demonstrated the physiological role of NO and eNOS in reg-
ulating aqueous humor outflow through the use of NO-donor and NOS-inhibitors. We also demon-
strated that spatial variations in eNOS expression in the SC correlates with regions of greater outflow
in the TM. Furthermore, we developed NO-sensitive biosensors to detect changes in NO produc-
tion in response to elevated IOP, showing that NO production was pressure-dependent. Finally, we
demonstrated that targeted delivery of NO to the outflow resistance sites in the TM results in a
⇠3-fold increase in outflow facility.
Taken together, these studies reveal that eNOS plays a crucial regulatory role in conven-
tional outflow physiology by modulating outflow resistance through NO production. This mechano-
regulatory feedback mechanism appears to be altered in glaucoma, and thus leads to ocular hyper-
tension and pathogenesis of the disease. Therefore, targeting the NO-regulatory machinery within
the outflow pathway may provide a promising therapeutic target for treating glaucoma.
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Chapter 1
Introduction and Background
1
1.1 Introduction
Glaucoma is a group of ocular diseases characterized by the irreversible damage caused to
the optic nerve head, commonly referred as "glaucomatous optic neuropathy", affecting more than
60 million people worldwide, of which 8.4 million are bilaterally blind[176]. The primary risk factor
associated with the development of glaucoma is elevated intraocular pressure (IOP); this increase
in IOP leads to the compression of the optic nerve head, which damages the retinal ganglion cells
responsible for transmitting visual information from the eye to the brain. Current glaucoma treat-
ments aim to lower IOP, through either surgical or drug interventions to slow the progression of
vision loss. However, these therapies are often unable to achieve a sustained IOP reduction, largely
because the treatments do not target the underlying root cause of elevated IOP; increased hydraulic
resistance of the outflow pathway. Thus, identifying the physiological mechanisms responsible for
the increased outflow resistance in the conventional outflow tract would provide more targeted and
efficacious glaucoma therapies.
The intraocular pressure is determined by the balance between the production of aqueous
humour (AH) by the ciliary processes and the drainage through the conventional outflow pathway
of the eye. Elevated IOP is associated with the increased hydraulic resistance of the conventional
outflow pathway (responsible for ⇠80% of AH drainage[92,118]), which consists of the trabecular
meshwork (TM), juxtacanalicular tissue (JCT) and the inner wall endothelium of Schlemm’s canal
(SC). The majority of the outflow resistance is generated proximal to or within close vicinity of the
endothelium of Schlemm’s canal; however, the mechanisms involved in outflow regulation are still
not well understood[116,118,147]. Recent data have suggested that nitric oxide (NO), a key signaling
molecule responsible for mediating various physiological functions, including modulating vascular
tone[154,155,232], neuronal signaling[31] and immunological processes[74], may also play an impor-
tant role in aqueous humour outflow regulation. NO is a diatomic free radical produced by the
family of enzymes, nitric oxide synthase (NOS), through the conversion of L-arginine to L-citrulline.
In the vascular and lymphatics system, NO is known to mediate endothelial permeability through
targeting cellular mechanisms such as soluble guanylate cyclase (sGC)[55,56] and junctional com-
plexes[57,175]; as the SC is derived from vascular endothelia [99,185] and expresses both vascular and
lymphatic markers[12,126,169,185], we hypothesize that SC cells possesses the same NO-regulatory
2
machinery and that this mechanism may contribute to the physiological regulation of conventional
outflow. Recent studies have demonstrated that SC cells in culture are shear-sensitive, and secrete
NO in response to increasing shear stress through the activation of endothelial NOS[11,135], simi-
lar to vascular endothelial cells [44,45]. Interestingly, at elevated IOP the SC lumen collapses and in
turn increases the shear stress acting on the SC cells in vivo, and is predicted to approach levels
of shear experienced by endothelial cells in arteries[73]. We hypothesize that SC cells function as
"stress-sensors" within this endogenous feedback loop that detects changes in IOP and regulates
AH outflow by modulating the outflow resistance sites, in part through NO signaling. Within this
regulatory feedback system, NO acts as an autocrine or paracrine signaling molecule[210] that can
freely diffuse either upstream to relax the TM/JCT cells [61,236,237] and/or along the circumference of
the canal to increase the permeability of the inner wall endothelium of SC by disrupting the adherens
junctions[44,57]. This leads to decreased outflow resistance and increased aqueous humour outflow,
which in turn restores IOP back to normal physiological levels (Figure 1.1).
Furthermore, the presence of NADPH-diaphorase1 labeling in the conventional outflow path-
way of human donor eyes, suggests endogenous NO production and NOS activity, whilst decreased
NADPH-diaphorase labeling has been reported in glaucomatous eyes[158]. Additionally, genome-
wide association studies[121,141,174] have linked polymorphisms in the NOS3 gene that encodes
eNOS to the pathogenesis of glaucoma, and overexpression of eNOS in a mouse model leads
to decreased outflow resistance and lower IOP[117,211]. Taken together, these data suggest that
endogenous NO signaling within the conventional outflow pathway by NOS enzymes contributes
to outflow regulation and that alterations in NO signaling in part mediates outflow dysfunction in
glaucoma. In this thesis, we examine the central hypothesis that the conventional outflow pathway
functions as a "dynamic mechano-regulatory system" that modulates the outflow resistance sites
through NO production to help maintain IOP homeostasis.
1NOS isozyme independent marker used to locate sites of NO synthesis.
3
Elevated IOP
SC Lumen
TM
eNOS
NO
Normal IOP
SC Lumen
TM
Elevated IOP
SC lumen narrows
increased shear stress
Increased NO production
Opens
 SC junctions Relaxes TM
Increased outflow
Normal IOP
Figure 1.1: Schematic representation of endogenous NO regulatory feedback mechanism for aqueous humour outflow.
(Left) At elevated IOP, the inner wall endothelium of SC distends into the lumen resulting in a collapsed canal. This
increases the theoretical hydrodynamic shear stress [73] acting on the shear-sensitive SC endothelial cells [11,135] and results
in increased NO production (green circle). NO can travel by retrograde diffusion upstream to relax the TM/JCT cells
and/or advection along the canal to disrupt SC cell-cell junctions to increase outflow. (Middle) NO mediates the outflow
resistance sites in the conventional outflow pathway to help increase outflow and restore IOP, resulting in a more open
SC lumen. (Right) NO mediated regulatory feedback mechanism to restore normal IOP. TM = Trabecular meshwork, JCT
= Juxtacanalicular connective tissue, Solid blue lines: transendothelial flow.
1.2 Background
In order to fully appreciate and understand the significance of the work presented in this
thesis, the reader will be provided with an background of the anatomy of the eye, the role of nitric
oxide in outflow physiology and how it is involved in aqueous outflow regulation.
1.2.1 Anatomy of the Aqueous Humour Outflow Pathway
The human eye is pressurised by a transparent fluid, called aqueous humour (AH), which
provides nutrients to the avascular tissues in the anterior chamber of the eye. This fluid is secreted by
the ciliary processes in the posterior chamber of the eye, and flows through the pupil and circulates
the anterior chamber before exiting the eye through either the conventional outflow pathway or the
unconventional outflow pathway. The majority of the fluid drains through the ’pressure-dependent’
conventional outflow pathway (also commonly referred to as the trabecular outflow pathway), which
consists of the trabecular meshwork, juxtacanalicular connective tissue and Schlemm’s canal (Fig-
ure.1.2A). The unconventional or uveoscleral outflow pathway only accounts for a small portion
(approximately 10%) of the bulk aqueous outflow, and is considered as the ’pressure-insensitive’
pathway[22,92].
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Once the majority of the fluid has entered the conventional outflow pathway, it filters through
the trabecular meshwork then crosses the inner wall endothelium of Schlemm’s canal into its lumen,
and flows circumferentially to its downstream collector channels that connect with the intra- and epis-
cleral venous system (Figure.1.2B)[90]. As the AH is secreted at a near constant rate (⇠2.5µl/min)
and the eye is considered as a closed system, it is the resistance of outflow system that determines
the IOP in the eye. It should be recognized that in healthy individuals, IOP is maintained within a nar-
row range of pressures throughout their lifetime[50,127] despite IOP fluctuations caused by choroidal
blood flow[124], and diurnal oscillations[138,139], in addition to other environmental factors. As previ-
ously mentioned, when the outflow resistance increases, the balance between AH production and
AH outflow is compromised which leads to elevated IOP, the primary risk factor for developing pri-
mary open angle glaucoma (POAG). Thus, by identifying the mechanisms involved in maintaining
IOP homeostasis, this would lead to more effective therapies for ocular hypertension and glaucoma.
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Figure 1.2: Schematic representation of the conventional outflow pathway in the human eye. (A) Aqueous humour (AH)
is produced in the posterior chamber by the ciliary processes, which flows into the anterior chamber though the pupil and
exits the eye by the iridocorneal angle (dotted blue lines). (Inset) The majority of AH leaves through the conventional
outflow pathway that consists of the trabecular meshwork (TM) and inner wall of Schlemm’s canal (SC), and into the
downstream collector channels (CC); whilst a small portion of the fluid leaves through the iris root between the muscle
fibers of the ciliary muscle (CM), commonly referred to as the unconventional outflow pathway (narrow blue arrow). (B)
The conventional outflow pathway experiences a basal-to-apical directed flow, where the AH filters through the different
layers of TM before crossing the inner wall endothelium of SC through transendothelial pores and drains circumferentially
to the downstream episcleral venous system.
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Unconventional Outflow Pathway
The unconventional or uveoscleral outflow pathway is considered as a major target for cur-
rent anti-glaucoma therapies, although interestingly only contributes to a small portion of the bulk
aqueous outflow (⇠ 10%). The uveoscleral pathway originally discovered in the mid-1960s by Bill [21],
showed that the AH leaves the eye through the iris root by passing through the connective tissues
and in between the muscle fibers of the ciliary muscle to the suprachoroidal spaces, from which
it is drained through the sclera and lymphatic vessels[6,160,244]. Early works conducted by Bill and
colleagues[21,22] have shown that the uveoscleral outflow is relatively insensitive towards elevations
in IOP when compared to the trabecular pathway, hence why this route is often referred to as an
"pressure-independent" pathway. This pressure insensitivity could be caused by the compression of
the supraciliary and suprachoroidal space, which results in suppressed uveoscleral outflow[160].
Conventional Outflow Pathway
The conventional or trabecular outflow pathway consists of the trabecular meshwork (TM),
the inner wall endothelium of Schlemm’s canal (SC), and the downstream post-trabecular outflow
pathway located in the iridocorneal angle (angle formed by the iris and cornea) that encircles the
eye. It is within this network of tissue structures that provides the resistance to AH outflow, and helps
maintain the IOP and structure of the eye.
Trabecular Meshwork
The trabecular meshwork consists of a network of connective tissue beams that encircles the
anterior chamber, bridging the iridocorneal angle of the eye and terminates as it blends in with the
stroma of the iris, ciliary body and scleral spur. The meshwork itself consists of three differentiated
layers: (i) the uveal meshwork (UTM), (ii) corneoscleral meshwork (CTM) and (iii) juxtacanalicular
meshwork (JCT; shown in Figure 1.3). The uveal and corneoscleral meshworks are porous struc-
tures composed of a series of trabecular beams or lamellae, which are made up of various collagen
sub-types (mostly type I and III), elastic fibers and proteoglycans. The lamellae are lined with a
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continuous monolayer of TM cells, that resides on a continuous basement membrane of extracel-
lular matrix (ECM) consisting of collagen type IV, laminin and fibronectin [2,90]. The flow within the
trabecular meshwork converges, as the intracellular spaces from the uveal meshwork (20 – 75 µm)
towards the corneoscleral meshwork (5 – 20µm)[32] become progressively smaller, hence the mesh-
work acts like a ’filtration system’ before the flow continues downstream to the Schlemm’s canal and
its collector channels.
Additionally, the trabecular cells have been documented to be phagocytic; this property al-
lows them to ingest both endogenous and exogenous materials, which helps keep the trabecular
outflow channels clear of potentially obstructive debris. [90,220] Because of the relatively high porosity
of the uveal and corneoscleral meshworks, this portion of the TM does not contribute significantly
towards outflow resistance. In contrast, the juxtacanalicular tissue (JCT, also called the cribriform
meshwork) situated adjacent to the inner wall of SC is considered as a primary site(s) of resistance
to AH in the eye. The JCT cells, unlike the TM cells from the uveal and corneoscleral meshwork,
are arranged in an irregular network of ECM, which form a loose connective tissue consisting of a
variety of macromolecules such as collagen IV, fibronectin, laminin, proteoglycans and glycosamino-
glycans (GAGs)[2,220]. Underlying the JCT is a network of elastic fibers (cribriform plexus) arranged
tangentially to the SC endothelium, which provide structural characteristics similar to those of the
trabecular beams. These elastic-like collagen fibers extend from the ciliary muscle into the scleral
spur, which attaches to the JCT and are closely connected to the inner wall of SC through the sheath
material surrounding the fibers[186,222]. The cribriform plexus allows for the translation of mechanical
forces from the ciliary muscle to the JCT and inner wall of SC. This is commonly experienced during
accommodation of the lens or after treatment with cholinergic agents such as pilocarpine, which has
been shown to affect the contractility of the ciliary muscle and effectively opens up the meshwork to
increase aqueous humour outflow through the tethering of the cribriform plexus[14,136,145]. Interest-
ingly, a small portion of TM cells have been shown to stain positive for ↵-smooth muscle actin, mainly
residing in the scleral spur insertion site suggesting that the TM cells possess contractile properties
similar to vascular smooth muscle cells [61,220]. Furthermore, the elastic fibers from the scleral spur
are continuous and extends into the TM beams and cribriform plexus in the JCT, changes in the
scleral spur cell tone would likely modulate the contractility function of the TM, and thus alter the
trabecular outflow resistance[140,220].
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Figure 1.3: Light micrograph of a meridional section through the trabecular meshwork. (B) is a magnification of (A). In the
plane of this section, Schlemm’s canal (SC) has two lumens that are separated by a septum. TM: Trabecular meshwork;
SS: Scleral spur; CM: Ciliary muscle; AC: Anterior chamber; JCT: Juxtacanalicular tissue; CTM: Corneoscleral trabecular
meshwork; UTM: Uveal trabecular meshwork. Arrows in B point to giant vacuoles in the inner wall endothelium of SC.
Magnification bars: 20 µm (A), 5 µm (B). Reproduced with permission from: Tamm, ER. The trabecular meshwork outflow
pathway: Structural and functional aspects. Experimental Eye Research 2009, 88: 648-655. [220]
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Schlemm’s Canal Endothelium
The Schlemm’s canal is a elliptical vessel that runs circumferentially around the eye, lo-
cated within the iridocorneal angle adjacent to the JCT, and is considered as the final barrier to
the drainage of AH in the conventional outflow pathway. The SC lumen directly connects to the
downstream collector channels and fuses with the downstream venous system of the eye[90]. Inter-
estingly, the inner wall of SC is lined with vascular-derived endothelial cells joined together by tight
junctions to form a continuous monolayer along the longitudinal axis of the canal, and is supported
by a discontinuous basement membrane. [69,90] Even though SC is a vascular-derived vessel, the
inner wall endothelia possess several unique features unlike most other endothelia. Firstly, the SC
endothelial cells experience a pressure gradient across the inner wall in the basal-to-apical direction
which pushes the cells off their basal lamina. As a result, the endothelium forms cellular outpouch-
ings (known as giant vacuoles; GVs) which distends into the lumen of SC and effectively narrows the
canal [120,225] (Figure 1.4). These so-called giant vacuoles are highly pressure-dependent, and act as
’smart one-way’ valves to AH flow. Giant vacuole formation are highly dynamic and undergoes large
cellular strains due to the direction of AH and pressure drop across the inner wall [28,69,166,170]. This
leads to the formation of micron-sized pores in the endothelial monolayer to allow for the drainage
of AH.
Secondly, the SC endothelia possesses unusually high hydraulic conductivity, in other words,
low flow resistance, similar to that of the renal glomerulus[69]. It is theorized that the dynamic
behavior of these SC endothelial cells are responsible for regulating the hydraulic conductivity of
the conventional outflow pathway, mainly through the formation of transendothelial pores in the SC
endothelium. These pores can form through two main pathways: (i) transcellularly through indi-
vidual cells (known as "I-pores"), through the fusion of the apical and basal cell membranes[28]
or the disruption of fusogenic proteins involved in the formation of "mini-pores" [108], and (ii) para-
cellularly through the disassembly of junctional complexes between neighboring cells (known as
"B-pores") [68,71]. Once the AH has crossed the JCT/SC barrier, the fluid drains circumferentially
towards the collector channels (CC) and aqueous veins, which pools together the AH at the site of
the deep intrascleral venous plexus (DIVP) and enters the vascular circulation, or connects directly
to the episcleral veins[32,90,227].
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Finally, the developmental origin of the SC endothelia has been a long-standing subject of
debate. The SC endothelial cells (SCECs) have drawn comparisons from both blood endothelial
cells (BECs) and lymphatic endothelial cells (LECs), and thus may explain the unique properties of
the SC vessel [185]. Recent studies have identified the molecular phenotypes involved in the develop-
ment of SC, indicating that transcription factor prospero-related homeobox1 (PROX1) and vascular
endothelial growth factor receptor 3 (VEGFR-3) are expressed in both developing and mature SC
in mice, both of which are key regulators of lymphatic fate[12,126,226]. In addition to lymphatic mark-
ers, the SC also expresses vascular endothelial markers CD312 and vascular endothelial cadherin
(VECAD)[73,106]. Taken together, the SC is considered to have characteristic traits of both BECs and
LECs, thus the SC endothelium may modulate AH flow through similar mechanosensory signaling
pathways to maintain IOP homeostasis in the eye.
A B
Figure 1.4: (A) Scanning electron micrograph of the inner wall of Schlemm’s canal as seen from the canal lumen. Arrow-
head shows a pore and inset shows high magnification image of pore. (B) A transmission electron micrograph showing
giant vacuoles (GVs) along the inner wall endothelium of Schlemm’s canal (SC). The classic "signet ring" appearance
is particularly well exhibited by the second giant vacuole from the left where the cell appears as a thin, continuous lin-
ing around the giant vacuole cavity with the nucleus (n) bulging to one side. The first and third giant vacuoles from the
left have basal openings or "meshwork pores" (asterisks) where, presumably, aqueous humour enters the giant vacuole
cavity from the underlying juxtacanalicular tissue (JCT). Note that the endothelial cells on the outer wall of Schlemm’s
canal, which is not typically involved in aqueous humour filtration, are flat. Reproduced with permission from: Overby,
DR et al. The changing paradigm of outflow resistance generation: Towards synergistic models of the JCT and inner wall
endothelium. Experimental Eye Research 2009, 88: 656-670. [166]; Pedrigi, RM et al. A model of giant vacuole dynamics
in human Schlemm’s canal endothelial cells. Experimental Eye Research 2011, 92: 57-66. [170]
Post-Trabecular Pathway: Limbal Vasculature
The post-trabecular outflow pathway consists of a complex network of micro-vessels that
connect the outer wall of SC to the downstream episcleral veins and conjunctival vessels. This net-
work of limbal vessels help transport the AH back towards the venous circulation[227]. Once AH
2Also commonly referred to as platelet endothelial cell adhesion molecule-1 (PECAM-1)
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has crossed the inner wall endothelium of SC into its lumen, the fluid flows circumferentially towards
the downstream collector channels and aqueous veins, where it reconnects with the venous system
(Figure 1.5). In the human eye, there are approximately 20–30 collector channels or aqueous veins
present, which are non-uniformly distributed around the circumference of the eye[101,103]. Collec-
tor channels drains AH from the SC lumen into the deep intrascleral venous plexus, where it can
then either directly join the venous circulation or continue to flow towards the deeper venous plexi
(mid and deep venous plexus), where it eventually connects with the perilimbal vessels or episcleral
veins[90,227]. In contrast, the aqueous veins connect the SC directly to the episcleral veins, by-
passing the intermediary venous plexi. Interestingly, these collector channels also possess similar
contractile properties to TM cells, as the vessels are surrounded by smooth muscle cells [54] that may
control the intrascleral vessel dimensions to influence the post-trabecular or distal outflow resistance
downstream of SC[188]. Additionally, the post-trabecular pathway has been shown to account for ap-
proximately 25% of the outflow resistance in human eyes[93,116], suggesting that the distal outflow
resistance may also play a regulatory role in aqueous humour outflow.
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Figure 1.5: Post-trabecular aqueous humour outflow pathway. (A) Schematic representation of the post-trabecular outflow
pathway. (B) Three-dimensional reconstruction of the limbal vessels of a normal mouse eye. All limbal aqueous and blood
vessels are detected in this reconstructed image of PECAM-1 immunostained corneoscleral wholemount from an ICR WT
mouse. The lateral boundaries of each image segment have been digitally transformed to show the continuity of vessels
around the limbus. Each of the vessel phenotypes were traced and colour-washed to show their anatomical relationship
with one another. The anterior ciliary (ACA) and circular limbal arteries (CLA) are indicated in red. The veins of the
perilimbal plexus (PLV) and those associated with the episclera (EPI veins) are indicated in blue. Corneal arcades arising
off the CLA are in red and become blue where they anastomose with veins of the PLV. Schlemm’s canal (SC) is in grey
and collector channels/aqueous veins (CC) are indicated in green. The long posterior ciliary artery (LPCA) is indicated
in yellow and arterial branches that feed the CLA segments are clearly seen. Arteriovenous anastomoses (AVA) are
indicated in the superficial limbus. Reproduced with permission from: van der Merwe, EL et al. The three-dimensional
organisation of the post-trabecular aqueous outflow pathway and limbal vasculature in the mouse. Experimental Eye
Research 2014, 125: 226-235. [228]
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1.2.2 Glaucoma
Glaucoma is a group of progressive optic neuropathies characterized by the irreversible
damages caused to the retinal ganglion cells (RGCs) and their axons at the site of the optic nerve
head. The loss of RGCs leads to progressive loss of vision and onset of irreversible blindness[176,235].
Elevated intraocular pressure (IOP) is commonly associated with the development of glaucoma,
where increases in IOP causes mechanical insult to the RGCs through the deformation of the lamina
cribrosa resulting in cell death[202]. Glaucoma is the world’s leading cause of irreversible blindness,
affecting more than 60 million people worldwide, of which 8.4 million are bilaterally blind[176]. Two of
the most prevalent forms of glaucoma are primary open angle glaucoma (POAG) and angle-closure
glaucoma (ACG). [177] POAG is the variant of glaucoma that poses the most interesting biological
question – what are the mechanism(s) responsible for the increase in outflow resistance in the eye?
The elevation of IOP is the primary risk factor for POAG, but the mechanism(s) responsible
for ocular hypertension remains unclear. Current treatments of ocular hypertension aim to lower
IOP, through either surgical or drug interventions to postpone the progression of vision loss. Majority
of pharmacological agents used to lower IOP target the uveoscleral pathway, with either muscarinic
agonists (pilocarpine) or prostaglandin analogues (latanoprost) [6], both treatments affect the ciliary
muscle tone to increase AH outflow. Alternatively, beta-blockers (timolol) and carbonic anhydrase
inhibitors[234,235] have also been used to reduce AH production to help lower IOP. However, these
therapies are often unable to achieve a sustained IOP reduction, largely because the treatments do
not target the underlying root cause of elevated IOP; increased outflow resistance of the conventional
outflow pathway. Thus, identifying the physiological mechanism(s) responsible for the increased
outflow resistance in the conventional outflow tract would provide more targeted and efficacious
glaucoma therapies.
1.2.3 Aqueous Humour Dynamics
The eye is considered as an closed system, where IOP is determined by the balance be-
tween aqueous humour production (Fp) and drainage (Fd), such that at steady state Fp = Fd. AH
outflow (Fd) is more accurately represented by the ’pressure-dependent’ conventional outflow (Fc)
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and the ’pressure-independent’ unconventional outflow (Fu). Additionally, the AH outflow is de-
termined by the difference in pressure between the anterior chamber (IOP) and the downstream
episcleral venous pressure (EVP), and the rate at which the fluid drains the eye is determined by the
resistance of the conventional outflow pathway (Rc). Therefore, the governing equation is defined
by the following relationship, known as the Goldmann’s Equation is shown below[33]:
F p =
(IOP   EV P )
Rc
+ F u (1.1)
This relationship could also be expressed as a function of outflow facility of the conventional pathway
(C), which is defined as the inverse measure of outflow resistance, as shown below:
F p = C ⇥ (IOP   EV P ) + F u (1.2)
The Goldmann’s equation can also be re-arranged as a function of IOP, as shown below:
IOP =
(F p   F u)
C
+ EV P (1.3)
1.2.4 Outflow Resistance Generation
Elevated intraocular pressure has been identified as the primary risk of factor for the devel-
opment of POAG for over a century now. Yet the underlying mechanism(s) responsible for regulating
the outflow resistance in the conventional outflow pathway are still inconclusive. It is widely accepted
that the majority of the outflow resistance lies within the vicinity of the JCT and inner wall region of
Schlemm’s canal, even though numerous pharmacological and morphometric studies have been
unable to attribute the bulk resistance to any one of these tissues[23,97,98,166]. The outflow resis-
tance generated by the uveal and corneoscleral meshworks are considered negligible due to its
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highly porous structures[32,90,116]. Grant and colleagues[93,188] have shown that by surgically re-
moving the uveal and corenoscleral meshworks did not significantly affect the outflow resistance in
enucleated human eyes. In contrast, when the entire JCT and inner wall of SC were removed, the
overall outflow resistance was reduced by approximately 75%, suggesting that the majority of the
outflow resistance was generated by the JCT and inner wall region[93]. Mäepea and Bill [146] also
showed that 50% or more of the outflow resistance lies within close vicinity of the JCT and inner
wall. Furthermore, the presence of giant vacuoles and pores in the SC endothelium cell layer only
accounts for 10% of the outflow resistance[72]. The distal resistances generated by the collector
channels and aqueous veins are also unlikely to generate significant resistance due to their large
vessel diameters (50 µm)[227]. Taken together, this suggests that the resistance generated in the
outflow pathway is not as straightforward as adding the resistances of each tissue layer together;
thus suggesting that there must be some form of interaction or "hydrodynamic coupling" between
the tissue structures, in particular, the JCT, basement membrane and inner wall of SC to account
for the bulk of outflow resistance. This hydrodynamic coupling between the different tissue layers is
supported by the "funneling model" [116,166].
1.2.5 Outflow Resistance: Synergistic Model
Hydrodynamic Coupling
The funneling model, originally theorized by Johnson and colleagues[118], is considered as
the primary synergistic model of outflow resistance generation in the eye. It is believed that pores
in the inner wall endothelium (⇠micron sized) are separated by an average distance of 20 – 30
µm[166], which implies that flow towards the inner wall are preferentially directed towards the regions
in the JCT close to a pore. In addition, Ethier et al. [72] has suggested that the JCT by itself does
not generate significant outflow resistance, unless the openings are filled with glycosaminogylcans
(GAGs) a major ECM component found in the TM. This suggests that GAGs and other ECM com-
ponents may control the spacing between the trabecular lamellae, and thus the outflow resistance
of the JCT. Therefore, by factoring in the JCT filled with extracellular matrix gel and the presence of
downstream pores, it is likely that the flow distribution in the JCT becomes non-uniform as AH fun-
nels toward the pores[166]. Furthermore, in human organ cultured eyes perfused with purified matrix
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metalloproteinases (MMPs), enzymes that digest ECM molecules, resulted in an increase in outflow
facility. Whilst the inhibition of endogenous MMP activity reduced outflow facility, thus supporting the
role of ECM in outflow resistance generation in the TM[30].
Mechanical Coupling
As previously mentioned, the hydrodynamic coupling between each tissue strata may ac-
count for the outflow resistance, but unfortunately does not take into consideration the mechanical
forces experienced by these tissue structures. The JCT and inner wall endothelium experiences a
basal-to-apical pressure drop as AH crosses the outflow pathway. This imposes a mechanical load
on the tissues, which causes morphological changes to the JCT and inner wall. In order for these tis-
sues to withstand these forces induced by changes in IOP, structural attachments must exist to hold
the subsequent tissues in place. Johnstone and Grant [120] first described the concept of mechanical
tethering between the JCT and inner wall by examining their morphological changes in response
to increasing IOP in human and monkey eyes. At low IOP, the inner wall endothelium is relatively
flat and the lumen is open allowing AH to flow through (Figure 1.6A). As IOP increases, the JCT
expands and pushes the inner wall endothelium into the lumen, and results in the formation of GVs.
This leads to the narrowing and partial collapse of the SC, reducing the cross-sectional area of the
lumen, which in turn increases the outflow resistance in the meshwork (Figure 1.6B). These results
show that the JCT and inner wall responds to elevations in IOP in a pressure-dependent manner,
and that changes in SC lumen dimensions are highly dependent on IOP.
The mechanical coupling of the JCT and inner wall exists through multiple mechanisms.
Johnstone[119] showed that cell-cell tethering exists between the two subsequent tissue layers,
whereby cytoplasmic processes from the SC cells anchors itself to the processes from the JCT
cells. Additionally, studies have shown that adherens junctions, in particular VE-cadherin and CD31
are abundantly expressed in the SC cells at the inner and outer wall [106,172,230]. Thus, suggesting
cell-cell tethering and junctional proteins may also be involved in the regulation of outflow facility.
Consistent with this notion, Lu et al. [143] showed in bovine eyes perfused with a rho kinase inhibitor
(Y27632), increased outflow facility by promoting cell relaxation through disassembly of actin stress
fibers and focal adhesions. In the same study, the Y-27 also caused an increase in separation length
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along the inner wall of the aqueous plexus (AP; analogous to human SC) from its underlying sub-
stratum. This disassociation in cell-cell or cell-ECM tethering introduces intercellular space between
the two resistance sites, thus reducing the resistance and allowing more uniform flow to occur.
Thus, suggesting that the aqueous outflow resistance is governed by this synergistic model, and
that the hydrodynamic and mechanical interactions between the different tissues (SC endothelium,
basement membrane and JCT) are crucial for regulating outflow.
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Figure 1.6: Schematic representation of the collapse of the Schlemm’s canal in the human eye. The conventional outflow
pathway experiences a basal-to-apical directed flow, where the AH filters through the different layers of TM before crossing
the inner wall endothelium of SC through transendothelial pores and drains circumferentially to the downstream episcleral
venous system. (A) At low IOP, the SC lumen is relatively flat and open. (B) At elevated IOP, the pressure-dependent
giant vacuoles form and distend into the SC lumen resulting in a collapsed canal. Solid blue lines: transendothelial flow,
Dashed blue lines: circumferential flow.
1.2.6 Segmental Flow of the Outflow Pathway
Aqueous humour filtration has long been recognized as non-uniform or "segmental" around
the circumference of the outflow pathway, such that only a fraction of the total area of the JCT and
inner wall of SC are actively involved with the drainage of AH at any given time. The mechanism(s)
responsible for this segmental flow behavior are still not well understood. Previous studies have used
tracers such as cationic ferritin [53,70,100] and fluorescent microspheres[102,123,143,231] to decorate and
identify preferential drainage routes in the trabecular outflow tract, which are separated into "high
flow" and "low flow" regions (as shown in Figure 1.7) [42]. These regions of preferential flow in the
TM are commonly referred to as the "effective filtration area" (EFA), which are active portions of the
meshwork involved in the filtration of AH. Studies have suggested that segmental filtration patterns
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are likely associated with regional variations in ECM proteins residing in the JCT. Previous studies
have shown that tracer patterns in the TM tend to correlate with the distribution of ECM proteins in
the trabecular outflow tract, in particular, versican[2,123,231] and SPARC (secreted protein acidic and
rich in cysteine) [218]. Interestingly, in human organ cultured eyes perfused with fluorescent tracers,
the flow patterns were inversely correlated with the distribution of versican in the TM[123]. Whilst in
a separate study, researchers found that in SPARC-null mice, the tracer patterns in the TM were
more uniformly distributed when compared against wild-type littermate controls [218]. Furthermore,
the inhibition of GAG biosynthesis in both porcine and human organ cultured eyes dramatically
increased outflow facility by 3-fold and 1.5-fold, respectively [122]. Taken together, these studies
suggest that ECM proteins and GAGs play a crucial role in regulating the local hydraulic conductivity
of the JCT/inner wall, and areas of higher ECM deposits tend to correlate with regions of lower tracer
labeling.
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Figure 1.7: (A) Macro-scale tracer image shown segmental filtration patterns (arrowheads) in the trabecular meshwork of
an enucleated human eye perfused with fluorescent microspheres. (B) Four images, each containing one quadrant, were
pieced together and displayed on the same intensity scale. Dotted lines indicate where quadrants were cut. S, superior;
T, temporal; I, inferior; N, nasal; OD, right eye. Reproduced with permission of the authors and the publisher [42].
Alternatively, segmental flow patterns could also be attributed to variable mechanical tether-
ing between the inner wall endothelium and the basement membrane or JCT, which could lead
regional variations in flow distribution (as previously mentioned in Chapter 1.2.5). Morpholog-
ical changes in the outflow tract have been associated with the segmental outflow patterns in
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bovine[17,143], monkey[144], and human[102,242] eyes, where regions of higher tracer accumulation
coincided with areas of greater separation between the SC endothelia and the underlying JCT. The
increased separation between the subsequent tissue layers effectively uncouples the hydrodynamic
influence of the inner wall, which has been described to eliminate the funneling effect and decrease
outflow resistance, leading to a more uniform flow distribution though the JCT[166]. Other factors
such as the non-uniform distribution of collector channels along the circumference of the eye[101,103],
and possible variable distal resistances of the episcleral venous system may also contribute towards
the segmental flow patterns in the JCT. Prior reports have shown that in both bovine[17] and hu-
man[42,102] eyes, tracer patterns tend to coincide with the distribution of collector channel ostia,
accumulating in regions of lower downstream resistance (as shown in Figure 1.8) [42].
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Figure 1.8: Micro-scale tracer images showing segmental filtration patterns in the JCT and inner wall (IW) endothelium
of SC of an enucleated human eye perfused with fluorescent microspheres. (A) High flow region of the JCT/IW with
the presence of collector channel ostia (*). (B) Low flow region of the JCT/IW with no observed presence of collector
channels. SC, Schlemm’s canal; CC, collector channel. Reproduced with permission of the authors and the publisher [42].
Taken together, these data suggests that segmental flow in the TM occurs over two different
length scales: (i) the macro scale (order of mm), and (ii) the micro scale (order of several µm). At
the macro-scale, the bulk flow preferentially drains towards regions of lower downstream resistance,
which are influenced by the distribution of collector channel ostias along the SC. Whilst at the micro-
scale, the ECM accumulation and morphology of the inner wall of SC influences the local filtration
function of the outflow pathway, which results in segmental distribution of AH. Currently, it remains
to be determined whether segmental distribution at the macro- and micro-scales are coupled, and
whether segmental flow patterns is considered as a static or dynamic process[42].
18
One plausible hypothesis is the presence of an endogenous feedback loop that detects
changes in IOP and regulates the local hydraulic conductivity of the outflow pathway, partly through
NO signaling to help restore IOP homeostasis, analogous to the vascular system. Stamer et al. [211]
originally hypothesized that the conventional outflow pathway acts as a mechano-regulatory sys-
tem, whereby changes in IOP expands the JCT and pushes the inner wall of SC into the lumen,
which effectively narrows the canal lumen. This in turn increases the shear stress acting on the
SC endothelial cells, increasing NO production which feeds back into the outflow pathway as an
autocrine/paracrine signaling molecule to modulate the local resistance sites. Interestingly, in a prior
study conducted by Ethier et al. [73] showed that the calculated theoretical wall shear stresses in the
SC are comparable to those experienced by the arterial system. Recent studies have also demon-
strated that SC cells secrete NO in response to elevated shear stress[11,135], similar to vascular
endothelial cells [44,45]. Therefore, in this scenario, increased shear stress in the SC up-regulates the
NO production, which is then convected downstream towards the collector channel ostias. This pre-
dicted elevation in NO concentration near the collector channel ostias may affect the local hydraulic
conductivity, and thus explain the segmental outflow patterns that tends to coincide with these re-
gions. In contrast, if large areas of the TM/JCT are starved of flow, this would result in decreased
shear stress and NO levels, which would further exacerbate the local outflow resistance contributing
to increased IOP and ocular hypertension[211].
This proposes several interesting questions: (i) what is the role of NO signaling in the con-
ventional outflow pathway? (ii) Does NO signaling contribute towards the spatial distribution of
segmental outflow in the eye? (iii) Can NO be utilized as a potential therapeutic for treating ocular
hypertension and glaucoma? In order to effectively address these questions, we need to first gain
an understanding of how NO is synthesized and how it functions as a signaling molecule and its
effects on biological systems, as described in the following section.
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1.2.7 Role of Nitric Oxide in Outflow Physiology
Nitric Oxide as a Signaling Molecule
Nitric oxide (NO) is a diatomic free radical and an important signaling molecule, that is re-
sponsible for mediating various physiological functions across multiple biological systems; these
include the modulation of vascular tone[153–155,232], neuronal signaling[31,52] and immunological pro-
cesses[74]. NO is synthesized by a family of enzymes, called nitric oxide synthases (NOS), which
catalytically convert the amino acid L-arginine to NO and L-citrulline through a two-step oxidation
process[80]. NOS enzymes are differentiated into three main types, endothelial NOS (eNOS), neu-
ronal NOS (nNOS) and inducible NOS (iNOS), all of which are expressed in mammalian tissues.
The active form of these enzymes are composed of heme-bound homodimers that transfer elec-
trons from nicotinamide-adenine-dinucleotide phosphate (NADPH) to its co-factors (flavin adenine
dinucleotide (FAD) and flavin mononucleotide (FMN)) and the heme moieties, where the substrate
L-arginine is oxidized to L-citrulline and NO[5,80].
The activity of all isoforms of NOS are mediated through calmodulin-binding. Thus, constitu-
tively expressed eNOS and nNOS activity are regulated by intracellular calcium (Ca2+) levels. Typi-
cally between 200 nM – 400 nM of Ca2+ is required to initiate calmodulin-binding to the enzyme[80].
Both eNOS and nNOS produce low basal levels of NO which are regulated by receptor-mediated
signaling pathways to maintain physiological functions (described in more detail below). In contrast,
iNOS expression is considered calcium-insensitive, as calmodulin binds to iNOS with extremely high
affinity even at low intracellular Ca2+ levels (<40 nM)[80]. iNOS is typically expressed in response
to inflammatory stimuli such as endotoxins and cytokines, producing NO as a important defense
mechanism against pathogens[56,81,154,167].
NO is produced and released by many cell types in the body, where it can act as an autocrine
or paracrine signaling molecule to target a number of enzymes and proteins[81]. The biochemical
reactions of NO under physiologically relevant conditions can be simplified to three main categories:
the activation of guanylate cyclase, responsible for signal transduction; the conversion to peroxyni-
trite (ONOO ) after reacting with superoxide (O 2 ), responsible for post-translational modifications of
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proteins such as S-nitrosothiols and 3-nitrotyrosines; and the scavenging of NO by oxyhemoglobin
(Hb-O2) to form nitrates[19,167,182]. The most physiologically relevant signaling pathway stimulated by
NO is the activation of soluble guanylate cyclase (sGC) and the generation of cyclic guanosine 3’-5’
monophosphate (cGMP)[19,56,80,81]. Nanomolar levels of NO binds to the heme moiety on the  -
subunit of sGC to activate the enzyme. This activation of sGC results in the conversion of guanosine
5’-triphosphate (GTP) to cGMP, increasing the levels of intracellular cGMP, which interacts with vari-
ous cyclic-nucleotide gated ion channels, protein kinase G (PKGs) and phosphodiesterases (PDEs)
to elicit physiological effects[55,56,81].
NO can also elicit other biological effects through cGMP-independent pathways such as
post-translational modification of proteins via S-nitrosylation, in which the NO moiety is coupled
to a reactive cysteine thiol to form S-nitrosothiols. This has been shown to play a role in cellular
signal transduction and provides a mechanism for redox-based physiological regulation[109,148]. In
addition, strong oxidants such as superoxide can react with NO to form peroxynitrite, resulting in the
nitration of the phenol moiety of tyrosine residues and the formation of 3-nitrotyrosine[19,184,219]. The
processes of S-nitrosylation and nitration have been shown to affect the function of various proteins
under both physiological and pathophysiological conditions[19,148,208]. Therefore, it is crucial to gain
an understanding of how NO regulates vascular tone and potentially how endothelial dysfunction
may contribute towards the pathogenesis of glaucoma[121,141,174,191,192].
The vascular endothelium is regulated by various signaling molecules and hormones, which
includes NO and endothelin-1 (ET-1), which act as opposing vascular modulators that help maintain
the vascular tone, endothelial permeability and general physiological function of the vascular sys-
tem.[153–155,232] NO, as previously mentioned, activates sGC to increase intracellular cGMP which
interacts with various downstream cellular targets to elicit physiological effects, including the most
common vasodilatory effect on blood vessels. In contrast, ET-1, is a potent vasoconstrictor secreted
by vascular endothelium and acts as an inhibitor of endothelial permeability [162,241]; together NO and
ET-1 help maintain vascular homeostasis. Interestingly, previous studies have shown that patients
with normal tensive glaucoma (NTG) have impaired blood flow in their forearms when compared
to age-matched controls. [35,107,214,215] Furthermore, increased plasma and aqueous levels of ET-1
have been detected in patients with primary open-angle glaucoma[67,161], which would induce vaso-
contraction of the blood vessels and decrease endothelial permeability. These results suggest that
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the pathogenesis of glaucoma may be associated with a systemic vascular endothelial dysfunction,
which could cause an imbalance between NO and ET-1 levels resulting in the lack of vasodilation in
the vessels.
In the context of outflow physiology, previous studies have also used NADPH-diaphorase
as an indicator of NOS activity, to label and identify NO production sites in the conventional outflow
pathway of human donor eyes[157,158]. Interestingly, the NADPH-diaphorase labeling was enriched in
the major outflow resistance sites, which included the trabecular meshwork, inner wall of Schlemm’s
canal endothelium and the downstream collector channels; whilst decreased NADPH-diaphorase la-
beling has been reported in glaucomatous eyes[157]. Additionally, genome-wide association studies
have linked polymorphisms in the NOS3 gene that encodes eNOS to the pathogenesis of glau-
coma[121,141,174]. Taken together, these data suggests that endogenous NO production within the
conventional outflow pathway by NOS enzymes may play a regulatory role in maintaining IOP home-
ostasis, and impaired NO signaling may in part lead to outflow dysfunction in glaucoma.
NO Production and Cellular Response
To fully appreciate how endogenous NO signaling may influence outflow facility and IOP
regulation, an understanding of how NOS enzymes are activated and regulated under physiological
conditions is required. Here we will be focussing on eNOS in particular, as it has been previously
reported to be the primary isoform expressed in the human outflow pathway[158] and polymorphisms
in the NOS3 gene have been linked to the pathogenesis of glaucoma[121,141,174]. Therefore, eNOS
may play a regulatory role in aqueous humour dynamics. As previously mentioned, constitutively
expressed eNOS is activated by an increase in intracellular Ca2+ that leads to enhanced binding
of calmodulin to the enzyme. This facilitates the flow of electrons from NADPH in the reductase
domain to the heme moiety in the oxygenase domain of the homodimers. However, eNOS can also
interact with several other proteins such as heat shock protein 90 (hsp90)[85], G protein-coupled
receptors (GPCRs)[91] and caveolin-1[209], resulting in either the inhibition or stimulation of NOS
activity. The location of eNOS within the cell can also determine its activity. When the enzyme is
located within the caveolae it can readily bind to caveolin-1, which has been shown to function as a
negative regulator or inhibitor of eNOS activity [80,94,196,209]. Whilst calmodulin and hsp90 binding to
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eNOS dissociates caveolin-1 from eNOS and activates the enzyme[94].
Mechanical stimuli such as fluid shear stress has also been shown to activate and mediate
eNOS activity [58,91,201], by activating various receptor-mediated pathways including the activation
of the phosphatidylinositol-3-OH kinase (PI(3)K) and downstream effector serine/threonine kinase
Akt/PKB3 pathway. Shear stress acting on endothelial cells results in the phosphorylation of eNOS
by PI(3)K/Akt-dependent pathway at serine 1177, which stimulates the flux of electrons to the re-
ductase domain, resulting in increased sensitivity to Ca2+ and enzyme activity [59,82]. eNOS can
also be phosphorylated at theronine 495, which functions as a negative regulatory site to decrease
the electron flux whilst also interfering with calmodulin-binding domain to decrease the enzyme’s
activity [78,80]. Hence, eNOS activity in vivo is mediated in part by shear stress induced phosphory-
lation of the enzyme. As previously mentioned, we theorise that the conventional outflow pathway
functions as a mechano-regulatory system, whereby changes in IOP expands the JCT and pushes
the inner wall of SC into the lumen effectively narrowing the canal lumen. This narrowing of the
SC lumen would lead to an increase in shear stress experienced by the SC endothelial cells, hence
up-regulates eNOS expression and leads to increased NO production. NO being a free radical gas
can rapidly diffuse across cell membranes to affect the biological activity of several proteins and
enzymes, to elicit an physiological response by mediating the outflow resistance sites to enhance
outflow facility and lowering IOP.
The precise mechanisms of how NO affects outflow facility and IOP remains unclear, but
likely involves mechanisms related to cellular contractility and endothelial permeability. NO is con-
sidered as the "messenger" or signaling molecule that initiates the sGC/cGMP/PKG signaling path-
way. One of the most important physiological responses to the activation of this signaling cascade,
is the vasodilatory effects on smooth muscle cells in the cardiovascular system mediated through
its cellular contractile properties; crucial for maintaining vascular tone[81]. It has been well estab-
lished that NO elicits smooth muscle relaxation by regulating intracellular Ca2+ levels, myosin light
chain phosphorylation and BKCa channels[81]. Interestingly, in the conventional outflow pathway, the
ciliary muscle, trabecular meshwork and downstream collector channels all possess similar con-
tractile properties to vascular smooth muscle cells, expressing common contractile proteins such as
↵-smooth muscle actin and smooth muscle myosin[54,79,236].
3PKB = Protein kinase B
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Previous studies have shown that in isolated bovine TM strips, pre-contracted with carba-
chol, when treated with NO donors and cGMP analog (8-br-cGMP; 8-bromoguanosine 3’5’-cyclic
monophosphate sodium salt) it reversed the effect of carbachol-induced contraction of the TM strips
and relaxed the TM cells [236,237]. In human TM cells, NO has also been shown to not only induce re-
laxation of TM cells [61], but also decrease TM cell volume through the activation of BKCa channel [60].
Furthermore, a reduction in phosphorylated myosin light chain was detected in TM cells treated with
NO donors when compared against vehicle-controls [61]. Consistent with this notion, downstream
collector channels are also surrounded by smooth muscle cells [54]. Therefore, NO production in the
SC and downstream collector channels, could potentially control the intrascleral vessel dimensions
and induce the relaxation of these vessels to influence the post-trabecular or distal outflow resis-
tance downstream of SC[188]; although the relationship between NO production and distal outflow
resistance has not been studied yet. These results suggest that NO can mediate the cellular con-
tractility of TM cells, which in part regulate outflow resistance and facilitate aqueous humour outflow
through the conventional outflow pathway.
NO has also been shown to induce relaxation of the ciliary muscle[18,84,89,236]. However,
the relaxation of ciliary muscle tends to oppose the effects of TM relaxation, as these two tis-
sues are connected through the extensive tendinous connections[165,186,187,222]. Therefore, the
contraction/relaxation of one tissue will affect the response in the other, functioning as an antag-
onist pair to regulate aqueous humour outflow[237]. Although it has been shown that the activation
of NO/sGC/cGMP pathway favors the relaxation of TM cells, and thus results in the increase of
aqueous humour outflow[236].
Alternatively, NO could also mediate endothelial permeability of the inner wall of SC by dis-
rupting the adherens junctions[44,57] or by altering the SC cell volume by activating the BKCa chan-
nel [65]; both mechanisms could potentially affect the porosity of the inner wall endothelium by modu-
lating the dimensions of pores or flow pathways to increase outflow facility. In contrast, earlier studies
carried out by Kubes et al. [132] showed the inhibition of NO production with L-NAME led to increased
endothelial permeability in the microvasculature, therefore it remains to be determined whether NO
increases or decreases permeability of the inner wall endothelium of SC. Interestingly, the SC en-
dothelium expresses key vascular endothelial markers such as CD31 and VE-cadherin[106], which
serves to maintain the endothelial barrier function to regulate aqueous humour outflow. The phos-
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phorylation state of VE-cadherin has been associated with the regulation of vascular permeability
both in vitro and in vivo [163]. NO production has been shown to be crucial for regulating VE-cadherin
phosphorylation in addition to stress fiber formation in endothelial cells by controlling the balance be-
tween Rho and Rac activation[57]. The loss of eNOS activity, and subsequent lack of NO, results in
the remodeling of the actin cytoskeleton by redistributing F-actin towards the cell periphery, enhanc-
ing cortical actin assembly and strengthened cell-to-cell adhesion in a TIAM1 (activator of Rac) and
Rac-dependent manner. The recruitment of TIAM1 to adherens junctions and VE-cadherin leads to
a reduction in VE-cadherin phosphorylation[57], thus in turn alters the endothelial permeability [163].
NO may also affect other aspects of aqueous humour dynamics; for example, NO donors
may decrease aqueous humour inflow[197], increase episcleral venous pressure[245], and affect
choroidal blood volume[125]. Therefore, it is possible that NO could target multiple potential mecha-
nisms to affect aqueous humour dynamics, and, depending on the site of NO activity and the species
being examined, NO may either increase or decrease IOP. While the cellular mechanisms by which
NO regulates IOP are certainly important, but to gain therapeutic effect in the context of physiolog-
ical regulation of outflow facility, we need to investigate the effects of NO on conventional outflow
physiology at the organ level.
Effects of NO on Conventional Outflow Physiology
Exogenously delivered NO typically decreases IOP and increases outflow facility, by reduc-
ing the outflow resistance situated in the conventional outflow pathway. The reduction of outflow
resistance is likely mediated through the activation of sGC-dependent signaling cascades, as pre-
viously described. The IOP-lowering effects of various NO donors has long been established in
various animal models, including in living monkeys[24,111,130,193], in living rabbits [20,24,41,129], and in
eyes obtained postmortem from pigs[62,65] and humans[191]. Recent efforts have resulted in the de-
velopment of several NO-donating compounds[24,113,130], including latanoprostene bunod (LBN), a
NO-donating prostaglandin F2↵ receptor agonist that has been shown to be more efficacious than
latanoprost at reducing elevated IOP in ocular hypertensive patients[233]. This improved IOP reduc-
tion is likely attributed to the effects of the NO-donating moiety targeting the TM/SC cells to enhance
aqueous humour outflow. Even with the recent success of the LBN compound and other exogenous
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NO-donating compounds on increasing outflow facility, it is still important to understand the physio-
logical role of endogenous NOS within the conventional outflow pathway, as this would lead to better
development of potential therapeutics to treat glaucoma. As previously mentioned, all three NOS
isoforms have been identified throughout the trabecular, post-trabecular, and ciliary muscle regions,
suggesting that endogenous NOS activity and NO production may influence outflow physiology.
Despite the potential role of other NOS isoforms, eNOS appears to be particularly important
for the physiological regulation of outflow facility. Stamer et al. [211] have shown that in enucleated
mouse eye perfusions, that elevated eNOS expression in eNOS-GFPtg mice leads to a reduction in
IOP and increases outflow facility when compared to litter-mate wild-type mice. Additionally, when
the eNOS-GFPtg mice were treated with NG-nitro-L-arginine methyl ester (L-NAME; non-selective
NOS inhibitor) the pressure-flow relationship of the transgenic mice returned to levels that were
comparable to those of wild-type mice. These results suggest that the endogenous NO regulation
may play a important role in regulating aqueous humour outflow. Interestingly, in a recent study con-
ducted in sGC↵1 deficient mice, the lack of ↵1-subunit of the protein has been shown to contribute
to ocular hypertension and glaucomatous optic neuropathy[37]. This is consistent with the hypoth-
esis that NO production and its subsequent physiological responses through the sGC/cGMP/PKG
signaling pathway may therefore play an important role in regulating aqueous humour dynamics.
Although, currently the mechanism by which eNOS is activated within the conventional out-
flow pathway remains to be determined. Recent data suggests that human SC endothelial cells [11]
and porcine angular aqueous plexus cells (the porcine equivalent of SC cells) [135] are both capable
of shear-induced NO production. This presents the possibility that eNOS may be activated through
shear stress acting on the inner wall through circumferential flow within the SC lumen. Stamer et
al. [211] originally outlined the hypothesis that with IOP elevation, SC lumen collapses, which in turn
increases the shear stress acting on the inner wall as the same volumetric flow rate of the aqueous
humour must now flow through a smaller SC lumen. Shear-induced NO release by SC cells then
increases outflow facility to oppose the IOP elevation to restore IOP homeostasis. This homeo-
static mechanism functions as a mechano-regulatory feedback loop, whereas in glaucomatous eyes
this homeostatic mechanism may become impaired as reflected by the reduced NOS activity in the
conventional outflow pathway[158]. Alternatively, TM in normal eyes have been shown to increase
in stiffness with age, whilst in glaucomatous eyes the TM stiffness is increased further [39,40,133].
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Increased TM stiffness could effectively desensitise the mechano-regulatory feedback loop by be-
coming less compliant and thus reduces the amount of SC collapse with increasing IOP. This would
lead to decreased shear stress and lower NO levels that feeds back into the system. Furthermore,
decreased cellularity in the TM as observed in older patients[8,40], can also contribute towards ele-
vations in IOP, due to less TM cells responding to the shear-induced NO release by SC cells to help
regulate aqueous humour outflow.
Taken together, NO-based therapeutics proves to be a potential viable option to make an
impact on glaucoma patients, by reducing IOP through the above mentioned mechanisms. Although,
depending on where NO is released in the anterior chamber and conventional outflow pathway, that
would dictate the physiological effects. Therefore, NO must be released in close proximity to the
juxtacanalicular region and inner wall of SC, where endogenous eNOS regulation of outflow normally
occurs. Additionally, targeting the NO-regulatory machinery within the conventional outflow pathway
may also provide a promising therapeutic target for treating glaucoma.
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1.3 Motivation of Thesis
The central hypothesis of this thesis focusses on the concept of a dynamic endogenous
regulatory system or a "feedback loop" that regulates the conventional outflow resistance to main-
tain IOP homeostasis. The majority of the outflow resistance is generated by the JCT, basement
membrane and inner wall of SC, which are considered as the main "controller(s)" of the feedback
circuit (as shown in Figure 1.9). Alternatively, increased episcleral venous pressure and resistance
generated by downstream aqueous/episcleral veins could also contribute to the outflow resistance to
AH drainage[203]. As the outflow resistance of the conventional outflow tract increases, this leads to
elevations in IOP. It is known that elevations in IOP leads to the collapse of SC[73,120], which reduces
the cross-sectional area of the SC lumen. This effectively increases the shear stress experienced
by the SC endothelial cells, as the same volumetric flow rate of AH must flow through a smaller
SC lumen. The SC cells functions as a "barostat" or "sensor" within this endogenous feedback
loop by detecting IOP-induced changes in shear stress. Elevated shear stress has been shown
to up-regulate eNOS activity in vascular-derived endothelial cells and increase NO production[11].
Therefore, we hypothesize that NO produced by the SC cells act as a "local mediator", which feeds
back into the circuit to help modulate the outflow resistance and restore IOP homeostasis. In the
context of the endogenous regulatory system, NO acts in a similar fashion as other autocrine or
paracrine signaling molecules[210], by either retrograde diffusing upstream to relax the TM/JCT cells
and/or advection along the circumference of the canal to increase the permeability of the inner wall
endothelium, and possibly affecting the distal resistance of episcleral veins further downstream.
Controller
site(s) of outflow resistance 
Sensor
IOP-dependent mechanosensor
INPUT or 
DESIRED IOP
FEEDBACK or
ACTUAL IOP
OUTPUT or
REFERENCE IOP
error signal
Figure 1.9: Schematic of eNOS regulatory feedback in the conventional outflow tract.
The goals of this thesis are: (1) to investigate the role of NO and endogenous NOS activity
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in the conventional outflow pathway, and its effects on aqueous humour outflow regulation, (2) to
develop new methods of detecting NO production levels in vivo, and (3) to investigate whether up-
regulation of eNOS expression and activity at the inner wall of SC influences the segmental outflow
patterns in the TM by modulating the local outflow resistance. In order to achieve these goals, five
specific aims were formulated, which are addressed in separate chapters of this thesis.
1.4 Specific Aims
Specific Aim 1: To investigate the role of NO and endogenous NOS activity in the conventional
outflow pathway of mice. Our study utilizes ex vivo mouse eyes from both wild-type (C57BL/6) mice
and transgenic mice with elevated eNOS expression tagged with GFP (eNOS-GFPtg), to determine
how exogenous NO-donors (S-nitroso-N-acteylpenicillamine; SNAP) and NOS-inhibitors (NG-nitro-
L-arginine methyl ester; L-NAME, and Cavtratin) may influence conventional outflow regulation. We
hypothesize that exogenous NO delivered to mouse eyes will decrease outflow resistance and in-
crease outflow[62,65,111,211], whilst the use of NOS-inhibitors would investigate whether the endoge-
nous NOS activity in mice contributes to outflow regulation, and if altered NO signaling contributes to
decreased outflow and potentially outflow dysfunction in glaucoma. This specific aim is addressed
in Chapter 2: Role of Nitric Oxide in Murine Conventional Outflow Physiology.
Specific Aim 2: To develop a NO-sensitive biosensor that can detect local changes in NO production
in both in vitro and in situ models. NO is highly reactive, with a extremely short half life (<1 to 30
seconds[167]), thus the detection of this elusive signaling molecule can be highly challenging. Our
NO-sensitive biosensor consists of tyrosine-containing peptides derived from proteins that are prone
to nitration, a selective oxidative process that results in the post-translational modification of tyrosine
residues to form 3-nitrotyrosine[19,184]. The conversion of tyrosine into 3-nitrotyrosine serves as
a biological footprint for local changes in NO levels. This specific aim is addressed in Chapter
3: Peptide-Functionalized Nanoparticles for Localized Detection of Nitric Oxide via Peroxynitrite-
Mediated Nitration.
Specific Aim 3: To investigate whether local eNOS activity in the SC correlates with segmental
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outflow patterns in the conventional outflow pathway. Aqueous humour filtration through the conven-
tional outflow pathway is non-uniform or "segmental", but it remains unclear what regulates segmen-
tal outflow patterns[42,70,102,143]. We hypothesize that spatial variations in the expression of eNOS
within the SC cells may effect the segmental distribution of outflow in the TM. Fluorescent tracers
are perfused into ex vivo mouse eyes from transgenic mice expressing GFP driven by the human
eNOS promoter superimposed on the C57BL/6 background expression of eNOS (eNOS-GFP; re-
porter mice), to determine whether regions of high eNOS expression coincides with regions of high
tracer intensity. This specific aim is addressed in Chapter 4: Preferential Outflow in Relation to
Endogenous eNOS Activity in Murine Conventional Outflow Pathway.
Specific Aim 4: To investigate the relationship between SC morphology and segmental outflow pat-
terns. Aqueous humour filtration patterns are considered segmental, but it remains unclear whether
the segmental outflow patterns are governed by the ECM accumulation at the micro-scale, or if the
bulk flow preferentially drains towards regions of lower resistance at the macro-scale[42,70,102,143].
We hypothesize that aqueous humour filtration is a "multi-scale" problem, that multiple factors in-
fluence the segmental outflow patterns, including the post-trabecular drainage pathways and distal
resistance sites. To determine the relationship between downstream episcleral vessels and the
tracer distribution, we aim to develop an imaging technique that will enable the visualization of the
downstream limbal vasculature in relation to the tracer distribution over the entire circumference of
the eye. This specific aim is addressed in Chapter 5: Imaging of Segmental Outflow in Ex Vivo
Mouse Eyes by Optical Projection Tomography.
Specific Aim 5: To develop a localized NO-drug delivery that directly targets the conventional out-
flow pathway. Current NO-donating drug therapies have shown varied success in decreasing IOP
and enhancing outflow facility [62,66,193,197,233,236,245], caused by off target effects of NO release within
the anterior chamber of the eye. Therefore, to achieve full therapeutic effect, NO must be released
in close proximity to the JCT and inner wall of SC where the main sites of outflow resistance are situ-
ated. This specific aim is addressed in Chapter 6: Targeted Delivery of Nitric Oxide to the Trabecular
Outflow Pathway via Enzyme Loaded Nanoparticles.
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Chapter 2
Role of Nitric Oxide in Murine
Conventional Outflow Physiology
This chapter consists of a paper published in AJP:Cell Physiology, reproduced with permission from
American Physiological Society.
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2.1 Introduction
Elevated intraocular pressure (IOP) is a primary risk factor for glaucoma. All current glau-
coma therapies aim to lower IOP, but no current treatments directly target the conventional outflow
pathway that serves as the primary drainage route for aqueous humor. Because decreased outflow
facility is the root cause of elevated IOP in primary open-angle glaucoma[210], identifying drugs that
enhance conventional outflow may lead to new, more effective therapies for ocular hypertension and
primary open-angle glaucoma.
Experimental evidence supports the idea that the bulk of aqueous humor outflow resistance
is generated proximal to or at the endothelium of Schlemm’s canal (SC)[117]; however, the mecha-
nisms responsible for outflow regulation are not well understood. Recent data suggest that exoge-
nous nitric oxide (NO) delivered via NO donors decreases outflow resistance and IOP in several
species[24,62,65,111,158,191,211], but it is unclear whether endogenous NO production by NO synthase
(NOS) enzymes has a physiological role in regulation of aqueous humor outflow. NO is well known
to mediate various physiological functions, including vasodilation, junctional complex assembly, and
permeability, in vascular and lymphatic endothelial cells [57,175], and because SC is derived from vas-
cular endothelia [99,185] and expresses both vascular and lymphatic markers[12,126,169,185], we hypoth-
esize that NO release from SC cells contributes to physiological regulation of conventional outflow.
Consistent with this notion, the presence of NADPH-diaphorase, an indicator of NOS activity, has
been identified in the conventional outflow pathway of human donor eyes and suggests endoge-
nous NO production by NOS enzymes[158], and decreased NADPH-diaphorase labeling has been
reported in glaucomatous eyes[158]. Recent studies have demonstrated that SC cells in culture se-
crete NO in response to increasing shear stress[11,135], similar to vascular endothelial cells [44,45], and
the shear stress acting on SC cells in vivo during SC narrowing is predicted to approach the shear
experienced by endothelial cells in arteries[73]. Genome-wide association studies[121,141,174] have
linked polymorphisms in the NOS3 gene encoding the endothelial-specific isoform of NOS (eNOS),
in addition to mutations in the caveolin genes (CAV1 and CAV2) [223,238] to the pathogenesis of glau-
coma, whilst the overexpression of eNOS in a mouse model leads to decreased outflow resistance
and lower IOP[211]. Taken together, these data suggest that endogenous NO signaling within the
conventional outflow pathway by NOS enzymes contributes to outflow regulation and that alterations
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in NO signaling in part mediate outflow dysfunction in glaucoma.
In this work, we test the hypothesis that endogenous NO production by eNOS influences
conventional outflow facility in mice. Our studies use ex vivo mouse eyes, because the conven-
tional outflow pathway in mice is anatomically and functionally similar to that in humans[165,204] and
pharmacological modulation of outflow facility in mice resembles the responses previously reported
in human eyes[25]. To investigate the role of NO and NOS activity, we measured the effect of NO
donors and NOS inhibitors on outflow facility. Studies were performed in eyes from wild-type (WT)
mice and from transgenic mice with elevated eNOS expression.
2.2 Materials and Methods
All experiments were conducted in compliance with the Association for Research in Vision
and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research under UK
Home Office Project License approval for research at Imperial College London and under Institu-
tional Animal Care and Use Committee approval for research at Duke University.
2.2.1 Experimental Design
This study investigated the influence of exogenous NO and endogenous NOS activity on
conventional outflow facility in enucleated mouse eyes. Eyes were obtained from C57BL/6 WT
or transgenic mice that express the human variant of eNOS fused to GFP (eNOS-GFPtg) super-
imposed on the C57BL/6 background expression of eNOS[211,229]. To examine whether exogenous
NO influences outflow facility, eyes were perfused with the NO donor S-nitroso-N-acetylpenicillamine
(SNAP) or its inactive analog N-acetyl-D-penicillamine (NAP). Because SNAP is light-sensitive, the
NO release kinetics of SNAP and NAP were first characterized to identify an optimal lighting condi-
tion, which was controlled for all SNAP/NAP perfusion experiments. To examine whether endoge-
nous NOS activity contributes to regulation of outflow facility, eyes were perfused with or without a
broad-spectrum NOS inhibitor [NG-nitro-L-arginine methyl ester (L-NAME)] or an eNOS-selective in-
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hibitor (cavtratin, caveolin-1 scaffolding domain peptide). All experiments were performed using both
WT and eNOS-GFPtg eyes, with the exception of L-NAME perfusions, since we previously reported
that L-NAME decreases outflow facility in eNOS-GFPtg eyes to levels consistent with WT eyes[211].
2.2.2 Calibration of NO-donor
Because SNAP and NAP are light sensitive, NO release from SNAP and NAP was first
characterized using a NO-sensitive electrode (ISO-NOS II, WPI, Hertfordshire, UK), calibrated fol-
lowing the manufacturer’s instructions. Briefly, the NO probe was placed in a solution containing
0.1M H2SO4 and 0.1 M KI to polarize the sensor and obtain a baseline current. To determine the
standard curve, changes in current were measured in response to incremental volumes of 50 µM
KNO2 added to the H2SO4/KI solution within a glass vial. Conversion of KNO2 to NO occurs rapidly
and follows 1:1 stoichiometry, such that the NO concentration is dictated by the added concentration
of KNO2.
Once the standard curve was generated, we examined NO release from SNAP and NAP.
Preliminary data indicated that NO release from SNAP depended on the intensity and duration of
light exposure. Thus we tested NO release under two lighting conditions that could be controlled
during the perfusion: 1) initial high-intensity light (700 – 1,000 lumens/m2) exposure of the stock
solution (113 mM) for 10 min (measured with a luminometer; Mastech, GuangDong, China) followed
by low-light (100 – 200 lumens/m2) conditions, where the NO donor was diluted to the working
concentration (0.1 – 1 mM) and protected from surrounding laboratory light with aluminum foil, and 2)
initial high-intensity light (700 – 1,000 lumens/m2) exposure of the stock solution for 10 min followed
by continuous light exposure of the working solution at the same level (700 – 1,000 lumens/m2). NO
release was measured over 60 min starting immediately after the initial 10-min light exposure for
both conditions. Condition 1 was used for subsequent SNAP/NAP perfusions. Because conversion
of SNAP to NO is catalyzed by metal ions and is temperature-sensitive, all NO measurements were
performed in perfusion solution (containing divalent cations) at 37°C. The probe tip was immersed
in 10 ml of solution within a glass vial during continuous mixing with a magnetic stir bar.
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2.2.3 Animal Husbandry
This study used transgenic mice of the same C57BL/6 background strain as the WT controls.
Perfusions were performed with enucleated (ex vivo) eyes from mice of either sex. eNOS-GFPtg
mice were 8 – 13 wk of age (for SNAP/NAP and cavtratin perfusions). WT mice were 6 – 12 wk of
age (for SNAP/NAP perfusions) or 25 – 30 wk of age (for L-NAME and cavtratin perfusions). Mice
were housed in individually ventilated cages, fed ad libitum, and maintained at 21°C with a 12:12-h
light-dark cycle, with lights on from 6 AM to 6 PM.
Transgenic mice express the human gene variant of eNOS fused to green fluorescent protein
(GFP) on a C57BL/6 background. The transgene contains the full-length human eNOS promoter,
such that transgene expression is regulated by endogenous transcriptional activity and is superim-
posed on the background expression of murine eNOS[229]. In these animals, eNOS-GFP expres-
sion has been shown to be specific to endothelial tissues, to lead to a twofold increase in plasma
NO concentrations in large arteries[229], and to cause decreased aqueous humor outflow resistance
and reduced IOP compared with age-matched controls [211]. eNOS-GFPtg mice also have reduced
mean aortic pressure, reduced heart rate, and lower systemic vascular resistance[229]. Transgenic
mice were a kind gift from Prof. Rob Krams (Imperial College London, UK) and Prof. Rini de Crom
(Erasmus MC, Rotterdam, The Netherlands).
Genotyping of transgenic mice was performed to detect sequences of GFP and the human
variant of eNOS present in the genome of eNOS-GFPtg mice but absent from the genome of WT
mice. Genotyping was performed using ear tissue samples obtained at weaning, with tissue lysis
and DNA purification performed according to the manufacturer’s instructions (DNeasy Blood & Tis-
sue Kit, Qiagen, Hilden, Germany). Separate PCRs were performed using a hot-start mix (KAPA2G
Robust HotStart ReadyMix, Kapa Biosystems, Cambridge, MA). For human eNOS, 29 cycles were
performed with an annealing temperature of 63°C using sense primer AGGGCGCAATGGTAAC-
CTGAAGAT and antisense primer AAAGCTCTGGGTGCGTATGCGG to yield a predicted product
of 699 bp. These sequences are specific for the human eNOS and are not predicted to react
with C57BL/6 murine eNOS. For GFP, 29 cycles were performed with an annealing temperature of
59.9°C using sense primer AGCTGACCCTGAAGTTCATCTG and antisense primer GACGTTGTG-
GCTGTTGTAGTTG to yield a predicted product of 327 bp. PCR products were resolved by gel
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electrophoresis (1% agarose) in the presence of DNA gel stain (SYBR Safe, Invitrogen, Carlsbad,
CA). Bands were visualized on an imaging station (Biospectrum 500, UVP, Upland, CA).
2.2.4 Ex Vivo Mouse Eye Perfusion
The first set of experiments examined the effect of the NO donor (SNAP; Calbiochem) com-
pared with its inactive analog (NAP; Sigma) on outflow facility. Treated eyes were perfused with 100
µM SNAP in Dulbecco’s phosphate-buffered saline (PBS) including divalent cations and 5.5 mM
D-glucose (DBG) passed through a 0.2 µm filter. Contralateral control eyes were perfused with 100
µM NAP in DBG. Stock solutions of SNAP or NAP at 113 mM in dimethyl sulfoxide (DMSO) were
divided into aliquots and stored at – 20°C, with care taken to protect the solutions from light at all
times. Working solutions were prepared immediately prior to each experiment, with high-intensity
light exposure of the stock solution for 10 min followed by low ambient light exposure of the working
solution (see above) immediately prior to initiation of the perfusion. Eyes were perfused at sequential
pressure steps of 8, 15, 20, and 25 mmHg to determine outflow facility (see below).
In the second and third sets of experiments, we used a nonselective NOS inhibitor (L-NAME;
second set) or an eNOS-selective inhibitor (cavtratin; third set) to examine the effect of NOS in-
hibitors on conventional outflow facility. For L-NAME experiments, the treated eye was perfused with
10 or 100 µM L-NAME in DBG, while the contralateral control eye was perfused with DBG alone.
L-NAME perfusions were performed only in WT mice, because we previously reported the effects of
L-NAME in eNOS-GFPtg mice[211]. L-NAME solution was prepared from powder immediately prior
to each experiment. For cavtratin experiments, the treated eye was perfused with 50 µM cavtratin
in DBG containing 0.6% DMSO, while the contralateral vehicle control eye was perfused with DBG
containing 0.6% DMSO without cavtratin. Cavtratin is a chimeric peptide that contains a cellular in-
ternalization sequence antennapedia (AP) domain fused to the caveolin-1 scaffolding domain, which
binds to and inhibits eNOS. Cavtratin has been shown to enter murine vascular endothelial cells and
inhibit eNOS activity and NO production for up to 20 h in vivo and in vitro [34,95,190,196]. Based on
these data, we expect that cavtratin should inhibit eNOS within the trabecular outflow pathway of the
murine eye. Cavtratin experiments were performed in WT and eNOS-GFPtg mice, with the contralat-
eral control eye perfused with DBG alone. In a second set of cavtratin experiments, the contralateral
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eye was perfused with a scrambled cavtratin domain but an intact AP domain (cavtratin-X) at the
same concentration (50 µM). Cavtratin was stored as a stock solution (8 mM in DMSO) at – 20°C
and diluted to a working concentration immediately prior to each experiment, with care taken to pro-
tect the solutions from light at all times. Eyes were perfused at sequential pressure steps of 4, 8,
15, and 20 mmHg. These pressure steps differ from those used in the first experimental set: be-
cause, in the first set of experiments, we observed nonlinear pressure-flow behavior at the highest
(25 mmHg) pressure step, we therefore decreased the pressure range in the second and third sets
of experiments to minimize this nonlinearity.
The eyes were enucleated within 10 min of death by cervical dislocation and stored in PBS
(Invitrogen) at 4°C until perfusion, typically within 1 – 3h. Experiments used paired contralateral
eyes, except in the cases where data from one eye were rejected on the basis of the stability criterion
described below. Paired eyes were perfused sequentially (one eye immediately after enucleation,
the second eye 2 – 3 h after enucleation), with the treatment assigned randomly to the first or second
eye to control for any time-dependent postmortem changes. No differences in outflow facility were
observed between untreated controls perfused immediately and those perfused 2 – 3 h later (not
shown).
Our perfusion method follows previously described techniques[25,27,134,211]. The eye was
affixed to a support using cyanoacrylate glue to stabilize the eye for cannulation by a 33-gauge
beveled needle (NanoFil, World Precision Instruments, Hitchin, UK), with the tip positioned in the
anterior chamber using a micromanipulator (Figure 2.1A). Before cannulation, each needle was
backfilled from the tip with 200 µL of the perfusate, a volume sufficient to last several hours dur-
ing perfusion. The needle was connected via pressure tubing to a glass syringe (25 µL; Hamilton
GasTight, Reno, NV) mounted on a motorized syringe pump (PHD Ultra, Harvard Apparatus, Cam-
bridge, MA). Custom-written LabVIEW software (National Instruments, Austin, TX) was used to
control the syringe pump flow rate to maintain the eye at a user-defined perfusion pressure[164],
which was monitored by a pressure transducer (model 142PC01G, Honeywell, Columbus, OH) lo-
cated upstream of the cannulation needle. Eye temperature was maintained at 34 – 37°C, with the
eye kept hydrated by submersion to the limbus in PBS and the cornea covered with moist tissue
paper. Both the experimental and control eyes were pressurized from a reservoir at 8 mmHg for 45
min before initiation of the perfusion to allow sufficient time for the pressure to stabilize within the eye.
37
NJO
1F
SGV
TJP
O
1S
FT
TV
SF
	N
N
)H


'MPX3BUF	-N
JO

'MPX3BUF4/"1
'MPX3BUF/"1
1FSGVTJPO1SFTTVSF
A
B
F
Pp
Syringe Pump
Computer Controller
Pressure
Transducer
+ -
Atm
Micro-manipulator
Reservoir
33G Needle
Microscope
Temperature-controlled
Waterbath (not drawn to scale)
Enucleated
mouse eye
34-37°C
Figure 2.1: Perfusion system to measure outflow facility in enucleated ex vivo mouse eyes. (A) Computer-controlled
syringe pump controls the perfusion flow rate (F) into the mouse eye to maintain a user-defined perfusion pressure
(Pp), which is measured by a pressure transducer (see Equation 2.1). Mouse eye is held within an isotonic bath at 34-
37°C and cannulated by a 33 gauge needle that is positioned into the anterior chamber using a micromanipulator while
the preparation is viewed under a stereomicroscope. Perfusion is open to a reservoir set to 8 mmHg above the eye
during needle insertion and during the initial pressurization period, but the reservoir is closed during the perfusion. (B)
Representative perfusion tracings showing the perfusion pressure (blue line) and flow rate data from paired eyes perfused
with 100 µM N-acetyl-D-penicillamine (NAP; grey line) or 100 µM S-Nitroso-N-acetylpenicillamine (SNAP; black line). Red
highlighted regions represent data used to calculate the average flow rate at each corresponding pressure step. Spikes
represent rapid increases in flow rate to maintain the user-defined perfusion pressure. Only one perfusion pressure tracing
is shown, but pressure tracings are generally similar for both eyes.
Each pressure step during perfusion was maintained for 20 – 30 min, and the average stable
flow rate was calculated over 10 min near the end of each pressure step (Figure 2.1B). Data were
considered acceptable if a stable flow rate was achieved in at least three of the four pressure steps.
Conventional outflow facility (C) was estimated by fitting our pressure-flow rate data to the modified
Goldmann equation[134]:
F = C ⇤ P p + F u (2.1)
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where F represents the average stable flow rate at each perfusion pressure (Pp) and Fu
represents the apparent flow rate at zero pressure. Equation 2.1 is only valid when aqueous hu-
mor production and episcleral venous pressure are zero (appropriate for enucleated eyes), when F
reaches equilibrium at each value of Pp, and when C and Fu are independent of Pp. The value of C
is estimated as the slope of the best-fit linear regression to the measured F vs. Pp data. At the end
of the perfusion, eyes were fixed by immersion in 4% paraformaldehyde for 1 h followed by long-term
storage in 0.1% paraformaldehyde.
2.2.5 Immunofluorescence Microscopy
The expression and localization of eNOS-GFP in the conventional outflow pathway were
examined by immunofluorescence microscopy of eyes from eNOS-GFPtg and WT mice (n = 2 each).
After immersion fixation, eyes were opened at the cornea and infiltrated with 30% sucrose in PBS
and then with a 1:1 mixture of 30% sucrose solution and cryostat embedding compound (Tissue-
Tek OCT, Sakura-Finetek, Torrance, CA). The eyes were embedded in cryomolds (Sakura-Finetek),
frozen on dry ice, mounted in a cryostat (Microm HM 525, ThermoFisher Scientific, Waltham, MA),
and sagittally sectioned in steps of 16 µm. Cryosections were dried for 1 h at room temperature,
rehydrated in PBS, permeabilized in 0.2% Triton X-100 in PBS for 5 min, and blocked in 10% normal
goat serum in PBS for 30 min. The sections were incubated with antibodies raised in rabbit against
GFP[212] at a dilution of 1:500 in PBS for 2 h at room temperature and then with rat anti-mouse CD31
antibodies (clone mec13.3, BD Pharmingen, Mississauga, ON, Canada) at a dilution of 1:100 for 2
h at room temperature to label the endothelium of SC. The sections were then incubated with Alexa
555 goat anti-rat and Alexa 647 goat anti-rabbit secondary antibodies (Life Technologies, Burlington,
ON, Canada) diluted 1:200 in PBS at room temperature for 2 h. The sections were incubated with 5
µM SYTOX (Life Technologies) for 10 min at room temperature to label nuclei, mounted in Prolong
Gold fluorescent mounting medium (Life Technologies), and examined with a confocal microscope
(LSM 510, Zeiss, Jena, Germany).
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2.2.6 Statistical Analysis
Differences in outflow facility between treated and untreated eyes were examined with the lin-
ear mixed model using commercial statistical software (SPSS, IBM) following previous methods[27].
The linear mixed model accounts for correlated errors between paired eyes from individual mice,
while allowing for unpaired eyes that arise when the contralateral eye fails to meet the stability crite-
ria. Differences were considered statistically significant when the P value (estimating the probability
that the null hypothesis was true) was <0.05.
2.3 Results
2.3.1 Effects of Light on NO-Donors
The initial 10-min exposure of the stock solution at 700 – 1000 lumens/m2 triggered NO re-
lease from SNAP that increased over 1 h under ambient light conditions (Figure 2.2A). Continuous
light exposure at 700 – 1000 lumens/m2, however, led to an initial rise in NO followed by a decline
to zero within 1 h (Figure 2.2A). These data reveal that NO release by SNAP is light-dependent,
whereby the irradiation of the NO donor with light leads to the release of NO (typically between the
UV and visible light range)[75], but that prolonged light exposure can disrupt NO release kinetics. Im-
portantly, this suggests that lighting conditions must be carefully controlled during SNAP perfusion
experiments. Therefore, for all subsequent SNAP/NAP experiments, the SNAP-containing solutions
were exposed to 700 – 1000 lumens/m2 for 10 min prior to the perfusion, which was performed under
low ambient light. After this protocol, the concentration of NO released from 100 µM SNAP reached
140 ± 20 nM (mean ± SD; N = 3) at 1 h (Figure 2.2B). The NO concentration released from 100 µM
SNAP far exceeds the Michaelis concentration (KM = 23 nM)[46] for the reaction between NO and
soluble guanylate cyclase (sGC) and, thus, likely yields a saturating dose of NO. In contrast, 100
µM NAP released no detectable NO (0 ± 4 nM; N = 3) under otherwise identical conditions (Figure
2.2B). We also examined an alternative NO donor (100 µM diethylenetriamine-NO; DETA-NO), but
we found that NO release by DETA-NO was nearly threefold less than NO release by the same
concentration of SNAP (140 ± 20 nM vs. 49 ± 9 nM; data not shown) over 60 min.
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2.3.2 Effect of NO-Donors on Conventional Outflow Facility
To determine whether NO donors affect conventional outflow facility, we perfused paired
eyes from WT or eNOS-GFPtg mice with 100 µM SNAP or 100 µM NAP. In WT mice, SNAP in-
creased the flow rate at each perfusion pressure and increased conventional outflow facility by 62 ±
28% compared with NAP (0.051 ± 0.015 vs. 0.031 ± 0.010 µL/min/mmHg; N = 6 vs. 5; P=0.016;
Figure 2.3A). In eNOS-GFPtg mice, SNAP had no detectable effect on the flow rate (Figure 2.3B)
and there was no difference in conventional outflow facility between SNAP- and NAP-treated eyes
(0.019 ± 0.006 vs. 0.021 ± 0.005 µL/min/mmHg; N = 5 vs. 4; P = 0.40). Taken together, these
data reveal that a NO donor increases outflow facility in WT mice but has no detectable effect in
eNOS-GFPtg mice.
2.3.3 Effect of NOS-Inhibitors on Conventional Outflow Facility
To determine whether endogenous NOS activity contributes to the regulation of conventional
outflow facility, we perfused WT mice with L-NAME, a nonselective inhibitor of all NOS isoforms. At
10 µM, L-NAME reduced the flow rate at each perfusion pressure relative to vehicle-treated eyes
(Figure 2.4A) and decreased conventional outflow facility by 36 ± 13% (0.014 ± 0.002 vs. 0.021
± 0.007 µL/min/mmHg; N = 5 each, P=0.012). However, 100 µM L-NAME had no apparent effect
on the flow rate or conventional outflow facility (0.028 ± 0.007 vs. 0.024 ± 0.005 µL/min/mmHg; N
= 9 vs. 8; P=0.22; Figure 2.4B). These data reveal that L-NAME has a biphasic effect on outflow
facility in WT mice: a decrease in conventional outflow facility at lower concentrations but little effect
on conventional outflow facility at higher concentrations.
To investigate specifically the influence of eNOS, as opposed to other NOS isoforms, we
perfused eyes with cavtratin, an eNOS-selective inhibitor. Cavtratin at 50 µM decreased conven-
tional outflow facility in WT eyes by 19 ± 12% relative to vehicle-treated contralateral eyes (0.021 ±
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Figure 2.2: Characterization of NO concentration following release by SNAP or NAP under varying lighting conditions.
(A): NO release following initial high-intensity light (700 – 1000 lumens/m2) exposure of stock solution (113 mM) for 10
min followed by dilution to the working solution [1 mM in Dulbecco’s PBS including divalent cations and 5.5 mM D-glucose
(DBG)] and either low-intensity (100 – 200 lumens/m2 or prolonged high-intensity (700 – 1000 lumens/m2) light. Data are
from 1 experiment but are representative of 3 individual experiments. Time 0 corresponds to the end of the initial 10-min
period, during which SNAP stock solution was exposed to high-intensity light and after which NO release was measured
in the working solution by the probe. (B): NO release from 100 µM SNAP or 100 µM NAP in DBG (N = 3 each; bars are
SD). Each stock solution was treated with an initial 10-min exposure to high-intensity light (700-1000 lumens/m2) followed
by low-intensity light (100-200 lumens/m2) starting at time 0. NO was measured using an NO – sensitive probe (ISO-NOS
II). Data in B are representative of NO release during 100 µM SNAP/NAP perfusions.
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Figure 2.3: The effects of NO-donor on conventional outflow facility in eyes from wild-type (WT) and eNOS-GFPtg mice.
(A) Perfusion flow rate measured as a function of pressure in enucleated eyes from WT mice perfused with 100 µM SNAP
(NO-donor; filled circles) or 100 µM NAP (inactive analog; open circles). Outflow facility was estimated based on the
slope on the linear regression through the data points, as described by Equation 2.1. (B) Perfusion flow rate measured
as a function of pressure in enucleated eyes from eNOS-GFPtg mice perfused with 100 µM SNAP (filled circles) or 100
µM NAP (open circles). Bars represent SD. Note different vertical axis scales in panels A and B.
0.009 vs. 0.025 ± 0.012 µL/min/mmHg; N = 7 vs. 8; P=0.011; Figure 2.4C). In a separate set of ex-
periments, we compared the effects of cavtratin with the effects of a control peptide with a scrambled
cavtratin domain and an intact AP domain (cavtratin-X) and found a similar 25 ± 17% reduction in
conventional outflow facility (0.019 ± 0.008 vs. 0.014 ± 0.007 µL/min/mmHg; N = 9 each; P=0.026;
not shown). However, in eNOS-GFPtg mice, 50 µM cavtratin decreased conventional outflow fa-
cility by 39 ± 25% relative to vehicle-treated contralateral eyes (0.008 ± 0.004 vs. 0.014 ± 0.006
µL/min/mmHg; N = 7 vs. 5 each; P=0.014; Figure 2.4D). These data suggest that eNOS may be the
predominant isoform involved in aqueous humor outflow regulation, decreasing conventional outflow
facility in both WT and eNOS-GFPtg mice.
2.3.4 Localization of eNOS Transgene Expression within the Conventional Outflow
Pathway
To confirm and localize expression of the eNOS transgene within the conventional outflow
pathway, eyes from eNOS-GFPtg mice were enucleated and processed for immunofluorescence mi-
croscopy. The immunofluorescence signal from antibody complexes against GFP in eNOS-GFPtg
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Figure 2.4: (A,B) Perfusion flow rate measured as a function of pressure in WT eyes perfused with L-NAME (non-
selective NOS inhibitor; filled circles) at 10 µM (A) or 100 µM (B) in DBG versus DBG vehicle alone (open circles). (C,D)
Perfusion flow rate measured as a function of pressure in eyes perfused with 50 µM cavtratin (eNOS-selective inhibitor;
filled circles) versus vehicle control (DBG + 0.6% DMSO; open circles) from WT (C) or eNOS-GFPtg (D) mice. Outflow
facility is estimated based on the slope on the linear regression through the data points, as described by Equation 2.1.
Error bars represent SD.
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Figure 2.5: Localization of transgene expression in the conventional outflow pathway of eNOS-GFPtg mice. (A) Sagittal
section through the trabecular meshwork (TM) and Schlemm’s canal (asterisk) labeled with the endothelial marker CD31,
showing labeling of SC endothelium as well as blood vessels (arrowheads) in the ciliary body (CB) and sclera. (B) Indirect
immunofluorescence against GFP from the same section shown in panel A, revealing co-localization of the eNOS-GFP
transgene along the endothelium of SC and along blood vessels in the CB. (C) Merged color image showing labeling for
CD31 and GFP superimposed on the brightfield image to show the location of SC and TM with respect to the CB, iris
and sclera. Inset : lower magnification of the brightfield sagittal section showing the location of the outflow pathway with
respect to the iris and lens. Data are representative images from two eNOS-GFPtg mouse eyes.
mice colocalized with the endothelial marker CD31 within blood vessels of the iris and ciliary body,
confirming the endothelial-specific expression of the eNOS-GFP transgene and its promoter [229].
In the conventional outflow pathway (Figure 2.5), GFP immunofluoresence was restricted to the
endothelium of SC, collector channels, and episcleral vessels, which also expressed CD31[106]. In-
terestingly, there was no apparent GFP staining of the trabecular meshwork (TM), and GFP labeling
was entirely absent from WT mice, which lacked the eNOS-GFP transgene. No obvious differences
were observed in the morphology of SC and TM between eNOS-GFPtg and WT mice.
2.4 Discussion
Exogenously delivered NO typically decreases IOP by increasing outflow facility. The outflow
facility-increasing effect of various NO donors was first demonstrated in living monkeys[111,193] and,
subsequently, in living rabbits [129] and in eyes obtained postmortem from pigs[62,65] and humans[191].
The current study demonstrates that exogenous NO, delivered via SNAP, also increases outflow
facility in enucleated eyes from C57BL/6 mice. This suggests a common outflow facility response
to exogenous NO across several species that can be examined in mice as a model system that
resembles the functional anatomy[165] and pharmacology[25] of the human outflow pathway.
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Precisely how NO affects outflow facility and IOP remains unclear but likely involves mech-
anisms related to cellular contractility or endothelial permeability. NO is a free radical gas that can
rapidly diffuse across cell membranes to affect the biological activity of several proteins and en-
zymes. For instance, sGC mediates the vasodilatory effect of NO on smooth muscle cells in the
cardiovascular system, and sGC is necessary for the increase in outflow facility following exoge-
nous NO in ex vivo pig eyes[65]. Deficiencies in sGC signaling contribute to ocular hypertension
and glaucomatous optic neuropathy in mice[37]. Similarly, NO induces relaxation of TM cells [61] and
decreases TM[60] and SC[66] cell volume to potentially affect the dimensions of inner wall pores or
flow pathways in the juxtacanalicular tissue. Alternatively, NO mediates the disruption of adherens
junctions to increase permeability of vascular endothelia [44,57] and, thereby, may disrupt the ad-
herens junctions along the inner wall of SC[106] to increase outflow facility. Downstream of SC, NO
may induce relaxation of smooth muscle cells that surround the collector channels[54] to increase
intrascleral vessel diameter and, therefore, may influence post-trabecular or distal outflow resistance
downstream of SC[188].
NO also induces relaxation of the ciliary muscle[18,84,89,236]. However, as pointed out pre-
viously [193,236], ciliary muscle relaxation tends to decrease outflow facility and oppose the increase
in outflow facility putatively caused by TM/SC relaxation. This effect should be more pronounced in
primates[186,187,222] and mice[165], which have a ciliary muscle with more extensive tendinous con-
nections to the juxtacanalicular tissue and inner wall endothelium of SC than other species such
as pigs[13,150]. NO may also affect other aspects of aqueous humor dynamics; for example, NO
donors may decrease aqueous humor inflow[197], increase episcleral venous pressure[245], and af-
fect choroidal blood volume[125]. Thus there are numerous potential mechanisms by which NO may
affect aqueous humor dynamics, and, depending on the site of NO activity and the species being
examined, NO may either increase or decrease IOP. While the downstream mechanisms by which
NO regulates IOP are certainly important, the current study focused upstream on the role of NOS
enzymes and how production of endogenous NO may be involved in the physiological regulation of
outflow facility.
Endogenous NO is produced in vivo by a family of NOS enzymes encoded by three genes
and their splice variants, including the calcium-dependent eNOS and nNOS, which are constitu-
tively expressed in endothelial cells and nitrergic neurons, respectively, and the calcium-independent
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iNOS, which is expressed predominantly in macrophages. While Nathanson and McKee[158] argue,
based on immunohistochemistry, that eNOS is the primary NOS isoform in the human outflow path-
way, the TM is innervated by nitrergic nerve fibers, which contain nNOS in primate and porcine
eyes[149,195]. Macrophages are commonly found within the TM, particularly after laser trabeculo-
plasty[7], and express iNOS[239], which, when activated, yields greater quantities of NO than ei-
ther eNOS or nNOS[158,191,192]. Within the TM, the NOS expression profile, particularly for iNOS,
changes in response to IOP[192]. Downstream of the TM, nNOS-labeled nerve fibers and terminals
surround episcleral veins in mice[165] and arteriovenous anastomoses within the intrascleral vessel
network in primates[83]. eNOS itself, while expressed by SC inner wall cells, is also expressed by
the endothelium of the intrascleral collector channels and aqueous humor veins[211]. In primates,
the longitudinal ciliary muscle fibers are enriched in eNOS[158] and insert directly into the juxta-
canalicular region[186,187]. Thus all three NOS isoforms, and likely their splice variants, are present
throughout the trabecular, post-trabecular, and ciliary muscle regions, suggesting multiple locations
where NOS activity may influence outflow physiology.
To examine the physiological role of endogenous NO in aqueous humor dynamics, we per-
fused enucleated mouse eyes with inhibitors of NOS enzymes and measured conventional out-
flow facility. By examining enucleated eyes, one can measure outflow facility independently of NO-
mediated effects on inflow, episcleral venous pressure, or unconventional outflow, since such effects
are very likely eliminated in enucleated eyes and would otherwise confound measurements in vivo.
This assumes that the outflow facility is unaffected by postmortem changes and that the NO sig-
naling pathways are preserved ex vivo. In support of the ex vivo model, Millar and colleagues[151]
showed that the outflow facility measured in vivo is not significantly different from that measured
immediately after death in the same mice prior to enucleation. Furthermore, the pharmacological
outflow facility response measured in enucleated mouse eyes mimics the response previously ob-
served in enucleated human eyes to several receptor-mediated compounds, including sphingosine
1-phosphate[25,216], prostaglandin EP4 agonist [25,152], and pilocarpine[14,165].
In WT mice, nonselective inhibition of NOS enzymes by 10 µM L-NAME decreased outflow
facility, suggesting that there is a basal tone of endogenous NO involved in regulation of outflow
facility. However, no detectable facility decrease was observed in response to 100 µM L-NAME. It
is puzzling why higher concentrations of L-NAME had no detectable effect on outflow facility; one
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possibility is that differential NOS inhibition between different tissues of the outflow pathway may,
in some cases, exert opposing effects on outflow facility. For example, one may speculate that the
higher concentration of L-NAME is more available to the ciliary muscle, where NO-mediated ciliary
muscle relaxation may tend to oppose the increase in outflow facility caused by NO action within
the TM (see above). Alternatively, the data may reflect differences in the inhibition of different NOS
isoforms by L-NAME, which tends to be more selective for nNOS (IC50 = 0.15 µM) than eNOS (IC50
= 2.7 µM) or iNOS (IC50 = 14 µM)[224], and perhaps the locations or actions of the different isoforms
have opposing effects on outflow facility. L-NAME must also be converted to a free acid to become
bioactive[173], and the kinetics of this reaction may vary between the TM and ciliary muscle, which ex-
ert opposing effects on outflow facility. Alternatively, L-NAME may act as a muscarinic antagonist [36],
affecting the M2 and M3 receptors within the ciliary body and iris sphincter of humans[87,111]. If a
similar receptor profile is present in mice, then L-NAME could presumably act directly on muscarinic
receptors to modulate ciliary muscle contractility, which affects outflow facility in mice[136,165]. Apart
from NOS, NO itself exhibits a biphasic effect on TM cell contractility [61] and IOP[131,156]; thus the
response to L-NAME that we observed may reflect the underlying biphasic nature of the effect of
NO on outflow facility. Regardless of the underlying mechanism, the literature is inconsistent on
how L-NAME affects aqueous humor dynamics. For example, in living monkeys, L-NAME does not
appear to affect IOP[111]; yet in monkey anterior segment organ culture perfusion, L-NAME lowers
IOP by increasing outflow facility [191]. More studies are necessary to better understand how NOS
inhibition by L-NAME influences aqueous humor dynamics and, in particular, outflow facility.
Despite the potential role of other NOS isoforms, eNOS appears to be particularly impor-
tant for the physiological regulation of outflow facility. Stamer et al. [211] showed that elevated eNOS
expression in eNOS-GFPtg mice leads to reduced IOP and increased outflow facility. However,
our data suggest that exogenous NO does not increase outflow facility in eNOS-GFPtg mice, al-
though it significantly increases outflow facility in WT mice. This demonstrates that the outflow
facility-increasing effect of NO becomes saturated under conditions of elevated eNOS expression.
When eNOS expression was selectively inhibited by cavtratin, outflow facility was reduced in WT
and eNOS-GFPtg mice, with a twofold greater reduction in the transgenic mice, which have elevated
eNOS activity. Similarly, Stamer et al. reported a similar reduction in outflow facility in the eNOS-
GFPtg mice in response to L-NAME. This is consistent with the hypothesis that NO production by
eNOS contributes to the normal physiological regulation of outflow facility in mice. Disruption of nor-
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mal eNOS activity, as may occur in some cases of glaucoma[121,141,174], may therefore contribute to
the pathogenesis of ocular hypertension associated with the disease.
One limitation of this study was that the baseline outflow facility was consistently larger in
WT than eNOS-GFPtg mice. In contrast, Stamer et al. [211] reported a twofold-larger outflow facility
in eNOS-GFPtg mice than in their WT littermates. Two important differences may contribute to this
discrepancy between the present study and that of Stamer et al. 1) Perfusions in the current study
were done at physiological temperature, with the eyes submerged under isotonic saline, whereas
perfusions in the prior study were conducted with the eyes at room temperature and exposed to room
air. Environmental factors such as temperature and hydration likely influence the measurement of
outflow facility [27] and, thus, may have contributed to differences in baseline outflow facility between
the current study and prior studies. 2) The current study did not directly compare transgenic and
WT mice from the same litter. Instead, WT mice used in the current study, despite being from
the same background strain, were obtained from a separate colony, which may have exhibited a
baseline outflow facility different from that of the transgenic colony. For these reasons, the current
experiments were not designed to detect differences in baseline outflow facility between WT and
eNOS-GFPtg mice but, rather, to examine the effect of NO donors or NOS inhibitors between paired
eyes of a given cohort.
The mechanism by which eNOS regulates outflow facility remains to be determined. How-
ever, expression of the eNOS- GFP transgene in the conventional outflow pathway was localized to
the endothelium of SC and the intrascleral vessels, with no apparent expression within the TM. This
strongly suggests that NO release by endothelial cells within SC or intrascleral vessels influences
outflow facility. Furthermore, because NO production by eNOS is shear-sensitive[44,45] and because
the shear stress acting on the inner wall reaches levels known to activate eNOS in vascular endothe-
lia [73], it is possible that SC cells produce NO in response to circumferential flow within SC. In fact,
recent studies have demonstrated shear-induced NO production by human SC cells [11] and porcine
angular aqueous plexus cells (the porcine equivalent of SC cells) [135]. This presents the possibility
that eNOS may act as part of an endogenous feedback loop to regulate IOP and offset any poten-
tial changes in outflow resistance within the TM. According to this hypothesis, originally outlined by
Stamer et al. [211], IOP elevation causes collapse of SC, which increases the shear stress acting on
the inner wall, because the same volumetric flow rate of the aqueous humor must then flow through
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a smaller SC lumen. Shear-induced NO release by SC cells then increases outflow facility to oppose
the IOP elevation. One should note that this scenario requires that both the original outflow obstruc-
tion and the action of NO on outflow facility occur within the TM, and not downstream of the inner
wall of SC. The same mechanism could respond to reductions in IOP, reducing basal NO production,
which would tend to increase IOP. Such a mechanism may underlie IOP homeostasis and contribute
to the relative consistency of IOP, which lies within a surprisingly narrow range, despite decades of
life, in healthy individuals[50,127]. This homeostatic mechanism may become impaired in glaucoma-
tous eyes, in which NOS activity in the conventional outflow pathway appears to be reduced[158]. Our
findings predict that, in order for NO-based therapeutics to achieve optimal IOP reduction, NO must
be released in close proximity to the juxtacanalicular region and inner wall of SC, where endogenous
eNOS regulation of outflow normally occurs. NO donors that release NO in the anterior chamber,
for instance, may not achieve full therapeutic benefit, and NO release in other tissues, such as the
ciliary muscle or episcleral veins, may be counterproductive and potentially lead to elevations in IOP.
Thus, targeting the NO-regulatory machinery within the conventional outflow pathway may provide
a promising therapeutic target for treating glaucoma.
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2.5 Appendix A: Effects of NO-Donor on the Inner Wall Endothelium
of Schlemm’s Canal
To examine the effects of NO-donor on the hydraulic conductivity of SC endothelium, we pro-
cessed WT mouse eyes perfused with SNAP and NAP for electron microscopy to determine whether
exogenous NO affects the hydraulic condctivity of the inner wall by changing its morphology, pre-
dominately through the disassembly of cell-cell junctions[44,57,175] and potentially through increased
pore formation.
2.5.1 Methods: Histology and Ultramicroscopy
To visualize the morphology of the TM and SC, immersion-fixed, whole globes from NAP
and SNAP perfused WT mouse eyes (N=2 each) were hemisected proximal to the equator and
cut into quadrants. The samples were prepared for standard light microscopy and transmission
electron microscopy (TEM). Briefly, the globes were immersed in 2.5% paraformaldehyde, 2.5%
glutaraldehyde in Sörensen’s buffer, post-fixed in 1% osmium tetroxide, dehydrated, infiltrated, and
embedded in Epon-Araldite (EMS, Hatfield, PA). Half-micron thick sagittal sections were cut across
the outflow region, mounted on glass slides, and stained with toluidine blue. Sections were examined
and photographed using a Zeiss Axiovert microscope. Ultra-thin sagittal sections (70–90 nm) were
cut with a diamond knife, mounted on formvar-coated single-slot or copper mesh grids, stained with
uranyl acetate and lead citrate, examined and photographed with a Hitachi H-7000 transmission
electron microscope (Hitachi, Clarksburg, MD).
Additionally, specimens from NAP and SNAP perfused WT mouse eyes (N=2 each) were
also processed for scanning electron microscopy (SEM), following previously established proto-
cols [73]. Briefly, eyes were hemisected proximal to the equator and cut into quadrants, where each
quadrant was cut into wedges for microdissection to expose the inner wall endothelium of the SC.
The SC was incised along its posterior margin and opened such that the TM and adherent inner
wall of SC could be imaged. The samples were incubated in 2% (w/v) tannic acid, 2% (w/v) guani-
dine hydrochloride in PBS for two hours, followed by one hour in 1% (w/v) osmium tetroxide in PBS.
51
Between each solution change, the tissue was rinsed thoroughly in PBS. The tissue specimen was
then dehydrated through a graded ethanol series, followed by two changes in hexamethyldisilazane,
air-dried, mounted on stubs with carbon cement, and sputter-coated with gold. An overview mon-
tage, composed of several contiguous smaller image tiles, was acquired to show the entire inner
wall surface within the wedge at x1000 magnification by SEM (Hitachi S-3400N VP; Hitachi, USA).
2.5.2 Results and Discussion
We firstly examined the gross morphology of the inner wall endothelium of SC and TM with
light microscopy, where we found no obvious differences in morphology between the SNAP- and
NAP-treated WT mouse eyes (Figure 2.6). We then examined the sagittal sections with electron
microscopy to get a closer look at the JCT and inner wall section of the outflow pathway. From the
electron micrographs of SNAP- and NAP-treated eyes, we found that in the NAP-treated eyes there
were less giant vacuole formations observed when compared to SNAP-treated eyes (Figure 2.7).
Additionally, in the SNAP-treated eyes the giant vacuoles appeared to be larger in size. Interestingly,
when examining the inner wall endothelium of SC with scanning electron microscopy, we observed
regions of greater porosity in the SNAP-treated eyes compared to NAP-treated eyes (Figure 2.8).
These results suggest that exogenously delivered NO to the conventional outflow pathway not only
affects the contractility of TM cells [61,236,237], but may also affect the hydraulic conductivity of the
inner wall endothelium by regulating pore formation in SC cells.
Although we did not observe this increased porosity in all our samples, this could possibly
be attributed to segmental outflow that occurs within the conventional outflow pathway. For instance,
depending on where the NO donor gets delivered along the circumference of the SC, we may or may
not observe regions of increased porosity. Therefore, it still remains to be determined whether NO is
involved in the regulation of pore formation along the inner wall endothelium of SC. One possibility
is to use NO-donors in addition to fluorescent tracers to identify regions of high and low flow, which
has previously been shown to correlate with increased pore density in the SC endothelium[29] and
examine those regions to see whether NO has affected the morphology of the inner wall.
52
Figure 2.6: Light micrograph of the conventional outflow pathway of a WT mouse eye perfused with SNAP and NAP..
(A-B) Representative image of WT mouse eyes perfused with NAP (N=2). (C-D) Representative image of WT mouse
eyes perfused with SNAP (N=2). Arrowheads = Giant vacuoles.
Figure 2.7: Transmission electron micrograph of the inner wall endothelium of SC in WT mice treated with SNAP and NAP
(x5000 magnification). (Left) Representative image of WT mouse eyes perfused with NAP (N=2). (Right) Representative
image of WT mouse eyes perfused with SNAP (N=2). Arrowheads = Giant vacuoles.
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Chapter 3
Peptide-Functionalized Nanoparticles
for in Situ Detection of Nitric Oxide via
Peroxynitrite-Mediated Nitration
This chapter consists of a paper in preparation for submission to ACS Nano.
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3.1 Introduction
Nitric oxide (NO) is a diatomic free radical with important physiological roles across mul-
tiple biological systems. NO is capable of rapidly diffusing across cell membranes and between
cells, where it may act as a signaling molecule to modulate vascular homeostasis, [153–155,232] neu-
ronal activity [31,52] and immunological processes. [74] NO dysregulation has been linked to the patho-
genesis of Parkinson’s and Alzheimer’s disease, [10,86,207] cardiovascular disease, [38,96,171,240] glau-
coma,[43,174,191,192] and cancer. [95,137] The detection and quantification of NO is therefore important
for physiology and pathophysiology, but the reactive nature of NO and its typically short half-life
(order of seconds[31,74,154,155,167,232]), makes the measurement of NO challenging.
To measure NO within biological systems, researchers generally rely on indirect detection
methods to assess NO-derived products, such as nitrates, nitrites or post-translational modifications
of proteins that form nitrosothiols or 3-nitrotyrosines. The Griess assay is one of the most widely
used NO detection techniques, which measures the concentration of nitrite (NO2–) produced in bio-
logical fluids after the oxidation of NO. Although the Griess assay provides a useful indication for NO
production with a detection limit of ⇠0.5µM,[19,110,167,217] the assay is unable to resolve nanomolar
concentrations typical of NO-mediated signal transduction. For instance, the activation of soluble
guanylate cyclase (sGC) that produces cyclic guanosine monophosphate (cGMP) responsible for
maintaining vascular tone, requires a minimum NO concentration of 5 – 10 nM, with typical physi-
ological NO concentrations on the order of hundreds of nanomoles (100 – 500 nM). [56,86,167,207,213]
Other factors such as the type of buffer or presence of amino acids[47,112] can interfere with the
Griess reaction. Furthermore, measurement of NO within native tissues is technically challenging
due to limitations with accessibility and extraction of sample volumes. Hence, there is a need for a
NO biosensor that can resolve nanomolar concentrations of NO within biological systems in situ.
3-Nitrotyrosine has been identified as a "footprint" of NO-dependent nitroxidative stress. [19,182,208]
The process of tyrosine nitration is an oxidative post-translational modification, driven by NO-derived
oxidants, such as peroxynitrite (ONOO–; ONOOH) and nitrogen dioxide radical (•NO2), that yield 3-
nitrotyrosine. Under normal physiological conditions, low levels of 3-nitrotyrosine can be detected in
healthy tissues, which reflect basal steady state levels of nitration and oxidation that occur in vivo.
However, nitration end products increase several-fold once the formation of oxidants and NO are
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augmented (e.g. during inflammation). [174,182,191,192] This results in elevated levels of 3-nitrotyrosine,
which is commonly associated with multiple disease progressions in both human and animal mod-
els. [16,86,95,137,171,181]
Nitration of tyrosine residues is predominately mediated through the peroxynitrite-dependent
pathway, which incorporates a nitro (–NO2) group to the aromatic ring to form 3-nitrotyrosine. [184]
The formation of peroxynitrite is generated through a diffusion-limited reaction between NO and su-
peroxide (O2•–) radicals. Under physiological conditions, both peroxynitrite anion (ONOO–) and its
protonated form peroxynitrous acid (ONOOH) are present in biological systems, and can participate
in the oxidation of biomolecules. Peroxynitrite is a short-lived oxidant species that readily reacts with
carbon dioxide (CO2) that yields an intermediate adduct, nitroso-peroxocarboxylate (ONOOCO2•–),
which quickly homolyses into carbonate (CO3•–), and •NO2 radicals. Alternatively, peroxynitrous
acid (ONOOH) can undergo a similar homolytic fission to generate hydroxyl (•OH) and •NO2 rad-
icals. These one-electron oxidants promote the formation of a tyrosyl radical intermediate (Tyr•),
which then combines at diffusion-limited rates with •NO2 to yield 3-nitrotyrosine. [1,19,76,114,167,182–184,208,219]
Nitration of tyrosine residues can therefore serve as an indirect indicator for local NO levels. How-
ever, conversion of tyrosine to 3-nitrotyrosine under nitroxidative conditions is sensitive to local amino
acid sequence and selective for specific proteins in vivo. [9,15,115,171,189]
Several site-specific tyrosine residues from native proteins have been identified as preferen-
tial targets for nitration in vivo. [167,181] Multiple mechanistic studies have shown that the local primary
structure of peptides play a crucial role in determining site-specific nitration of tyrosine residues,
whereby proximal charged residues increase nitration yield whilst hydrophobic residues tend to
yield lower nitration through possible steric hindrance of bulky side groups. [1,63,64,128,178,194,240,243]
Therefore, by mimicking the amino acid sequence of nitration-prone sites within native proteins, we
have the opportunity to design and synthesize peptide-based biosensors that are sensitive to local
changes in NO production. In this study, we synthesized four tyrosine-containing peptides (P1-4)
and compared their relative sensitivity towards NO-derived oxidants. Three of the peptides were
derived from nitration-prone proteins, with two of these peptides (P1-2) from prostacyclin synthase
(PGI2 synthase) [63,159,171,189,206] and one peptide (P3) from manganese superoxide dismutase (Mn-
SOD). [1,15,219,240] Additionally, we designed a fourth peptide (P4) with multiple tyrosines flanked by
charged amino acids with the aim to amplify nitration. Incorporating adjacent charged amino acids
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such as glutamate (E) and arginine (R) has been shown to enhance the selective nitration of tyro-
sine residues in proteins. [1,63,64,115] As illustrated in Figure 3.1, each of the synthetic peptides were
covalently bound to fluorescent nanoparticles (NPs) such that the nitration reaction is confined to
the NP surface. In the presence of NO-derived oxidants, the tyrosine residues within the peptide be-
come nitrated resulting in the formation of 3-nitrotyrosine. The detection of 3-nitrotyrosine residues
were carried out by incubating the peptide-NPs with a commercially available monoclonal antibody
that is selective for 3-nitrotyrosine, followed by incubation with a secondary fluorescently-labeled
antibody. 3-Nitrotyrosine yields were assessed based on its immunofluorescence signal intensity
relative to fluorescence signal intensity of the NPs themselves. By combining the specificity of im-
munochemical techniques and exploiting the selective nitration process of tyrosine residues, we have
the opportunity to develop bio-inspired peptide-based NO sensors that can monitor local changes
in NO production whilst overcoming the limitations of the standard Griess assay. The goal of this
study was to demonstrate proof-of-concept that our peptide-NP biosensors are capable of detecting
peroxynitrite-mediated nitration in vitro as well as NO released from endothelial cells in response to
physiological levels of shear stress.
3.2 Materials and Reagents
FluoSpheres580/605 (carboxylated-nanoparticles, 500nm in diameter) were purchased from
Molecular Probes (Invitrogen). 9-Fluorenylmethoxycarbonyl (Fmoc)-protected amino acids, Rink
amide 4-Methylbenzhydrylamine (MBHA) resin, N,N-diisopropylethylamine (DIEA), 2-(1Hbenzotriazol-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), dichloromethane (DCM), dimethyl-
formamide (DMF), 80:20 dimethylformamide/ piperidine pre-mix, and spectroscopic grade acetoni-
trile (ACN) were purchased from AGTC Bioproducts, UK. Peroxynitrite and 3-nitrotyrosine were both
purchased from Cayman Chemical and stored at – 80°C and at room temperature, respectively.
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS)
and 2-(N-morpholino)ethanesulfonic acid (MES) were all obtained from ThermoFisher Scientific.
Mouse monoclonal anti-nitrotyrosine (clone 2A8.2; MAB5404) antibody was obtained from Merck
Millipore; goat anti-rabbit VE-Cadherin (XP® monoclonal #2500) antibody was obtained from Cell
Signaling; Alexa Fluor 488 goat anti-rabbit IgG secondary antibody was obtained from Life Tech-
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nologies Inc., and goat anti-mouse IgG secondary antibody (IRDye® 800CW) was obtained from
LI-COR Biosciences.
3.3 Methods
3.3.1 Peptide Synthesis
Four synthetic peptides (P1: EKKDFY421KDGKRL-CONH2; P2: GKRLKNY430SLP-CONH2;
P3: LHHSKHHAAY34VNNLNV-CONH2; and P4: GGREYYY-CONH2; Figure 3.6) were prepared ei-
ther by manual solid phase peptide synthesis (SPPS) or on a PTI Quartet peptide synthesizer using
standard Fmoc solid phase peptide synthesis chemistry [142] on a Rink-amide MBHA resin. Briefly,
Fmoc deprotection was performed with 20% piperidine in dimethylformamide (DMF) for 10 min, re-
peated twice. Amino acid couplings were carried out with (4 equivalents) Fmoc protected amino
acids, (3.75 equivalents) HBTU, and (6 equivalents) of DIEA in DMF for 1 to 2 h. The peptides were
cleaved from the resin and deprotected with 95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane
(TIS), and 2.5% distilled water (dH2O) for 4 hours. The TFA was removed using rotary evaporation,
and the peptide was precipitated and washed with cold diethyl ether. For purification, the peptide
was dissolved in a solution of 4.9% ACN in ultrapure water with either 0.1% TFA or NH4OH and pu-
rified using reverse-phase preparative high performance liquid chromatography (HPLC; Shimadzu)
running a mobile phase gradient of ultrapure water with 5% ACN to 100% ACN with 0.1% TFA or
NH4OH. The phenomenex C18 Gemini column was 150 x 21.2 mm and had a 5 µm pore size and
100 Å particle size. The HPLC fractions were checked for the correct mass using matrix-assisted
laser desorption spectroscopy (MALDI; Waters), and the pure peptide solution was rotary evapo-
rated to remove ACN and lyophilized on a freeze dryer (Labconco). After lyophilization, the purified
peptides were confirmed with analytical HPLC and MALDI (Supplemental Figure 3.6) then stored at
– 20°C until needed.
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3.3.2 Detection of Nitrated Peptides in Solution
Peptides were dissolved in phosphate buffered saline (PBS, pH 7.4) supplemented with 10%
dimethyl sulfoxide (DMSO) at stock concentration of (1 mM) then diluted to a working concentration
of 0.1 mM for the nitration experiments. For nitration experiments, each peptide were incubated
with peroxynitrite (0.5mM) for 1 hr at 37°C followed by UV-Vis spectrophotometry (Beckman Coulter
DU 800). Peroxynitrite was used as an intermediate NO-derived oxidant to simulate peroxynitrite-
mediated nitration. Peroxynitrite concentration was measured spectrophotometrically using ✏302 =
1670 M-1 cm-1 before each experiment. Sodium hydroxide (0.01M NaOH) was used as a vehicle
control, as peroxynitrite is supplied in NaOH to maintain its stability. Peroxynitrite and vehicle treated
peptides were both measured under basic conditions by raising the pH with NaOH to better distin-
guish the 3-nitrotyrosine peaks. 3-Nitrotyrosine has a characteristic spectral shift upon alkanization,
which is reflected by the secondary maximum shifting from 357nm to 430nm.[48,49]
3.3.3 Peptide-Nanoparticle Conjugates
The peptides were covalently bound to the carboxyl-functionalized nanoparticles (NPs) using
standard EDC/NHS chemistry, as illustrated in Figure 3.1. The nanoparticles were initially washed
with 0.1 M MES buffer (pH 4.7), followed by activation of surface carboxylic acids with EDC (⇠20
mM) and NHS (⇠50 mM) for 15 min before conjugation in MES buffer. Once the carboxyl groups
have been activated, the pH of the buffer was then raised from 4.7 to 7.4 using PBS to improve
coupling efficiency. Tyrosine-containing peptides (P1-4) were then conjugated to the NPs, each
peptide was conjugated to the NPs at 1mM final concentration in PBS and incubated overnight on
a temperature-controlled shaker at 1,000 rpm and 4°C (Thermomixer; Eppendorf). After incubation,
the peptide-NP complex was washed with PBS three times; the unbound peptides were removed
after each centrifugation step (10 min at 14,000 rpm). Finally, the peptide-NP complex was re-
suspended in PBS at 1% (v/v) stock solution.
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Figure 3.1: Schematic representation of peroxynitrite-induced nitration. (I) The fluorescent nanoparticle, (II) conjugation of
peptides with EDC/NHS cross-linker (P1-4), (III) non-nitrated peptides conjugated to surface of nanoparticles, (IV) nitration
of tyrosine through peroxynitrite-mediated pathway, (V) immunostaining of nitrated peptides with anti-nitrotyrosine IgGs
and fluorescent secondary IgGs. (Step I-III): Carboxyl-functionalized red fluorescent polystyrene nanoparticles (⇠ 500nm
in size) are coated with tyrosine-containing peptides (P1-P4, green strands). Step IV: Peroxynitrite-mediated nitration of
tyrosine residues resulting in the formation of 3-nitrotyrosine. Step V: Immunostaining of nitrated peptides with monoclonal
anti-nitrotyrosine IgGs (MAB5404; Millipore) and fluorophore conjugated secondary IgGs.
3.3.4 3-Nitrotyrosine Detection on Nanoparticle Complex
To induce nitration, each peptide-NP complex was incubated with varying concentrations of
peroxynitrite in a 96-well plate and incubated for 1 hr at 37°C, then followed by 3-nitrotyrosine de-
tection. Nanoparticles conjugated with 3-nitrotyrosine amino acids served as a positive control for
all immunoassay studies whilst NaOH (0.01M) treated peptide-NP complex were used as negative
vehicle controls. To determine the sensitivity of 3-nitrotyrosine conversion, peptide-NP complexes
were loaded on a nitrocellulose membrane with a Bio-Dot® microfiltration system using gravity flow
(Bio-Rad Laboratories, Inc.). After loading, the membranes were incubated in 5% nonfat dry milk in
Tris buffered saline containing 0.2% Tween-20 (TBS-T) which served as a blocking buffer. Nitrated
NPs were detected with a mouse monoclonal anti-nitrotyrosine antibody (1:500) diluted in blocking
buffer and incubated with membranes overnight at 4°C. Membranes were then washed with TBS-T (4
times; 10 min each) and incubated for 1 hr at room temperature in a goat anti-mouse IgG secondary
antibody (1:5,000) diluted in blocking buffer. This was followed by TBS-T wash (4 times; 10 min each)
prior to visualization. Immunoreactivity was visualized using an infrared imaging system (Odyssey®
CLx, LI-COR), where the 3-nitrotyrosine signals were detected at 778ex/794em, whereas the NPs
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were detected at 580ex/605em. 3-Nitrotyrosine antibody signal (Gi) was corrected for background
binding signal (Gb) obtained from the vehicle-treated peptide-NPs and then divided by the nanopar-
ticle fluorescence of each peptide-NP complex (Ri), this allowed for normalization of 3-nitrotyrosine
signal to concentration of NPs loading on the nitrocellulose membrane. The background fluores-
cence from the nanoparticles were negligible, and thus was not included in the correction for the
fluorescence signals. Each experimental reading was carried out in triplicates to minimize dot-to-dot
variations in loading, thus we obtain a normalized 3-nitrotyrosine antibody signal (G*) as represented
in Equation 3.1.
G* =
Gi  Gb
Ri
(3.1)
3.3.5 Cell Culture
Human umbilical vein endothelial cells (HUVEC-2; BD Biosciences, MA) were cultured in
Medium 199 (Invitrogen) supplemented with 15% fetal bovine serum (Premium select; Atlanta Bio-
logics), heparin sodium salt (90 µg/ml), endothelial mitogen (0.1 mg/ml; Biomedical Technologies,
MA), penicillin (100 U/ml), streptomycin (0.1 mg/ml), and glutamine (0.29 mg/ml) at 37°C and 5%
CO2. Cells from passages 3-7 were used for the shear stress experiments.
3.3.6 Shear Stress Experiments
HUVECs were seeded at confluence (1 x 105 cells/cm2) into µ-slides I0.6 (Ibidi, Munich, Ger-
many) and cultured overnight (⇠18-20 hours) in an incubator at 37°C with 5% CO2 to allow for cell
attachment. The µ-slides were then connected to the Ibidi pump system (Ibidi) and exposed to either
low (1.5 dynes/cm2) or high (15 dynes/cm2) shear stress for 24 hours. Low and high levels of shear
stress were chosen to help better distinguish shear-dependent NO release from the endothelial cells.
Cells exposed to the high shear were subjected to a gradual increase in shear stress levels over the
first hour (1.5, 5 to 15 dynes/cm2) to allow for adaptation to continuous laminar flow (following the
manufacturer’s protocol). Each µ-slide was loaded with 0.01% (v/v) of peptide-NP complexes in the
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media at the start of the shear experiment. After 24 hours of shear stress, the media was collected
and the peptide-NPs were pelleted (30 mins at 14,000 rpm). The supernatant was frozen at – 20°C
and used for quantifying nitrite concentration using the Griess assay. The peptide-NPs (in the pellet)
were washed and centrifuged in PBS for 10 mins at 14,000 rpm; this process was repeated three
times. The peptide-NPs were re-suspended in PBS for immunodetection of 3-nitrotyrosine by dot
blot.
3.3.7 Immunofluorescence Microscopy
Following each shear stress experiment cells were fixed with 4% paraformaldehyde (PFA)
in PBS at 4°C for 30 min. Cells were washed in PBS (3 times; 5 min each) then permeabilized
with 0.2% Triton X-100 in PBS for 15 min at room temperature and blocked with 10% goat serum
in PBS for 1 hr or overnight at 4°C. The cells were then incubated with an antibody raised in rabbit
against VE-cadherin at a dilution of 1:400 in blocking solution for 3 hours at room temperature,
followed by Alexa Fluor 488 goat anti-rabbit secondary antibody diluted 1:1000 in PBS for 1 hr.
Finally, nuclei were labeled by incubating the cells for 5 min at RT in 2 µg/mL DAPI in PBS and
mounted in ProLong® Diamond anti-fade reagent. Images were acquired using a Leica SP5 confocal
microscope with a 20x objective.
3.3.8 Statistical Analysis
To analyze our data, we performed a two-tailed Student’s t-test analysis to determine the
statistical differences between treatment groups. The statistical significance threshold was taken to
be a P value of 0.05. Results are expressed as mean ± 1-standard deviation (SD).
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3.4 Results and Discussion
3.4.1 Characterization of Unbound Peptides to Nitration
To characterize the sensitivity of unbound peptides to nitration, each peptide was solubi-
lized and treated with saturating levels of peroxynitrite (0.5 mM) in PBS for 1 hour at 37°C. 3-
Nitrotyrosine yields were measured at 430 nm using UV-Vis spectrophotometry (Figure 3.2). P1
(EKKDFYKDGKRL; derived from PGI2 synthase) was the most susceptible to peroxynitrite-mediated
nitration, exhibiting a 69-fold increase in 3-nitrotyrosine signal compared to vehicle-treated control
(0.231 ± 0.018 vs. 0.003 ± 0.001; N = 3; p = 0.002). P2 (GKRLKNYSLP; also derived from PGI2
synthase) showed a 52-fold increase in 3-nitrotyrosine signal compared to vehicle-treated control
(0.163 ± 0.006 vs. 0.003 ± 0.001; N = 3; p = 0.0006). P3 (LHHSKHHAAYVNNLNV; derived from
MnSOD) displayed a high background signal (see Supplementary Figure 3.7) and exhibited only a
5-fold increase in 3-nitrotyrosine signal compared to vehicle-treated control (0.104± 0.045 vs. 0.022
± 0.012; N = 3; p = 0.07). P4 (GGREYYY) containing three tyrosines yielded a 39-fold increase in
3-nitrotyrosine signal compared to vehicle-treated control (0.117 ± 0.003 vs. 0.003 ± 0.002; N = 3;
p = 0.0004). Additionally, we also examined the dose-dependent response of each peptide over a
range of peroxynitrite concentrations (10 – 500 µM) to determine their relative detection limits (Sup-
plementary Figure 3.7). Each peptide produced different levels of 3-nitrotyrosine signal in response
to peroxynitrite-mediated nitration, suggesting that nitration is a selective process that is sensitive
towards the local amino acid sequence.
Peptides P1 and P2, derived from PGI2 synthase, were the most susceptible towards peroxynitrite-
mediated nitration. The amino acid sequence of P1 consists of alternating acidic (E and D) and basic
(R and K) residues in close proximity to the hydrophobic residues (F and Y), whilst P2 consists of
mainly basic (R and K) and polar (N and S) residues adjacent to the target tyrosine. This may have
created a local hydrophilic environment around the tyrosine residue, increasing the exposure and
susceptibility of tyrosine residues to peroxynitrite-meditated nitration. In contrast, P3 derived from
MnSOD, consists of several hydrophobic residues (H, A and V) that may limit the accessibility of per-
oxynitrite to the target tyrosine residue, thus resulting in lower 3-nitrotyrosine yield. P4 was designed
with an acidic and basic residue proximal to three tyrosine residues to potentially amplify the tyro-
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sine nitration signal. Interestingly, this peptide was outperformed by P1 and P2 suggesting that the
nitration process is highly selective and sensitive towards the amino acid sequence, whilst the pres-
ence of additional tyrosines does not necessarily yield greater nitration. Additionally, the nitration of
tyrosine residues within native proteins are not only influenced by the local amino acid sequence,
but also the existence of secondary and tertiary structures. Most notably, the interaction between
peroxynitrite and metal- or heme prosthetic group binding sites, [181] which promote the formation of
secondary radicals that enhances peroxynitrite-mediated nitration. Therefore, the lack of secondary
and tertiary structures in our peptide biosensors could exhibit lower nitration yields, which may re-
flect our results shown in P3. Furthermore, the detection limit for peroxynitrite-mediated nitration
with UV-Vis was approximately 10 µM, which is not sensitive enough to measure basal physiological
concentrations around 100 nM.[19,167] Therefore, to overcome this detection limit we incorporated
immunochemical techniques specific towards 3-nitrotyrosine with our peptide-sensors to amplify the
detection of nitrated peptides.
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Figure 3.2: 3-Nitrotyrosine detection with UV-Vis spectrophotometry. (A) Representative spectra of 3-nitrotyrosine detec-
tion for each peptide. Peptides (P1-4; 0.1mM) were exposed to peroxynitrite (0.5mM) in phosphate buffer (pH 7.4) for 1 hr
at 37°C; nitration yields were determined with UV-Vis. The presence of 3-nitrotyrosine in P1 (solid black line), P2 (dashed
black line), P3 (dashed blue line) and P4 (solid blue line) was shown as an increase in absorbance at 430nm, where it was
compared to peroxynitrite alone (dashed red line). (B) Average 3-nitrotyrosine detection shown (black bars) compared to
vehicle controls (white bars). Error bars represent SD.
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3.4.2 Characterization of Peptide-NPs to Nitration
We conjugated the peptides to nanoparticles to confine and concentrate the peptide-sensors
for immunochemical detection (Figure 3.3A). 3-Nitrotyrosine signal was detected by immunofluo-
rescence using fluorescently-labeled antibody in a dot blot immunoassay. The sensitivity of each
peptide-NP complex towards peroxynitrite-mediated nitration was determined by generating dose-
response curves utilizing 0.01% (v/v) peptide-NP solutions treated with increasing concentrations
of peroxynitrite (500nM – 500µM; Figure3.3B). P2-NPs was found to be the most sensitive towards
nitration with an EC50 value of 8.4µM while P1, P3 and P4-NPs had EC50 values of 16, 35 and
91µM, respectively. We went on to determine whether the sensitivity of each peptide-NP complex
towards peroxynitrite changes with respect to peptide-NP concentration (0.0015% v/v – 0.025% v/v;
y-axis) over a greater range of peroxynitrite concentration (100 nM – 1 mM; x-axis), as shown in
Figure 3.3C.
To better illustrate the relative sensitivities of each peptide-NP complex, the averaged 3-
nitrotyrosine signal was presented in a pseudo-color-heatmap (N=3 per peptide-NP complex), as
shown in Figure 3.3D. From the heatmap generated, P2-NPs exhibited the most consistent dose-
dependent response with increasing peroxynitrite treatment that was independent of peptide-NP
concentrations, whilst the other peptide-NPs showed more variability in fluorescence signal as a
function of peptide-NP concentrations. When comparing the detection limits of these peptide-NP
complexes, P2-NPs had the greatest sensitivity towards the lower ranges of peroxynitrite treatment
achieving detection limits of ⇠100 nM, whilst P1-NPs showed more variability in its detection of sub-
micromolar levels of peroxynitrite. P3 and P4-NPs were both less sensitive towards peroxynitrite-
mediated nitration, especially at the micromolar range of peroxynitrite. Moreover, both P3 and P4-
NPs showed greater variability in its immunofluorescence signals compared to P1 and P2-NPs.
These results are consistent with the UV-Vis data, showing a similar trend in peptide sensitivity
towards peroxynitrite-mediated nitration, but with further enhanced detection sensitivity by 2-orders
of magnitude (from 10 µM down to 100 nM) for P1 and P2-NPs. Taken together, this suggests
that P1 and P2-NPs may be the better candidates for detecting low levels of NO-derived oxidants,
affirming the use of immunochemical detection methods to amplify the signal and detection limit of
our peptide-sensors platform.
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One limitation of the peptide-bound NPs is the potential loading differences on the surface
of the nanoparticles, which could be attributed to the individual peptide sequences. These potential
loading differences could reflect differences in detection sensitivity between peptide-NP complexes.
Hence, our platform focuses on the relative change in 3-nitrotyrosine signal of each peptide-NP
complex and it’s ability to detect different levels of peroxynitrite-mediated nitration.
3.4.3 Detection of Shear-Mediated Nitric Oxide Produced by HUVECs
To determine whether our peptide-NPs can detect NO production by living cells, we intro-
duced the peptide-NPs into the circulating media of an in vitro shear stress model lined with human
umbilical vein endothelial cells (HUVECs) whilst under different levels of shear stress over 24 hours
(Figure 3.4A). Endothelial cells are shear responsive, [88,221] exhibiting changes in cell morphology,
and increased NO production in response to shear stress. HUVECs were exposed to either low
(1.5 dynes/cm2) or high (15 dynes/cm2) physiological levels of shear stress. Cells exposed to low
shear did not align in the direction of flow or exhibit any obvious changes in cell morphology (Figure
3.4B). In contrast, cells exposed to high shear aligned in the direction of fluid flow after 24 hours,
changing their morphology from cobblestone-like to elongated spindle-shaped, as demonstrated by
immunolabeling for the endothelial cell-cell junctional protein VE-cadherin (Figure 3.4C).
To determine the level of NO produced by the cells, the flow-through media collected from
each individual experiment was centrifuged and separated into the following: (i) the supernatant,
which was used for the traditional Griess reaction assay and (ii) the peptide-NPs, which was used for
the 3-nitrotyrosine immunoassay (as shown in Figure 3.5A). The Griess assay served as a positive
control for NO detection, and a basis for comparison against our NO-detection platform. Results
showed that cells exposed to higher levels of shear stress (15 dynes/cm2) resulted in increased
levels of nitrite in the media when compared to the low shear condition (1.5 dynes/cm2) (1.82 ± 0.62
µM vs. 0.98 ± 0.33 µM; N = 24 vs. 22; P < 0.001) after 24 hours exhibiting a ⇠2-fold increase in
NO production (Figure 3.5C; left panel), consistent with previous findings. [11]
To compare the relative nitration yields for each peptide-NP complexes, the pelleted peptide-
NPs were dot-blotted and analyzed for 3-nitrotyrosine signals after 24 hours of low and high shear
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Figure 3.3: Representative immunoassay of peroxynitrite-induced nitration of nanoparticle-complex. (A) Schematic rep-
resentation of peptide-nanoparticle complex treated with peroxynitrite in a 96-well plate and incubated at 37°C for 1 hr,
followed by centrifugation/wash step (at 14,000 rpm for 10 min – x3) and dot blotted onto a nitrocellulose membrane.
(B) Dose-response curves of each peptide-nanoparticle complex as a function of increasing concentration of peroxynitrite
(500nM – 500µM). Peptide-nanoparticles were loaded at 0.01% v/v concentration (N=2). (C) Representative immunoarray
of 3-nitrotyrosine detection sensitivity as a function of concentration of peptide-nanoparticles or peroxynitrite. Nanoparticle
auto-fluorescence is shown in red; anti-nitrotyrosine immunofluorescence signal is shown in green; vehicle treated con-
trols: [sodium hydroxide (0.3 M NaOH; -ve); 3-nitrotyrosine-conjugated nanoparticles (+ve)]. Fluorescence was detected
with an two-channel infra-red scanner (Odyssey; Licor). (D) Averaged fluorescence intensity of 3-nitrotyrosine detection
as a function of peptide-nanoparticles concentration (y-axis; same concentrations as panel C) or peroxynitrite concentra-
tion (x-axis) presented in a heat map (N=3). Each dot blot fluorescence signal was normalized against the nanoparticles
auto-fluorescence to account for variations nanoparticle concentration. Normalized fluorescence intensity (G*) is shown
on a log-scale to show the sensitivity of the 3-nitrotyrosine antibody signal.
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Figure 3.4: HUVECs exposed to different levels of shear stress. HUVECs were sheared under low and high shear
stress for 24 hours with peptide-nanoparticles circulating in the culture media. HUVECs at low shear (1.5 dynes/cm2; left
panel) exhibited the characteristic cobblestone morphology, whilst HUVECs exposed to high shear (15 dynes/cm2; right
panel) showed elongated cell shapes aligned with the direction of flow. Cells were stained for nuclei (white) and junctional
proteins as an indication of cell monolayer confluency (VE-cadherin; green), which localized to cell borders. The arrow
indicates the direction of laminar flow applied to the cells.
stress (Figure 3.5B). Each of the peptide-NP complexes were able to detect NO production at both
low and high levels of shear stress. When comparing the averaged 3-nitrotyrosine signals (Figure
3.5C; right panel), P1-NPs had the highest fluorescence signals but also exhibited greater variability
in fluorescence signal between experimental samples, which resulted in a⇠3-fold increase in shear-
induced nitration when comparing the high shear to low shear condition (N=6 and N=5, respectively;
P<0.05). P2-NPs had the second highest fluorescence signals whilst exhibiting less variability be-
tween experimental samples, which resulted in the best signal-to-noise ratio with a ⇠5-fold increase
in 3-nitrotyrosine signal when comparing the high shear to low shear condition (N=6 and N=5, re-
spectively; P<10 5). These results are consistent with the nitration immunoassay previously shown
in Figure 3.3. P3 and P4-NPs had lower fluorescence signals but was still able to detect changes in
NO production when exposed to low and high shear stress. For the high shear condition, the aver-
age fluorescence intensities increased by ⇠4-fold for both P3 and P4-NPs (N=6 for each condition,
P<10 5 and P<0.05, respectively) when compared to low shear. Interestingly, from these results the
69
novel peptide (P4) designed with features that enhance nitration did not outperform the bio-inspired
peptides (P1, P2 and P3) in detecting NO-induced peroxynitrite nitration, suggesting that the nitra-
tion process is highly selective and sensitive towards the amino acid sequence and the presence of
additional tyrosines does not necessarily yield greater nitration.
The nitration of these peptide-NP complexes are governed by the peroxynitrite-mediated
pathway, which is generated through a diffusion-limited reaction between NO and O2•–. Elevated
shear stress is known to increase NO production by endothelial cells [88,221], but simultaneously, in-
creased shear stress could also lead to an increase in O2•– production in blood vessels with an
impaired endothelium[96]. Therefore, these peptides could potentially be detecting an increased
production of O2•– in addition to NO, although uncoupling the interaction between NO and O2•– re-
mains to be determined. Additionally, when comparing between high and low levels of shear stress,
increased flow rates at the high shear condition could also promote better mixing and detection of
NO compared to low shear conditions, which could potentially bias the detection of NO production.
In spite of these potential limitations, we demonstrated that our peptide-NP platform could detect
shear-induced NO production by HUVECs in culture, through the highly selective and specific nitra-
tion process, whilst also achieving greater dynamic range and sensitivity towards NO detection than
the traditional Griess assay.
3.5 Conclusions
In summary, we have demonstrated that our bio-inspired peptides can be utilized as po-
tential biosensors to detect low levels of NO in vitro by exploiting the highly selective nitration pro-
cess. Each of the peptide-sensors consists of specific amino acid sequences that promote nitra-
tion when exposed to NO-derived oxidants, which result in the detection of a stable by-product
– 3-nitrotyrosine. The relative sensitivities of each peptide-sensor was charaterized with UV–Vis,
achieving a detection limit of 10 µM for peroxynitrite-mediated nitration. This detection limit was fur-
ther enhanced by 2-orders of magnitude (from 10 µM to 100 nM) by conjugating the peptide-sensors
to fluorescent nanoparticles to concentrate the 3-nitrotyrosine signals for immunoassay detection.
Finally, we demonstrated that our peptide-NP complexes can successfully detect NO release from
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Figure 3.5: 3-Nitrotyrosine detection of cells under shear stress. (A) Schematic representation of HUVECs cultured under
low and high shear with the presence of circulating peptide-nanoparticle complex to detect NO production. Step 1: Cells
were seeded at confluency (1x105 cells/cm2) and allowed to acclimate overnight (18-24 hours). Step 2: Each µ-slide was
loaded with peptide-nanoparticle complex (at 0.01% v/v) at the start of the shear experiments. Step 3-4: After 24 hours of
shear stress, both media and nanoparticles were collected and pelleted. Step 5: Peptide-nanoparticles were washed and
analyzed for 3-nitrotyrosine formation (panel B). The collected media was stored for nitrite detection (by Griess assay).
(B) Representative dot blot immunoassay comparing the amount of 3-nitrotyrosine binding for each peptide-nanoparticle
complex (P1-4) under either low or high shear stress. For each peptide-nanoparticle complex six individual experiments
were conducted, each with triplicate measures per experimental condition. (C) Comparison of NO accumulation assays.
(Left) Griess reagent assay detection for nitrite concentration. Nitrite release (24 hours – accumulation) was assayed
from the supernatant of each sheared experiment. Data shows the averaged nitrite release from HUVECs between low
vs. high shear (N = 22 vs. 24; p<0.01). (Right) Averaged 3-nitrotyrosine signal for each peptide-nanoparticle complex
normalized against nanoparticles auto-fluorescence to account for loading differences. Data are expressed as mean±SD
for all shear experiments (N=6) except for P1 and P2-NPs at low shear with only N=5 each. Error bars represent SD.
endothelial cells in response to different levels of shear stress, exhibiting an increased sensitivity
towards changes in NO production (⇠5-fold increase in 3-nitrotyrosine signal; P2-NPs) over the tra-
ditional Griess assay (⇠2-fold increase in nitrite signal), where both detection assays provide an
integrated NO signal over the time course of the experiment. The development of this NO detec-
tion platform lends itself to a multitude of potential applications; for example, the NO-sensors may
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be introduced into the circulation to access specific tissues of interest to monitor NO activity in situ
(e.g. the progression of neurodegenerative diseases caused by NO dysregulation[86,114,207,243]);
the NPs may be functionalized to target specific tissues to detect "localized" NO production (e.g.
the localized detection of pressure-induced NO production in the trabecular outflow pathway in
the eye[42,100,102,211]); and potential cell-based/therapeutic screening of basal peroxynitrite levels
to monitor pro-nitroxidative stress in biological samples.
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Figure 3.6: Chemical structures, MALDI and analytical HPLC trace of the purified peptide sensors. (A) P1: EKKD-
FYKDGKRL (MW 1526). (B) P2: GKRLKNYSLP (MW 1175). (C) P3: LHHSKHHAAYVNNLNV (MW 1854). (D) P4:
GGREYYY (MW 906).
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Figure 3.7: Nitration sensitivity of synthetic tyrosine-containing peptides with UV-VIS spectrophotometry. (A-D) Peptides
(P1-4) sensitivity towards nitration as a function of increasing concentration of peroxynitrite treatment (10µM – 500µM;
black lines). 3-Nitrotyrosine absorbance is measured at 430nm under basic conditions (⇠pH 10). Red lines = vehicle
treated controls.
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3.7 Appendix A: Solid-phase peptide synthesis – (Fmoc)
The methods detailed in this section utilizes established protocols in solid-phase peptide
synthesis, we will be using an automated peptide synthesizer (Symphony Quartet, Protein Tech-
nologies, Inc) to create our desired peptide sequence by following the subsequent steps (illustrated
in Figure 3.9).
i. Preparing resin for amine-terminated peptides
Firstly, we start with a Rink amide MBHA resin (AGTC, UK) which has been functionalized with
a protected amine supported by a insoluble polystyrene bead via an acid-labile linker; the amine
group are protected by a temporarily base labile ↵-amino protecting group, Fmoc. In order to
obtain maximum binding between the desired amino acid and resin, we need to "swell" the resin
in dichloromethane (DCM) which exposes the amine binding sites on the resin by 3-5 fold. The
resin will then be agitated on a shaker for at least 30 minutes, before filtering off the DCM from
the peptide synthesis vessel leaving only the resin behind.
ii. Fmoc deprotection
In order to prepare for the amino acids (AA) to couple to the resin, we need to deprotect the
amine group attached to the resin, with 20% piperidine in dimethylformamide (DFM) solution.
This solution was added to the reaction vessel and left on the shaker for 5-10 minutes and then
drained; this Fmoc deprotection step was carried out twice to ensure all the protecting groups
are off and the amine group are exposed. Wash steps follow after, in the order of DMF wash
(2x), then DCM (2x).
iii. Amino acid coupling
Once the resin has been washed, we can then measure out 4x molar excess Fmoc amino acid
(in our case - tyrosine (Y)). Add 4: 3.95: 6 ratio of AA: HCTU1: DIPEA2, all of which are relative
to resin. For example, for 0.25 mmol resin, measure out 1 mmol of amino acid, 0.95 mmol of
HCTU, 1.5 mmol of DIPEA; hence we always want more amino acid than HCTU. Now we add
20mL of DMF to the amino acid coupling cocktail and vortexes throughly to completely mix and
dissolve all components. Leaving this mixture to incubate at room temperature for ⇠2-3 minutes
1HCTU=(2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate)
2DIPEA = N,N-Diisopropylethylamine
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to allow for the activation of the -COOH group. Note: The HCTU was used to activate the
carboxyl group of the Fmoc amino acid under basic conditions (hence the addition of DIPEA) to
react with the free amine on resin. Now the amino acid coupling cocktail are ready to be added
to the peptide reaction vessel, and placed on the shaker for ⇠1-2 hours or even left reacting
overnight. This was then followed by draining the synthesis vessel and wash steps were carried
out; DMF (3x) whilst agitating the resin followed by wash with DCM (2x).
iv. Cleaving the peptide from the resin
When cleaving the peptide off the resin, we need to make sure that we have removed the final
Fmoc on the last amino acid before cleaving. The cleaving solution consists of 95% Trifluo-
roacetic acid (TFA), 2.5% TIS, and 2.5% water by volume3. Now we fill the vessel ⇠ 1/2 full of
the cleavage solution, and place on the shaker for at least 2 hours but no more than 5 hours.
Once the cleavage is complete, we drain the vessel into a round bottom flask, whilst using DCM
to wash the resin and drain DCM into the flask. Now we can use the rotary evaporator (ro-
tavap) to remove the DCM and TFA off the sample leaving the peptide. This was then followed
by precipitating the peptide in cold diethyl ether and washed with ether, which helps recover
the peptide and also purifies out the protecting groups (which are soluble in ether). For ether
washes, we centrifuge the solution at 6500rpm at 4°C for 10 mins, wash steps were repeated
two extra times (with fresh cold ether). Once the peptide precipitate was washed, it was then
put in a vacuum desiccator overnight to remove the residual ether. This was then followed by
dissolving the peptide in milliQ water, freezer at -80°C and lyophilized on the freeze dryer and
stored at 20°C before purification.
v. Peptide evaluation
To evaluate the composition of our peptide synthesis, a preliminary (crude) mass spectral anal-
ysis was conducted to determine the molecular weight of the sample. This was then followed
by high-performance liquid chromatography (HPLC) to determine the purity of the sample, and
preparative HPLC were used to fragments of the desired peptide, filtering out the fragments that
are a by-product of the peptide synthesis. HPLC was done on a water/acetonitrile gradient under
acidic conditions (0.1% TFA). The collected fragments can then be pooled together and sent for
further mass spectral analysis and analytical HPLC to determine the final purity of the peptide.
3Note: this cleavage solution is designed for peptides without cysteine or tryptophan amino acids
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Chapter 4
Preferential Outflow in Relation to
Endogenous eNOS Activity in the
Murine Conventional Outflow Pathway
This chapter consists of a paper in preparation for submission to PLoS Biology.
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4.1 Introduction
Aqueous humor outflow regulation plays a central role in maintaining normal ocular function
and physiology. The balance between aqueous humor production and outflow determines intraoc-
ular pressure (IOP). Increased outflow resistance results in elevated IOP, a key contributor to the
pathogenesis of glaucoma.[210] The majority of outflow resistance is generated within close vicin-
ity of the inner wall endothelium of Schlemm’s canal (SC), its underlying basement membrane and
juxtacanalicular connective tissue (JCT) of the trabecular meshwork (TM)[117,166]. These resistance
sites are located in the iridocorneal angle, which encircles the anterior portion of the eye and serves
as regulators of aqueous humor drainage in the conventional outflow pathway. However, the mech-
anism(s) responsible for modulating these resistance sites are not well understood.
Aqueous humor filtration is non-uniform or "segmental" around the circumference of the out-
flow pathway, such that only a fraction of the trabecular meshwork is considered filtration-active at
any given instant. Previous studies have used tracers such as cationic ferritin [53,70,100] and fluo-
rescent nanoparticles[42,102,123,143,231], to decorate and identify preferential drainage routes in the
outflow pathway. These segmental filtration patterns are presumably associated with regional vari-
ations in local hydraulic conductivity1 and have been linked to variations in the extracellular matrix
(ECM) composition[122,123,218,231], pores in the SC[29] and/or the local architecture of the outflow tis-
sues[17,102,143,144,242]. It should be recognized that despite segmental outflow in healthy individuals,
IOP is maintained within a narrow range of pressures throughout their lifetime[50,127], suggesting
that a regulatory mechanism must be involved in maintaining IOP homeostasis. In contrast, in
glaucomatous eyes, the filtration-active regions of the meshwork appear to be further reduced in
comparison to normal human eyes[53], which further exacerbates the local hydraulic conductivity of
the outflow pathway contributing to elevated IOP[211]. Hence, understanding the mechanism(s) con-
trolling segmental outflow could contribute towards the development of more efficacious treatments
for glaucoma.
Recent studies have shown that nitric oxide (NO) increases aqueous humor outflow by de-
creasing outflow resistance and subsequently IOP in several species[24,62,65,111,158,191,211]. In partic-
1The hydraulic conductivity Lp is defined as the ratio of flow rate (Q) to the pressure drop ( P) across the resistive
barrier, normalised by the area (A) of the barrier. Hence, Lp = Q/ P ⇤A.
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ular, our previous study[43] showed that exogenous delivery of NO leads to increased outflow facility
in wild-type mice, whilst the pharmacological inhibition of endothelial NO synthase (eNOS) leads to
a decrease in outflow facility. Moreover, data indicates that in both human SC cells [11] and porcine
angular aqueous plexus cells (the porcine equivalent of SC cells) [135] are shear-sensitive, producing
NO in response to increasing shear stress, similar to vascular endothelial cells [44,45]. Interestingly,
the lumen of SC narrows as IOP increases, which effectively reduces the cross-sectional area of
the lumen[120] and increases the shear stress experienced by the SC cells, reaching levels known
to activate eNOS in vascular endothelia [58,73,91,201]. We hypothesize that eNOS plays a crucial reg-
ulatory role in maintaining IOP homeostasis, by modulating the local outflow resistance sites within
the TM in part through NO. Furthermore, genome-wide association studies[121,141,174] have linked
polymorphisms in the NOS3 gene that encodes eNOS to the pathogenesis of glaucoma. Consistent
with this notion, this homeostatic mechanism may become impaired in glaucomatous eyes, in which
NOS activity in the conventional outflow pathway appears to be reduced[157]. Taken together, these
data suggest that endogenous NO signaling within the conventional outflow pathway by eNOS may
be involved in physiological regulation of aqueous humor outflow. We therefore hypothesize that NO
release from SC cells contributes to the regulation of local hydraulic conductivity in the TM, and thus
may contribute towards changes in segmental outflow.
In this study, we investigate two hypotheses: 1) that spatial variations in eNOS expression
within the SC lumen correlates with the segmental filtration patterns in the TM, and 2) increases in
IOP results in the up-regulation of eNOS promoter expression and activity leading to increased NO
production in the conventional outflow pathway. To test these hypotheses, fluorescent nanoparticles
(tracers; NPs) functionalized with a NO-sensitive peptide sequence were perfused into enucleated
eNOS-GFP transgenic mouse eyes to label the outflow pathway. The spatial expression of eNOS-
GFP, tracer distribution and NO-detection with the biosensor in relation to perfusion pressure were
all visualized with flat-mount en face confocal microscopy.
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4.2 Materials and Methods
4.2.1 Experimental Design
This study investigated the relationship between endogenous eNOS expression within the
SC endothelium and the segmental outflow patterns in the TM, to determine whether these flow
patterns change in response to pressure in enucleated mouse eyes. Our studies use ex vivo mouse
eyes, because the conventional outflow pathway in mice is anatomically and functionally similar to
that in humans[26,165,204,205] and pharmacological modulation of outflow facility in mice resembles
the responses previously reported in human eyes[25]. Eyes were obtained from transgenic mice
expressing GFP driven by the human eNOS promoter (eNOS-GFP) superimposed on the C57BL/6
background expression of endogenous eNOS. This study is divided into three parts: (1) to examine
whether the spatial variations in eNOS expression in the SC relates to segmental outflow patterns
in the TM; (2) to investigate whether the spatial variations in eNOS expression are sensitive to
changes in pressure; and (3) to examine whether elevated IOP correlates to higher production of NO
in situ. To investigate these goals, mouse eyes were perfused with fluorescent NPs, which served
as tracers to decorate the flow patterns. Additionally, the nanoparticles were functionalised with a
peptide sequence sensitive towards NO-derived oxidants that drives the nitration process of tyrosine
residues, resulting in the formation of 3-nitrotyrosine (3-NT), which serves as an in situ sensor for
detecting local changes in NO production through immunochemical detection (ref. Chapter 3).
4.2.2 Animal Husbandry
All experiments were conducted in compliance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research under UK Home Office Project License approval for
research at Imperial College London. Perfusions were performed with enucleated (ex vivo) eyes
from mice of either gender. eNOS-GFP mice were aged 10 to 15 weeks. Mice were housed in
individually ventilated cages, fed ad libitum and maintained at 21°C with a 12-hour light (6 AM to 6
PM) and 12-hour dark cycle.
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Mouse Genotyping
Transgenic mice express the human gene variant of the eNOS promoter fused to green fluo-
rescent protein (GFP; as a reporter) on a C57BL/6 background. The transgene contains the human
eNOS promoter region only, such that transgene expression is regulated by endogenous transcrip-
tional activity but there is no over-production of nitric oxide. In these animals, GFP expression has
been shown to be specific to endothelial tissues, with no increase in endogenous NO-production.
Transgenic mice were a kind gift from Prof. Rob Krams (Imperial College London, UK) and Prof.
Rini de Crom (Erasmus MC, Rotterdam, The Netherlands). Genotyping of transgenic mice was per-
formed to detect sequences of GFP and the human variant of eNOS promoter present in the genome
of eNOS-GFP mice but are absent from the genome of WT mice. Genotyping was performed using
ear tissue samples obtained at weaning, with tissue lysis and DNA purification performed according
to manufacturer’s instructions (Kapa Express Extract; Kapa- Biosystems, Cambridge, MA). Sep-
arate PCR reactions were performed using a hot-start mix (KAPA2G Robust HotStartReadyMix;
Kapa- Biosystems, Cambridge, MA). For human eNOS promoter, 29 cycles were performed with
an annealing temperature of 59.3°C using the sense primer ACCAGGGCATCAAGCTCTTC and the
antisense primer TCTGTGATGTGGCACCAGAC to yield a predicted product of 500 bp. These se-
quences are specific for the human eNOS promoter and are not predicted to react with C57BL/6
murine eNOS. For GFP, 29 cycles were performed with an annealing temperature of 59.9°C using
the sense primer AGCTGACCCTGAAGTTCATCTG and the antisense primer GACGTTGTGGCT-
GTTGTAGTTG to yield a predicted product of 327 bp. PCR products were resolved by gel elec-
trophoresis (1% agarose) in the presence of DNA gel stain (SYBR Safe; Invitrogen, Carlsbad, CA).
Bands were visualized on an imaging station (Biospectrum 500; UVP, Upland, CA).
4.2.3 Peptide-Nanoparticle Synthesis and Conjugation
The peptide (GKRLKNYSLP) was synthesized using standard Fmoc solid phase peptide
synthesis chemistry on a Rink-amide MBHA resin, purified and confirmed with analytical HPLC and
MALDI, as previously described (ref. Chapter 3). The purified peptide was then conjugated to the
carboxyl-functionalised fluorescent NPs (200 nm) using standard EDC/NHS chemistry. Briefly, the
nanoparticles were washed with 0.1M 2-(N-morpholino) ethanesulfonic acid (MES, pH 4.7) buffer,
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followed by activating the surface carboxylic acids with 1-Ethyl-3-(3-dimethylaminopropyl) carbodi-
imide hydrochloride (EDC, ⇠20mM) and N-hydroxysuccinimide (NHS, ⇠50mM) for 15 min before
conjugation. Once the carboxyl groups have been activated, the pH of the buffer was raised from 4.7
to 7.4 with phosphate buffered saline (PBS, Invitrogen) to improve the coupling efficiency. The pep-
tide (at 1mM concentration) was then coupled to the NPs and incubated overnight on a temperature-
controlled shaker at 4°C (Thermomixer; Eppendorf). After incubation, the peptide-NP complex was
washed with PBS three times; the unbound peptides were removed after each centrifugation step
(10 min at 14,000 rpm). Finally, the peptide-NPs were re-suspended in PBS at 1% (v/v) stock solu-
tion. Prior to all perfusion experiments the peptide-NP containing solutions were sonicated to break
up aggregates.
4.2.4 Fabrication of Microfluidic Chip
The microfluidic chips were constructed from polydimethylsiloxane (PDMS) using standard
soft lithographic techniques. PDMS base and curing agent (Sylgard 184; Dow Corning, Wiesbaden,
Germany) were mixed in a 10:1 w/w ratio. This mixture was then degassed and poured over a SU8
master and cured overnight at 65°C. The PDMS layer was peeled off and inlet and outlet holes were
punched through. The device was treated with oxygen plasma for 30 seconds before sealing to a
glass microscope slide and cured overnight at 65°C.
4.2.5 Ex Vivo Mouse Eye Perfusion
To examine the relationship between the spatial distribution of eNOS expression in the SC
and the segmental outflow patterns in the TM, paired eyes were obtained from eNOS-GFP mice and
perfused with a fixed volume of peptide-NPs (6.5 µL; ⇠1x105 particles) to decorate the flow pat-
terns. Additionally, to determine whether changes in IOP will affect the spatial distribution of eNOS
expression, and thus in turn the segmental outflow patterns, the enucleated eyes were subjected to
either 8 or 16 mmHg of applied pressure. In enucleated mouse eyes both episcleral venous pressure
and aqueous humour production are reduced to zero, where typically episcleral venous pressure is
between 6–9 mmHg in vivo [26,203]. Therefore, we used 8 and 16 mmHg of applied pressure for our
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perfusions to simulate the pressure drop across the conventional outflow pathway resulting in a phys-
iological and elevated IOP of 16 and 24 mmHg, respectively. Hence, treated eyes were perfused at
elevated IOP (16 mmHg), while the contralateral control eyes were perfused at normal physiological
IOP (8 mmHg). The perfusate used for all mouse eye perfusions consisted of PBS including diva-
lent cations and 5.5mM D-glucose passed through 0.2 µm filter (referred to as "DBG"). The eyes
were enucleated within 10 minutes of death by cervical dislocation and stored in PBS at 4°C until
perfusion, typically within 15 min. Experiments used paired contralateral eyes, which were perfused
simultaneously on two identical iPerfusion systems[200], with the treatment assigned randomly to the
either the left or right eye.
Our perfusion method follows previously described techniques[25,27,43,134,211]. Briefly, eyes
were affixed to a support using cyanoacrylate glue to stabilize the eye and submerged in PBS
in a thermo-regulated bath at 35°C. A 33-gauge beveled needle (Nanofil; World Precision Instru-
ments, Europe; Hitchin, UK) was connected to a two-channel microfluidic chip, one channel filled
with peptide-NPs (NPs line; red) and the other channel filled with DBG perfusate (DBG line; black ).
The microfluidic chip allowed for the careful control and delivery of small volumes of perfusate (DBG
and peptide-NPs) to the eye. The eye was then cannulated with the tip of the needle positioned in
the anterior chamber using a micro-manipulator (Figure 4.1A). The pressure and flow rate inside the
eye were measured using a wet-wet differential pressure transducer (PX409, Omegadyne, US) and
a flow sensor (SLG64-0075, Sensirion, Switzerland), respectively. The flow sensor was also used to
monitor the volumes of each perfusate delivered to the eye. Each eye received three boluses of per-
fusate (6.5 µL each), consisting of (i) DBG, followed by (ii) peptide-NPs suspended in DBG and (iii)
DBG (shown in Figure 4.1B). The initial DBG bolus served as an acclimatisation step that allowed
the eye to stabilize at the applied pressure. The second bolus was the peptide-NPs, which served
as both a tracer and a biosensor for in situ NO-detection. The final DBG bolus was used to flush
the peptide-NPs circulating in the anterior chamber towards the meshwork. After each perfusion the
eyes were fixed in 4% paraformaldehyde (PFA) overnight at 4°C.
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Figure 4.1: Schematic representation of controlled delivery of perfusates via a microfluidic chip. (A) The mouse eye is
submerged in an isotonic bath at 35°C and is cannulated by a 33-gauge needle positioned into the anterior chamber using
a micromanipulator while viewing under a stereomicroscope. The needle is connected to an upstream microfluidic chip
with two-channels; (i) filled with DBG and (ii) filled with NPs. The three-way valves (1) and (2) controls which perfusate
is delivered to the eye. The flow rate (F ) and perfusion pressure (Pp) are measured by a flow sensor and pressure
transducer upstream of the cannulated eye. (B) Schematic representation of the protocol for delivering a bolus of known
concentrations of NPs to the eye. (i) The eye is pressurised from the reservoir at 8 or 16 mmHg with DBG, followed by
(ii) delivering a bolus of tracers (6.5µL at a concentration of ⇠1x105 nanoparticles), then (iii) flushing the eye with DBG to
allow the tracers to reach the meshwork.
4.2.6 Anterior Eye Cup Flat Mounting
After immersion fixation, the eyes went through a series of PBS washes then hemisected
just posterior to the limbus (see Figure 4.2). The lens and remaining retina were carefully removed
to obtain the anterior eye-cups. The iris and ciliary body were left in place due to its close tethering to
the trabecular outflow pathway[119,145,165], which if removed could damage and alter the segmental
outflow patterns. Once the anterior eye-cups were obtained, four centripetal cuts were made to
relax the eye-cup and facilitate flat mounting onto the slide. The anterior eye-cups were stored in
0.1%PFA until GFP-imaging and immunofluorescence was carried out.
86
dissection line
an
te
rio
r s
eg
m
en
t
po
st
er
io
r s
eg
m
en
t
lens
optic nerve head
retina
cornea
SC
TM
CC
Iris
PLV
CM
conventional outflow pathway
sagittal view
en face viewcentripetal cuts
A B
C
Schlemm’s canal lumen
Peptide-nanoparticle complex (200 nm)
Aqueous veins/ perilimbal veins
Figure 4.2: Schematic representation of flat-mount procedure to visualize segmental tracer distribution in the outflow
tract.(A) The eye is enucleated and the anterior eye cup is dissected away along the equator of the eye (red line). Next,
the lens are removed from the eye-cup leaving the iris and ciliary body intact. (B) Schematic representation of segmental
tracer distribution viewed sagittally, as presented in cyrosections. (C) For flat-mount confocal imaging, four centripetal
cuts were made to the anterior eye cups to relax the cup to facilitate mounting and image acquisition.
4.2.7 Immunofluorescence and Confocal Microscopy
Flat Mount Imaging
Anterior eye-cups were washed with 1x PBS multiple times after storage in 0.1% PFA. Each
eye was first imaged with confocal microscopy (to visualize the eNOS-GFP signal and the segmen-
tal outflow patterns of the peptide-NPs) then followed by immunofluorescence staining (to visualize
the 3-nitrotyrosine staining on the peptide-NPs) and re-imaged with confocal microscopy. The im-
munofluorescence staining was carried out after the first set of image acquisitions to account for
possible loss of tracers during antibody incubation and PBS washes. For the immunofluorescence
staining of 3-nitrotyrosine, the eye-cups were incubated in blocking buffer (10% goat serum and 1%
Triton X-100 in 1x PBS) overnight at 4°C to block nonspecific binding of antibody and permeabilize
the tissue. This was followed by an additional blocking step with unconjugated Fab fragment goat
87
anti-mouse IgG (20 µg/mL; Stratech, UK) in 1% Triton X-100 and 1x PBS overnight at 4°C. Once the
blocking steps were completed, the eye-cups were then incubated with goat anti-mouse monoclonal
3-nitrotyrosine antibody (1:100; MAB5404, Calbiochem) diluted in 200 µL of blocking buffer for 2
days, with rocking at 4°C. The eye-cups were washed three times over a 3-hour period with 1x PBS
containing 0.1% Tween-20. The antigen was then detected with Alexa 546 goat anti-mouse IgG2b
secondary antibody (1:500, Life Technologies) diluted in blocking buffer. The immunostained eye-
cups were washed three times over a 3-hour period with 1x PBS. Eye-cups were then flat-mounted
on slides in ProLong® Diamond anti-fade mounting media (Molecular Probes).
For confocal imaging, each eye was mounted with the cornea side down (facing the objec-
tive). The eNOS-GFP (Ex: 505 nm/ Em: 520 nm), 3-nitrotyrosine (560/575) and tracers (580/605)
were imaged en face using a Leica SP5 confocal microscope with a 10x/0.4 NA dry objective. Im-
ages were acquired with the sequential scan mode to minimize potential bleed over between the
3-nitrotyrosine and tracer channels. The ’Tile Scan’ mode was also used to automate collection
of images and stitched together to create a montage encompassing the entire eye. Images were
obtained as a z-stack starting from the external ocular surface of the corneoscleral shell (imaging
the perilimbal vessels; PLV) and stretching 50–80 µm deep into the TM (Figure 4.3). During the
acquisition of confocal images, each pair of eyes were imaged under the same confocal settings
allowing for paired image analysis.
Cryosection Imaging
The expression and localization of eNOS-GFP in the conventional outflow pathway was
examined by immunofluorescence microscopy of non-perfused eyes (N=2). Additionally, to confirm
the specificity of the anti-nitrotyrosine antibody to the surface of peptide-NPs, perfused eyes (N=2)
were also processed for sagittal cryosection imaging. Both set of eyes were immersion fixed in
4% PFA for 20 mins, followed by series of PBS washes then incubated in 20% sucrose in PBS
overnight at 4°C. This was followed by a 1:1 mixture of 20% sucrose solution and cryostat embedding
compound (Tissue-Tek OCT; Sakura-Finetek, Torrance, CA). The eyes were embedded in cryomolds
(Sakura-Finetek), frozen on dry ice, mounted in a cryostat (Cryostat OTF/AS; Bright Instrument Co
Ltd, Cambridgeshire, UK), and sagittally sectioned in steps of 7 µm. Cryosections were dried for
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1 hour at room temperature, rehydrated in PBS, permeabilized in 0.2% Triton X-100 in PBS for 5
minutes and blocked in 10% goat serum in PBS for 30 min in a humidifying chamber at 37°C. The
sections were incubated with goat anti-mouse 3-nitrotyrosine (1:100) or rat anti-mouse CD31 (1:100;
Clone MEC 13.3, BD Pharmingen) IgGs in blocking buffer for 1 hour in a humidifying chamber at
37°C. The sections were then detected with the appropriate species-specific secondary antibody
(either Alexa 546, or 594 at 1:500 dilution) in blocking buffer for 30 mins in a humidifying chamber at
37°C. PBS washes were carried out after each incubation step. The sections were then mounted in
anti-fade media and imaged with a 20x/0.7 NA multi-immersion objective.
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Figure 4.3: eNOS-GFP expression throughout the conventional outflow pathway visualized using flat-mount mouse eyes.
(A) Schematic drawing of conventional outflow pathway as imaged in the transverse plane. (B) Representative Z-stack
images identifying the eNOS-GFP expression is localized to the SC. (C) Individual confocal scans of eNOS-GFP expres-
sion imaged en face from the outer surface of the corneoscleral shell through to the TM. TM: trabecular meshwork, JCT:
juxtacanalicular connective tissue, SC: Schlemm’s canal, CC: collector channels, CB: ciliary body, DIVP: deep intrascleral
venous plexus, PLV: perilimbal veins. Scale bars, 500µm.
4.2.8 Colocalisation Analysis
For the colocalisation analysis, the confocal z-stacks were restricted to only include images
from the outer wall of SC inward towards the TM. This range encompasses both the spatial eNOS-
GFP expression throughout the SC lumen and the fluorescent NPs enmeshed in the outer layers
of the TM. Additionally, downstream perilimbal and aqueous veins were excluded from the confocal
z-stacks, as the fluorescence signals from the vessels may influence the fluorescence intensity
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values. Maximum projection images were then created from the confocal z-stacks and used for the
analysis (Figure 4.3C). To examine the spatial relationship between endogenous eNOS expression
in the SC and the tracer distribution in the TM, fluorescence intensities from the confocal z-stack
images were measured. Each eye was assigned 16 regions of interest (ROIs), with 160 ROIs per
treatment condition (eyes perfused at either 8 mmHg or 16 mmHg), and data from each ROI yielded
a single data-point for the colocalisation analysis between eNOS-GFP intensity and tracer intensity
(Figure 4.4). The ROI aspect ratio (200 µm x 200 µm) was chosen to allow for spatial variations
in tracer distribution in the TM whilst still capturing the eNOS-GFP expression in the SC lumen.
To maximize the range and provide sufficient leverage for the colocalisation analysis, ROIs were
typically chosen from regions with high or low eNOS-GFP intensity. Within each ROI both the eNOS-
GFP and tracer intensities were measured as the average pixel intensity over the entire ROI, as
outputted by FIJI (NIH, MD, USA). A linear regression analysis was then applied to the dataset using
MATLAB (v2014b, MathWorks, MA, USA) to determine whether there is any relationship between
eNOS-GFP expression in the SC lumen and tracer labeling enmeshed in the TM as a function of
IOP.
4.2.9 Image Processing
3-Nitrotyrosine Signal Analysis
The confocal z-stack images were separated into individual fluorescent channels; the 3-
nitrotyrosine and tracers channel. From this we created a maximum intensity projection of the tracers
channel for each individual eye, to identify regions of the outflow pathway occupied by tracers. This
maximum intensity projection image was then imported into a custom-built MATLAB graphical user
interface (GUI) script, that allows for the manual segmentation of the regions of interest. Each
eye was assigned 4 ROIs, where each ROI corresponds to an individual quadrant of the eye. The
selected ROIs were used as a ’mask’ for all subsequent image analysis to clearly separate the
background signal from the signal of interest. Masks were generated for each individual eye and
then applied to the raw confocal z-stack images for both tracer and 3-nitrotyrosine channels.
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Figure 4.4: Colocalisation analysis between tracer intensity and eNOS-GFP expression. (A)Maximum intensity projection
image of eNOS-GFP expression in the SC after isolating the perilimabl and aqueous veins. (B) Maximum intensity
projection image of tracers (NPs) throughout the TM and SC of the same stack of confocal images. Four 200µm x 200µm
ROI’s were applied to the image to determine the average fluorescence intensities of the eNOS-GFP and tracer channels
(white dashed boxes). Scale bar, 500µm.
Once the selected ROIs were applied to all the images in the z-stack, the fluorescence
signals were subjected to an ’Otsu-like’ thresholding algorithm to optimize the signal-to-noise ra-
tio. The ’Otsu-like’ thresholding algorithm calculates the pixel intensity threshold which minimizes
within-class variance and maximizes the between-class variance to eliminate the background signal
from the true signals of interest. This thresholding algorithm was applied to each layer of the z-stack
images, and based upon the distribution of pixel intensities from the 3-nitrotyrosine and tracer chan-
nels, a quantitative threshold value was generated for each individual eye. Fluorescence signals
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above the determined quantitative threshold values were then used for further signal analysis.
To account for potential variability in tracers delivered to each individual eyes, the fluores-
cence intensity of the 3-nitrotyrosine channel was normalized by the fluorescence intensity of the
tracer channel on a pixel-by-pixel basis, generating an array of fluorescence intensity ratios for each
layer of the z-stack images. Once all the layers have been processed, an integrated matrix for
each image was obtained by summing across the layers to produce an aggregated ratio of fluo-
rescence intensity for the i th pixel of the j th layer. All non-valid numbers (NaNs) and 0/0 divisions
were discarded from the normalization step. By processing the images layer-by-layer it eliminates
the possibility of over-saturation of fluorescence signal for a given x,y location that may mask the
signal of the same location in subsequent layers. The aggregated ratios were then averaged and
normalized by the number of elements of that ROI, giving a mean value of the normalized signal.
This normalization takes into account of the fluorescence intensity and ROI sampling variations be-
tween eyes, resulting in a non-parametric fluorescence intensity ratio for each eye that allow for
comparisons between eyes and treatment conditions. Once all the dataset has been analyzed and
processed into non-parametric fluorescence intensity ratios, we performed a paired eye analysis to
compare the fluorescence signals based upon treatment group, eyes perfused at 8 and 16 mmHg.
4.2.10 Statistical Analyses
In order to perform statistical analysis on the data acquired, we needed to first determine
the underlying probability distribution of the dataset. The Shapiro-Wilk test was used to determine
the normality of the dataset, where small p-values reject the null hypothesis that the data is normally
distributed. Both the eNOS-GFP and tracer intensities were better represented by a lognormal
distribution than a normal distribution (p=0.029 vs. p<10 6 and p=0.005 vs. p<10 6, respectively,
with the significance level defined at p < 0.01), therefore, in order to use standard statistical tools
such as paired Student’s t-test the data was log-transformed into the normal domain.
To determine whether there was a relationship between eNOS-GFP expression and tracer
intensity, a linear regression was applied to the dataset, whereby each ROI contributes to a single
data point in the regression analysis. However, due to possible variability in fluorescence intensity
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values that may arise from the dataset, the GFP and tracer intensity values were normalized to
eliminate the inter-pair variability, whilst preserving the intra-pair variability, as each pair of eyes were
imaged under the same confocal settings. This allows for all the ROI data points to be compared
on a single linear regression. For each pair of eyes, the raw fluorescence intensity values were
normalized according to F ⇤i,k = [Fi,k   µˆ(Fk)]/ ˆ(Fk), where F represents the raw fluorescence
value of either the GFP or tracer channel, the asterisks represent normalized values, the subscript
i and k refer to the ith ROI of the kth pair of eyes, and µˆ and  ˆ represent the estimated mean and
standard deviation of fluorescence values for all the i ROIs within the kth pair of eyes. Note that the
normalization of the raw fluorescence intensities expresses both GFP and tracer intensity in terms
of units of standard deviation. The linear regression analysis applied to the aggregate data assumes
that all the data points (160 ROIs per pressure condition) are from a single dataset, therefore leads
to an inflated statistically significant p-value. A two-tailed Student’s t-test was used to determine
whether the slope of the linear regression was significantly different from the null hypothesis of zero
slope, with significance defined at p < 0.05.
To overcome this, we computed the Spearman’s rank correlation coefficient (⇢) for the rela-
tionship between GFP and tracer intensity for each individual eye at each pressure condition (N=10
for eyes perfused at 8 and 16 mmHg). This assumes a monotonic relationship between the variables
and avoids the assumption of linearity. To find the average "individual-level" correlation, the Fisher r
to z transform[77], was applied to each individual correlation (this is required because the coefficient
is not normally distributed). The average z value was computed and the inverse transform was ap-
plied to get the average correlation coefficient. A two-tailed Student’s t-test was used to determine
statistical significance (p < 0.05).
Additionally, to quantify whether elevated IOP correlates with higher production of NO in
situ, we isolated the fluorescence intensities obtained from the 3-nitrotyrosine and tracer channels,
and normalized the signals to obtain a non-parametric fluorescence intensity ratio for each eye (as
previously described in "3-Nitrotyrosine Signal Analysis"). From the non-parametric fluorescence
intensity ratios we can then perform paired eye analyses to determine whether elevated IOP leads
to greater NO production when compared to physiological IOP. Student’s t-test was used to deter-
mine statistical significance between treatment conditions, with significance defined at p < 0.05. All
statistical analyses was performed using MATLAB.
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4.3 Results
4.3.1 Visualization of eNOS transgene expression within the conventional outflow
pathway
To confirm the localization of the eNOS transgene within the conventional outflow pathway,
eyes from eNOS-GFP mice were enucleated and processed for immunofluorescence microscopy. In
the conventional outflow pathway, the eNOS-GFP fluorescence signal was restricted to the endothe-
lial lining of the SC lumen, blood vessels of the ciliary body, collector channels and downstream
episcleral vessels, with no staining detected in the TM (Figure 4.5). The eNOS-GFP signal colo-
calized with the endothelial marker CD31, which has been previously identified in human SC[106],
confirming the endothelial-specific expression of the eNOS-GFP transgene.
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Figure 4.5: Localization of eNOS-GFP expression in the conventional outflow pathway of eNOS-GFP mice. (Left) Sagittal
section through the trabecular meshwork (TM) and Schlemm’s canal (asterisks) indicating that eNOS-GFP expression
is labeling the SC endothelium as well as blood vessels (arrowheads) in the ciliary body (CB) and sclera. (Middle)
Endothelial marker CD31 labeling the SC endothelium. (Right) Merged color image showing colocalisation of eNOS-GFP
and CD31. (Inset) Bright field image of the conventional outflow pathway. C: cornea, and CB: ciliary body. Data are
representative images from two eNOS-GFP mouse eyes. Scale bar, 100µm.
To visualize the spatial variations in eNOS-GFP expression in the conventional outflow path-
way, typically en face imaging is carried out by removing the ciliary body and iris to expose the outer
segments of TM and outflow pathway[165]. However, the ocular drainage structures in mouse eyes
are delicate and easily damaged, thus the removal of the ciliary body and iris to expose the TM for en
face imaging is technically challenging due to the close tethering between the TM and ciliary muscle
(CM)[119,145,165] and could also disrupt the tracer filtration patterns. Therefore, we have adapted the
flat-mount imaging procedure established by Kizhatil et al. [126] to visualize the tracer distribution pat-
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terns along with the eNOS-GFP expression around the circumference of the eye, whilst preserving
the structural integrity of the tissue. Flat-mount imaging of the eNOS-GFP expression was visual-
ized by imaging through the corneoscleral shell, from this imaging method we were able to visualize
the entirety of the conventional outflow pathway, which extended several hundred microns from the
external ocular surface to the iris root, as illustrated by the Z-depth color coding (Figure 4.6). The
superficial structures such as the perilimbal plexus and episcleral vessels were indicated by codes
blue to cyan, whilst the inner structures of the outflow pathway such as the SC lumen was shown as
codes pink to magenta (Figure 4.6B).
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Figure 4.6: Schlemm’s canal visualized via flat-mount imaging. (A) En face view of SC and limbal vessels. (Left)
Brightfield image of a flat-mount eye. SC and limbal vessels are located in the region of the limbus. (Middle) Localization
of the limbal vessels and the SC are visualized by the GFP fluorescence of the eNOS-GFP transgene in a Z-projection
of confocal stacks encompassing the entire whole mount. The whole-mount stacks were Z-depth color-coded (ICE LUT).
Color scale shows depth code colors of all structures expressing eNOS-GFP from inside the eye to the outer surface
of the corneoscleral shell. (Right) Overlay of brightfield and eNOS-GFP fluorescence image. (B) Higher magnification
showing the SC in relation to perilimbal vessels (PLV). The perilimbal vessels (cyan) are located closer to the external
ocular surface than the SC (magenta). CC: collector channel, CB: ciliary body. Scale bar, (A) 500µm, and (B) 100µm
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4.3.2 Relationship between eNOS-GFP expression and tracer intensity
To determine the relationship between eNOS-GFP and tracer intensity, we examined the
spatial variations in eNOS-GFP expression in the SC in relation to the segmental outflow patterns
in the TM via flat-mount confocal imaging. The GFP signal functions as a reporter for endoge-
nous eNOS expression (Figure 4.7A), whilst the tracers (200 nm) were used to label the preferential
drainage routes in the outflow tract. Confocal z-stack images were acquired to fully capture the tracer
signal throughout the entire outflow pathway from the TM/JCT towards the SC lumen and onto the
distal vasculature (Figure 4.7B). From these images, it was clear that aqueous humor outflow was
segmental, as illustrated by regions of high vs. low tracer labeling in the outflow pathway where
majority of the tracers were found enmeshed in the TM/JCT with little to no tracers observed down-
stream of the SC and in the distal vasculature. Hence, these tracer patterns can be considered as
representative active filtration regions in the outflow pathway. Local regions of high tracer decoration
varied in size from focal spots that were ⇠100 µm wide to broader regions that extended several
millimeters along the outflow pathway. Interestingly, the observed segmental filtration patterns in the
JCT tend to coincide with the spatial variations in eNOS-GFP expression in the SC (Figure 4.7D-F),
where regions of high eNOS-GFP expression reflected higher tracer decoration (arrowheads), and
regions of low eNOS-GFP expression had lower tracer decoration (asterisk ). Additionally, no ob-
vious correlations were observed between the tracer distribution and the post-trabecular perilimbal
plexus (Figure 4.7G-I).
To quantify the spatial relationship between eNOS-GFP expression within the SC and seg-
mental tracer distribution in the TM/JCT, we measured the fluorescence intensities within each indi-
vidual ROI for a given eye (16 ROIs per eye) subjected to either 8 or 16 mmHg. A linear regression
analysis was then applied to the aggregate data which includes all 320 ROIs from 10 paired eyes, of
which 160 ROIs were taken from eyes at each pressure condition. From the linear regression anal-
ysis, positive correlations were observed between GFP and tracer intensity when considering eyes
perfused at both 8 and 16 mmHg, both achieving statistically significant correlations (R2 = 0.272,
p<10 6 and R2 = 0.071, p<10 4, respectively; Figure 4.8A). As the linear regression analysis as-
sumes that all the data points are independent, statistical significance is inflated. The Spearman’s
rank correlation coefficient (⇢) for each individual eye were computed and averaged to obtain the
relationship between GFP and tracer intensity for each pressure condition (N=10 for eyes perfused
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Figure 4.7: Representative whole mount confocal imaging of eye perfused at 8 mmHg to visualize the relationship be-
tween segmental tracer distribution in the TM and spatial variation of eNOS-GFP expression in the SC. (A) En face view
of eNOS-GFP expression for the conventional outflow pathway. (B) En face view of segmental tracer distribution in the
eye. (C) Merged color image showing the relationship between segmental tracer distribution and eNOS-GFP expression
in the conventional outflow pathway. (D-F) Regional variations of eNOS-GFP expression (D) and tracer distribution (E)
in the JCT/SC region. (F) Overlay of eNOS-GFP expression and tracer distribution in the JCT/SC region. Regions of
high tracer accumulation in the TM/JCT (arrowheads) tend to colocalize with regions of higher eNOS-GFP expression in
the SC, whilst low tracer accumulation tends to colocalize with regions of lower eNOS-GFP expression (asterisks). (G-I)
Isolated superificial perilimbal plexus and episcleral veins (G) in relation to segmental tracer distribution (H). (I) Overlay of
perilimbal vessels with segmental tracer distribution. Dotted lines outline the area occupied by the SC lumen. Scale bar,
500µm.
at 8 and 16 mmHg). These results also showed a positive correlation between GFP and tracer inten-
sity for eyes perfused at 8 or 16 mmHg, both of which achieved statistically significant correlations
(⇢ = 0.451, p=0.003 and ⇢ = 0.299, p=0.049, respectively; Table 4.1).
To determine whether elevated pressure has an effect on GFP intensity and tracer intensity,
we averaged the fluorescence intensities per eye and carried out a Student’s t-test on the paired eye
data. When considering the effect of pressure on tracer intensity for all the eyes, the averaged tracer
intensity at 16 mmHg (2.906 ± 0.413; mean ± SD; N=10) was greater than the averaged tracer
intensity at 8 mmHg (2.092 ± 0.448; N=10), resulting in a statistically significant increase in tracer
accumulation at the higher pressure (p = 0.003; Figure 4.8B). However, when considering the effect
of pressure on GFP intensity for all the eyes, no statistical significance was detected between 8 and
16 mmHg (31.492 ± 6.480 vs. 30.658 ± 7.800; N=10; p = 0.559). Taken together, these results
show that increased GFP intensity correlates with increased tracer intensity in the TM, suggesting
that regions of higher eNOS expression within the SC lumen coincides with regions of higher outflow
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in the TM. However, the correlation between GFP intensity and tracer intensity was not affected by
changes in IOP. The lack of a detectable increase in GFP intensity in response to increased IOP,
may be due to time dependent effects of maturation and accumulation of GFP and may not reflect
the true changes in eNOS expression. Furthermore, it still remains to be determined whether higher
eNOS expression in the SC is an effect of increased shear stress within the SC lumen or increased
outflow is caused by regional variations of eNOS activity and NO production, as the two factors are
interlinked and is difficult to discern.
However, Increased IOP led to higher local tracer accumulation within the TM, suggesting a
pressure-dependent mechanism that may be responsible for increased aqueous humor outflow. The
increased outflow could potentially be attributed to an increase in hydrodynamic shear stress, as a
result of the collapse of SC lumen at elevated IOP. SC endothelial cells have previously been shown
to produce NO, presumably through the up-regulation of eNOS expression and activity, in response
to elevated shear stress in vitro [11,135], which could potentially lead to increased local hydraulic con-
ductivity in the outflow pathway. Therefore, to confirm the increased eNOS activity within the outflow
pathway in response to increased IOP, we went on to quantify spatial changes in NO production with
NO-sensitive peptide-sensors coupled to the surface of the tracers.
Table 4.1: Summary of the correlations between GFP intensity and tracer intensity.
Aggregate data (All ROIs) Individual eye data (n=10) Paired eye data (n=10)
Pressure (mmHg) Linear Regression Analysis Correlation Analysis
p-value R2 Slope p-value Avg. Spearman’s rank (⇢) Avg. Tracer Intensity Avg. GFP Intensity
8 < 10 6 0.272 + 0.003 0.451 2.092 ± 0.448 31.492 ± 6.480
16 < 10 4 0.071 + 0.049 0.299 2.906 ± 0.413 30.658 ± 7.800
p = 0.003 p = 0.559
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Figure 4.8: Relationship between eNOS-GFP expression and tracer intensity. Both GFP and tracer intensity have been
normalized to allow for linear regression analysis. (A) Normalized tracer intensity plotted against normalized eNOS-GFP
intensity for all 320 ROIs obtained from all the eyes separated by pressure conditions (black circles = 8 mmHg; red
circles = 16 mmHg). Solid black line = linear regression for eyes perfused at 8 mmHg (160 ROIs). Solid red line = linear
regression for eyes perfused at 16 mmHg (160 ROIs). Shaded region represents the 95% confidence bounds on the linear
regression. (*) denotes normalized fluorescence intensities. (B) Modified boxplot of the averaged tracer intensity for each
individual eye as a function of applied pressure. Solid black line indicates the 95% confidence interval of eyes perfused at
each pressure. Solid red line represents the mean tracer intensity. Dashed black lines represents ± 1-standard deviation.
4.3.3 Effect of elevated IOP on NO production in situ
To examine local NO production in the conventional outflow tract we utilized a NO-sensitive
peptide. When exposed to endogenous levels of NO-derived oxidants, tyrosine residues in the NO-
sensitive peptide become nitrated thus forming a detectable end-product – 3-nitrotyrosine. These
NO-sensitive peptide-sensors have previously been shown to detect shear-induced NO production
in HUVECs in culture (as shown in Chapter 3). Here we utilize these probes to examine the effect
of IOP on NO production in the conventional outflow tract.
In order to detect localized NO production in situ, perfused eyes were sagittally cryosec-
tioned and then detected immunochemically with a monoclonal antibody that is selective for 3-
nitrotyrosine, followed by incubation with a secondary fluorescently-labeled antibody. We then pro-
ceeded to determine if increased IOP results in elevated NO production by analyzing 3-nitrotyrosine
levels in paired eyes perfused at 8 and 16 mmHg (physiological and elevated IOP, respectively). The
fluorescence signals from the 3-nitrotyrosine staining and NP tracer channels were isolated from
the flat-mount confocal z-stack images and processed to obtain a non-parametric fluorescence in-
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tensity ratio for each individual eye (3-NT/tracer intensity ratio; as described in the Methods). The
3-NT/tracer intensity ratio provides a comparative measure of the level of NO detected in situ by
the NO-biosensors in the conventional outflow pathway. This also allows for paired eye analysis of
the dataset to determine whether elevated IOP results in the increased NO production, presumably
through the up-regulation of eNOS expression and activity.
The majority of the peptide-NPs were found enmeshed in the TM/JCT region which is lo-
cated adjacent to the inner wall endothelium of SC within the conventional outflow pathway corre-
lating with the fluorescence from the NP tracers (Figure 4.9). Minimal non-specific ↵-3-nitrotyrosine
signal was observed in the surrounding tissues of the conventional outflow pathway. This suggests
that NO production was localized to the tissues residing in the JCT and inner wall of SC endothelium.
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Figure 4.9: Localized detection of NO-mediated nitration in the conventional outflow pathway. (A) Sagittal section through
the trabecular meshwork (TM) and Schlemm’s canal (asterisks) indicating that eNOS-GFP expression is labeling the SC
endothelium as well as blood vessels (arrowheads) in the ciliary body (CB), iris, choroid and sclera. (B) Fluorescent
tracers (NP tracers) enmeshed in the TM labeling filtration-active regions of the outflow pathway. (C) Localized detection
of NO-mediated nitration of peptide-conjugated nanoparticles enmeshed in the outflow pathway. The nitration of the
peptide-sensors results in the formation of 3-nitrotyrosine, which was detected with anti-nitrotyrosine IgGs and fluorescent
secondary IgGs. (D) Merged color image showing colocalisation of 3-nitrotyrosine detection and tracers, indicating the
antibody detection was specific for the nitrated peptide-sensor and is located only on the surface of the nanoparticles with
minimal non-specific binding. Data are representative images from two eNOS-GFP mouse eyes. Scale bar, 50µm.
For each individual pair of eyes, we detected higher NO production at 16 mmHg compared
to 8 mmHg. This relationship holds true for all pairs, despite the variability in levels of NO detected
between individual animals (N=10; Figure 4.10A). When considering the averaged 3-NT/tracer in-
tensity ratio between the pressure conditions, the averaged 3-NT/tracer intensity ratio at 16 mmHg
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was ⇠3-fold greater than the averaged 3-NT/tracer intensity ratio at 8 mmHg (0.173 ± 0.110 vs.
0.055 ± 0.044; N=10 each; P=0.006; Figure 4.10B). Furthermore, the distribution of the data was
generated for each pressure condition, which considers all the 3-NT/tracer intensity ratios across all
the eyes in the dataset. From the population distribution, we detected higher amounts of 3-NT/tracer
intensity ratios at 16 mmHg compared to 8 mmHg, as shown by the shift in distribution of the data
towards the higher values of 3-NT/tracer intensity ratios (red tracing; Figure 4.10C). Interestingly,
when comparing the 3-NT/tracer intensity ratios between the two pressures, the data seem to fol-
low a similar distribution for the lower values of 3-NT/tracer intensity ratios, but as the 3-NT/tracer
intensity ratio increases the distribution of the 16 mmHg dramatically increases (dotted black line),
resulting in more counts of 3-NT/tracer intensity ratios detected. Taken together, these results show
that a basal NO tone is present at physiological IOP and that elevated IOP results increased NO
production in the JCT/SC.
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Figure 4.10: Comparison of 3-nitrotyrosine detection in the conventional outflow pathway as a function of IOP. (A) Paired
eye comparison of 3-nitrotyrosine (3-NT) detection. The 3-nitrotyrosine signal was normalized by the tracer signal to
obtain a non-parametric ratio of 3-NT/tracer intensity detected per eye. Each data point corresponds to an individual eye
perfused at 8 or 16 mmHg (black circles and red circles, respectively). The 3-NT/tracer intensity ratio for each pair of eyes
are compared and shown in ascending order from lowest to highest fluorescence intensity detected for eyes perfused
at 16 mmHg. (B) Modified boxplot of the normalized 3-NT/tracer intensity ratio for each individual eye as a function of
applied pressure. Solid black line indicates the 95% confidence interval of eyes perfused at each pressure. Solid red line
represents the mean 3-nitrotyrosine/tracer ratio. Dashed black lines represents ± 1-standard deviation. (C) Distribution
of the normalized 3-NT/tracer intensity ratios for all the eyes perfused at either 8 or 16 mmHg. For each given eye, the
3-NT/tracer intensity ratios were normalized by the area of the ROI to account for differences in ROI selection between
eyes. Note that the 3-NT/tracer intensity ratios are presented on a log-scale.
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4.4 Discussion
In this study, we demonstrated that in enucleated eNOS-GFP mouse eyes, perfused with
fluorescent tracers, regions of higher tracer labeling in the TM coincided with regions of higher
eNOS-GFP expression in the SC. This suggests that segmental tracer distribution may be partially
regulated by the endogenous eNOS activity within the SC. Furthermore, the fluorescent tracers were
functionalised with a NO-sensitive peptide that can detect local changes in NO production within the
conventional outflow pathway in situ. We showed that these NO-biosensors were capable of detect-
ing NO production at physiological IOP, suggesting a basal NO tone is present. We further showed
that NO production within the conventional outflow pathway was pressure-dependent, resulting in a
3-fold increase in NO production at elevated IOP. To our knowledge this is the first demonstration
that endogenous NO production increases in response to elevated IOP, where NO acts as a local
mediator of outflow resistance within a mechano-regulatory system, which influences segmental
outflow distribution within the conventional outflow pathway.
According to this pressure-dependent mechano-regulatory system, originally outlined by
Stamer et al. [211], increases in IOP leads to the expansion of the JCT and pushes the inner wall
endothelium into the SC lumen, leading to the collapse of SC lumen. [73,120,136] This effectively re-
duces the cross-sectional area and increases the circumferential flow rate within the canal, leading
to increased shear stress experienced by the SC endothelial cells, as the same volumetric flow rate
of AH must flow through a smaller SC lumen. Interestingly, these shear levels approaches theoreti-
cal wall shear stresses that are comparable to those experienced by the arterial system[73] that are
known to up-regulate eNOS expression[51] and activity [58,91]. Increased eNOS activity consequently
leads to an increase in NO production, which can act as an autocrine/paracrine signaling molecule
to restore IOP homeostasis by modulating the local outflow resistance sites predominately involving
mechanisms related to cellular contractility or endothelial permeability. NO is widely known to dif-
fuse across cell membranes to affect the biological activity of several proteins and enzymes in the
outflow tract. Most notably, the activation of sGC/cGMP/PKG signaling pathway, responsible for the
relaxation of TM cells [61] and the decrease in TM[60] and SC[66] cell volume through activation of
BKCa channels. Alternatively, NO could also mediate the endothelial permeability of the inner wall of
SC by disrupting the adherens junctions[44,57] to potentially affect the dimensions of inner wall pores
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and/or flow pathways in the JCT. Downstream of SC, NO may induce relaxation of smooth muscle
cells that surround the collector channels[54] to increase intrascleral vessel diameter and therefore,
may influence post-trabecular or distal outflow resistance downstream of SC[188].
Our results show that regions of higher eNOS-GFP expression in the SC lumen coincides
with regions of higher tracer labeling in the TM, suggesting the spatial variations in eNOS-GFP ex-
pression may be partially responsible for the segmental tracer distribution within the outflow pathway.
Furthermore, at elevated IOP, higher tracer labeling was detected in the TM compared to physiolog-
ical IOP, showing a pressure-dependent increase in aqueous humour outflow. As elevated IOP
causes the collapse of the SC lumen, the increased outflow is likely associated with NO-mediated
effects resulting from the up-regulation of eNOS expression and activity in response to elevated
shear within the SC lumen. However, the lack of a detectable increase in GFP intensity in response
to elevated IOP could potentially be due to time dependent effects of maturation and accumulation
of GFP. Previous studies have shown that the maturation time for GFP fluorescence can take up to
⇠2-4 h post-protein expression[4,104,105], hence the GFP fluorescence may not be sensitive towards
changes in IOP for the given experimental time (⇠4.5 and 2 h for eyes perfused at 8 and 16 mmHg,
respectively; Supplementary Table 4.2). However, shear-induced eNOSmRNA expression has been
shown to increase after 1 h of shear stress in bovine aortic endothelial cells (BAECs)[51]. Therefore,
the lack of detectable changes in GFP intensity does not necessarily reflect the true endogenous
eNOS expression and activity in response to pressure-induced shear stress within the SC lumen.
We proceeded to further investigate whether increases in IOP leads to increased eNOS ac-
tivity through the detection of NO production within the conventional outflow pathway. NO-sensitive
peptide sensors were utilized to detect local changes in NO production at the outflow resistance
sites, through the NO-mediated nitration of the peptide sensors conjugated to the surface of fluores-
cent tracers. Previous studies have shown that human SC endothelial cells [11] and porcine angular
aqueous plexus cells (the porcine equivalent of SC cells) [135] are shear-sensitive and secrete NO in
response to increasing shear stress in vitro. Consistent with this notion, eyes perfused at 16 mmHg
exhibited an average 3-fold increase in 3-NT/tracer intensity ratio compared to eyes perfused at 8
mmHg. Furthermore, majority of the tracers were found enmeshed in the TM/JCT region, located
adjacent to the inner wall endothelium of SC. Therefore, this data strongly suggests that elevations
in IOP results in the up-regulation of eNOS activity, which can be attributed to increased hydrody-
103
namic shear stress within the SC, leading to an increase in NO production. Secreted NO could then
feed back into the mechano-regulatory system as an autocrine/paracrine signaling molecule by ret-
rograde diffusion into the TM and/or advection along the circumference of the canal to modulate the
outflow resistance sites to increase outflow facility in the eye. This endogenous feedback mechanism
described here reaffirms previous studies[121,141,158,174] indicating that eNOS activity plays a crucial
regulatory role in maintaining IOP homeostasis. One caveat to this study was that the perfusion
studies were carried out using a pressure-controlled system held at constant-pressure, therefore we
were unable to characterize the effect of NO release from the SC cells to restore IOP homeostasis,
as we would expect from an endogenous regulatory mechanism in vivo.
While our data and others[43,158,191] strongly suggest that eNOS is the primary isoform in the
conventional outflow pathway, studies have shown that both nNOS[149,165,195] and iNOS[192,239] are
expressed in the TM region of the outflow pathway by nitrergic nerve fibers and resident macrophages,
respectively. Therefore, endogenous NO production may not be limited to eNOS activity in the out-
flow tract. Further studies are required to help differentiate between the various NOS isoforms that
may contribute towards this mechano-regulatory feedback mechanism. Previous data have shown
that the selective inhibition of eNOS, with cavtratin, reduced outflow facility in WT mice compared to
its contralateral control, suggesting a basal NO tone is involved in the regulation of outflow facility [43].
Consistent with this notion, our data also showed a basal NO tone in eyes perfused at physiological
IOP, and increases in IOP leads to increased NO production in the SC. Therefore, by introducing
the eNOS-selective inhibitor with the NO biosensor, we could potentially determine whether eNOS
is the primary isoform responsible for this mechano-regulatory feedback loop, and in turn influence
the segmental outflow distribution observed in the TM and NO secreted by the SC cells.
In conclusion, we have shown that segmental outflow in the TM is partially regulated by
an endogenous NO-regulatory mechanism within the outflow tract, predominately through the up-
regulation of eNOS expression and activity within the SC. Elevated IOP leads to increased NO pro-
duction, and acts as the local mediator of outflow resistance in the TM and SC, by altering the local
hydraulic conductivity, and thus the segmental outflow patterns in the outflow pathway to help restore
IOP homeostasis. This homeostatic mechanism may become impaired in glaucomatous eyes, which
leads to reduced NOS activity [157] and decreased NO production in SC cells [11], and thus resorts in
increased outflow resistance and elevated IOP. Therefore, by targeting the NO-regulatory machinery
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within the conventional outflow pathway may help restore the regulatory feedback mechanism and
provide an sustained therapy for treating glaucoma.
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Figure 4.11: Relationship between eNOS-GFP expression and tracer intensity. Both GFP and tracer intensity have been
normalized to allow for linear regression analysis. (A) Normalized tracer intensity plotted against normalized eNOS-GFP
intensity for all 160 ROIs obtained from all the eyes pressurised at 8 mmHg (diamonds). Each mouse was separated
into different colors to represent the distribution of ROIs for a given eye. (B) Normalized tracer intensity plotted against
normalized eNOS-GFP intensity for all 160 ROIs obtained from all the eyes pressurised at 16 mmHg (circles). Each
mouse was separated into different colors to represent the distribution of ROIs for a given eye. Solid red line = linear
regression for eyes perfused either at 8 or 16 mmHg. Shaded region represents the 95% confidence bounds on the linear
regression. (*) denotes normalized fluorescence intensities.
Table 4.2: Outflow facility data. "Baseline" facility was the average facility measured at time = 30 mins during the first
bolus of perfused DBG. "Post-tracer" facility was the average facility measured at the end of the perfusion during the
second bolus of perfused DBG. Average facility measurements were taken over 10 mins of stable data.
Eye Sex Age [wks] Perfusion Time [hr:min] Outflow Facility (nl/min/mmHg)
ID L/R Perfusion Pressure [mmHg] Baseline Post-tracer
1 L 16 M 10 1:40 5.52 30.23
R 8 1:49 23.77 35.20
3 L 8 F 10 4:01 5.99 15.32
R 16 2:40 11.68 9.10
4 L 16 F 10 2:23 4.89 13.47
R 8 3:15 6.24 22.92
6 L 8 M 10 2:35 9.62 25.59
R 16 0:58 16.42 23.92
7 L 8 M 10 3:20 6.66 17.32
R 16 2:22 6.70 12.24
8 L 16 F 15 1:56 11.61 10.69
R 8 4:00 7.03 16.70
9 L 16 M 15 1:06 14.48 17.47
R 8 5:48 2.68 12.02
12 L 16 F 15 1:26 11.17 15.24
R 8 6.33 5.75 5.62
14 L 16 M 15 3:22 4.89 8.64
R 8 6:58 4.98 7.16
15 L 8 M 15 5:54 2.48 14.59
R 16 2:04 7.69 13.09
Mean ± SD (n=10) Eyes perfused at 8 mmHg 4:25 7.52±6.07 17.24±8.82
Eyes perfused at 16 mmHg 1:59 9.51±4.14 15.41±6.86
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Chapter 5
Imaging of Segmental Outflow in Ex
Vivo Mouse Eyes by Optical Projection
Tomography
This chapter consists of a paper in preparation to be submitted to Experimental Eye Research:
"Methods in Eye Research".
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5.1 Introduction
The majority of aqueous humor outflow resistance is generated within close proximity to the
inner wall endothelium of Schlemm’s canal (SC), its underlying basement membrane and subse-
quent juxtacanalicular connective tissue (JCT) of the trabecular meshwork (TM)[117,166]. However,
the hydrodynamic details of how aqueous humor filters through these tissues remain unclear. Aque-
ous humor outflow has been suggested to be non-uniform or "segmental" around the circumference
of the TM[53,70]. This indicates that only a portion of the meshwork is considered filtration-active at
any given time, and thus may influence the delivery of anti-glaucoma therapeutics that aim to lower
IOP. Previous studies have shown that segmental outflow patterns are influenced by multiple factors
occurring at both the macro- and micro-scale[42], therefore suggesting that aqueous humor outflow
regulation should be considered as a multi-scale problem.
To study segmental outflow in the TM, researchers have often relied upon fluorescent tracers
to identify and label preferential drainage routes in the outflow pathway[17,102,123,218,231]. The visual-
ization of segmental outflow patterns are typically carried out with established imaging techniques
such as epifluorescence and confocal microscopy. For these imaging techniques, typically the eye
is dissected into smaller wedges for en face imaging, whereby the images are post-processed and
merged together to re-create the segmental filtration patterns of the outflow pathway. However, by
dissecting the eye it can potentially disrupt the flow patterns and introduce artifacts or result in the
loss of information from processing the tissue for imaging. Hence, the ability to image segmental
filtration patterns over the entire circumference of the eye without dissecting the tissue would be
highly advantageous.
Optical projection tomography (OPT)[199] is a recently developed optical imaging technique
that is capable of imaging small biological samples in three-dimensions (3D), typically for specimens
that range between 1 to 10 mm[198]. This technology has already proven to be a valuable tool in
developmental biology[179,198,199], being able to obtain high-resolution optical projections of fluores-
cent and non-fluorescent biological samples over 360°rotation. However, this technology has been
limited to mainly embryonic studies, and has yet been adopted for wider applications such as the
study of fluid dynamics in the eye. This is mainly due to two limiting factors: (i) the need to clarify bio-
logical samples to enable the transmission of light, and (ii) the quenching of fluorescent labels when
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processed with tissue clarifying chemicals; both of which are essential for the 3D reconstruction of
the optical projections.
In this study, we demonstrate for the first time, the use of fluorescence OPT combined with
a novel embedding protocol to visualize the segmental outflow patterns in enucleated mouse eyes,
without the need to dissect or optically clear the tissue with toxic chemicals, thus preserving both
the anatomical structures of the eye and the fluorescence signals of interest. Furthermore, with
this protocol, we have also illustrated that fluorescence OPT can potentially be used as a tool to
correlate fluorescently labeled anatomical structures with segmental outflow patterns, to potentially
understand the interconnectivity between the macro- and micro-scale components that may influ-
ence segmental outflow behavior in the eye.
5.2 Materials and Supplies
5.2.1 Animal Husbandry
All experiments were conducted in compliance with the Association for Research in Vision
and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research under
UK Home Office Project License approval for research at Imperial College London. This study
used transgenic mice which express the human gene variant of the endothelial nitric oxide synthase
(eNOS) promoter fused to green fluorescent protein (GFP) on a C57BL/6 background, as well as
C57BL/6 wild-type (WT) mice. Perfusions were performed with enucleated (ex vivo) eyes from mice
of either sex. eNOS-GFP mice were 8 – 15 wk of age (endogenous GFP labeled mice). WT mice
were 8 – 12 wk of age (in vivo tracer injection experiments). Mice were housed in individually
ventilated cages, fed ad libitum, and maintained at 21°C with a 12:12-h light-dark cycle, with lights
on from 6 AM to 6 PM.
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5.2.2 eNOS-GFP transgenic mice
Transgenic mice express the human gene variant of the eNOS promoter fused to green fluo-
rescent protein (GFP; as a reporter) on a C57BL/6 background. The transgene contains the human
eNOS promoter region only, such that transgene expression is regulated by endogenous transcrip-
tional activity but there is no over-production of nitric oxide. In these animals, GFP expression has
been shown to be specific to endothelial tissues, with no increase in endogenous NO-production.
Transgenic mice were a kind gift from Prof. Rob Krams (Imperial College London, UK) and Prof.
Rini de Crom (Erasmus MC, Rotterdam, The Netherlands). Genotyping of transgenic mice was per-
formed to detect sequences of GFP and the human variant of eNOS promoter present in the genome
of eNOS-GFP mice but are absent from the genome of WT mice. Genotyping was performed using
ear tissue samples obtained at weaning, with tissue lysis and DNA purification performed according
to manufacturer’s instructions (Kapa Express Extract; Kapa- Biosystems, Cambridge, MA). Sep-
arate PCR reactions were performed using a hot-start mix (KAPA2G Robust HotStartReadyMix;
Kapa- Biosystems, Cambridge, MA). For human eNOS promoter, 29 cycles were performed with
an annealing temperature of 59.3°C using the sense primer ACCAGGGCATCAAGCTCTTC and the
antisense primer TCTGTGATGTGGCACCAGAC to yield a predicted product of 500 bp. These se-
quences are specific for the human eNOS promoter and are not predicted to react with C57BL/6
murine eNOS. For GFP, 29 cycles were performed with an annealing temperature of 59.9°C using
the sense primer AGCTGACCCTGAAGTTCATCTG and the antisense primer GACGTTGTGGCT-
GTTGTAGTTG to yield a predicted product of 327 bp. PCR products were resolved by gel elec-
trophoresis (1% agarose) in the presence of DNA gel stain (SYBR Safe; Invitrogen, Carlsbad, CA).
Bands were visualized on an imaging station (Biospectrum 500; UVP, Upland, CA).
5.2.3 Fluorescent Tracers for Ex Vivo Perfusions and In Vivo Injections
Fluorescent tracers (200 nm, carboxyl-coated nanoparticles) were purchased from Life Tech-
nologies (Austin, TX, USA). For ex vivo tracer perfusions, the perfusate consisted of a final concen-
tration of 0.1% (v/v) red fluorescent tracers (580nm/605nm; 3.1x1011 particles/mL) resuspended in
Dulbecco’s phosphate buffered saline (PBS) including divalent cations and 5.5mM D-glucose (DBG)
that was passed through a 0.2 µm filter. For in vivo tracer injections, yellow-green fluorescent trac-
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ers (505nm/515 nm) were resuspended in UltraTM DNase/RNase free water (dH2O; Invitrogen) and
was delivered via 1.5µl bolus injections (⇠1x105 particles/eye) to decorate the segmental outflow
patterns in living WT mice.
5.2.4 Anesthesia
The anesthetic solution consisting of ketamine (66.6 mg/kg, Fort Dodge Animal Health, Fort
Dodge, IA) and medetomidine hydrochloride (Domitor® 0.66 mg/kg, Orion Pharma, Berkshire, UK)
was diluted in sterile dH2O (Hameln Pharmaceuticals, Gloucester, UK) and delivered to the mice
via intraperitoneal injection. Antisedan® (atipamezole hydrochloride; 1.5 mg/kg, Orion Pharma,
Berkshire, UK) was delivered via intraperitoneal injections after intracameral injections to assist with
the recovery of mice from anesthesia.
5.2.5 Embedding of Mouse Eyes for OPT Imaging
Enucleated mouse eyes from each experiment were casted in a clear arcylic cylindrical
container (25 mm x 8mm; RS Components Ltd, UK) with polydimethylsiloxane (PDMS; Sylgard
184, Dow Corning, Wiesbaden, Germany) or following established standard agarose embedding
and tissue clearing protocol for OPT imaging[180]. For the standard OPT sample preparation, 1%
agarose (low melting point) solution was used for the embedding of the tissue sample, followed by
the dehydration of the tissue with 100% methanol and tissue clearing with BABB (2:1 mixture of
benzyl alcohol and benzyl benzoate).
5.2.6 Glass Needles for In Vivo Injections
Custom-made glass needles were used for tracer injections. Needles were made out of
borosilicate glass capillaries (BF100-50-10, Sutter Instruments, CA, US) with an inner diameter of
0.5 mm and outer diameter of 1 mm. Capillaries were pulled using a laser-based micropipette puller
(P2000, Sutter Instruments, CA, US). Pulled capillaries were then further processed to obtain a nee-
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dle tip diameter of ⇠100 µm, by carefully pushing the needle tip against another needle positioned
perpendicularly. Each needle was then inspected on an inverted microscope to control for the tip
diameter. Prior to use, needles were autoclaved at 120°C and stored in 70% ethanol.
5.3 Detailed Methods
5.3.1 Experimental Design
The goal of this study was to develop a novel embedding protocol that can be used for OPT
imaging of enucleated mouse eyes, in order to examine segmental outflow patterns globally and
also be able to visualize the limbal vasculature of the outflow pathway in the same sample. Here, we
propose two set of experiments to demonstrate a proof-of-concept that our embedding protocol is
compatible with OPT imaging technique and presents an alternative to the standard agarose/BABB
tissue clearing protocol commonly used for developmental biology[179,180,198]. For the first set of
experiments, eyes obtained from eNOS-GFP mice were used to visualize the limbal vasculature,
which expresses the transgene in vascular-derived endothelial cells that line the post-trabecular
outflow pathway. These same set of mice were also perfused with fluorescent tracers to decorate
the segmental outflow patterns in the TM. eNOS-GFP perfused eyes were then processed for OPT
imaging with either the standard agarose/BABB protocol or the newly developed PDMS embedding
protocol. The second set of experiments examined whether segmental outflow patterns in eyes
obtained from living WT mice were comparable against ex vivo eyes. These experiments aim to
validate the newly developed PDMS embedding protocol is compatible with OPT imaging, whilst
preserving the fluorescence signals of interest from chemical quenching during sample preparation.
5.3.2 Ex Vivo Tracer Perfusions
Eyes obtained from eNOS-GFP mice were perfused with fluorescent tracers to decorate the
segmental outflow patterns in the TM. Additionally, the GFP signal from the eNOS-GFP expression
in the SC and downstream perilimbal vessels are used to identify the post-trabecular outflow path-
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way and limbal vasculature in the mice. The eyes were enucleated within 10 minutes of death by
cervical dislocation and stored in PBS at room temperature until perfusion, typically within 15 min.
Experiments used paired contralateral eyes, which were perfused simultaneously on two identical
iPerfusion systems[200] under identical experimental conditions.
Our perfusion method follows previously described techniques[25,27,43,134,211]. Briefly, the
eye was affixed to a support using cyanoacrylate glue to stabilize the eye and submerged in PBS
in a thermo-regulated bath at 35°C. A 33-gauge beveled needle (Nanofil; World Precision Instru-
ments, Europe; Hitchin, UK) was used to cannulate the eye, with the tip of the needle positioned
in the anterior chamber using a micro-manipulator. The pressure and flow rate inside the eye were
measured using a wet-wet differential pressure transducer (PX409, Omegadyne, US) and a flow
sensor (SLG64-0075, Sensirion, Switzerland), respectively. The enucleated eyes were perfused
with DBG supplemented with red fluorescent tracers (0.1% concentration (v/v)) at 8 mmHg for 3
hours to decorate the segmental outflow patterns. After each perfusion the eyes were fixed in 4%
paraformaldehyde (PFA) overnight at 4°C ready for further processing for OPT imaging.
5.3.3 In Vivo Tracer Injections
For this set of experiments WT mice were used to study the preferential drainage routes
in the conventional outflow pathway of living WT mice, and whether the outflow patterns are con-
sistent with the segmental outflow patterns observed in ex vivo eyes. WT mice were anesthetized
with ketamine (66.6 mg/kg) and Dormitor® (0.66 mg/kg) via intraperitoneal injection. Dilation drops
(phenylephrine hydrochloride (2.5% w/v) and tropicamide (1% w/v); Bausch & Lomb, Rochester,
NY) were then applied to both eyes to minimize potential damage to the iris during cannulation of
the glass needle. Each mouse was subcutaneously injected with 5 mg/kg enrofloxacin antimicrobial
(Baytril; Bayer Healthcare, Leverkusen, Germany) and their eyes were kept moist with artificial tears
(Vidisic® Bausch & Laumb, Rochester, NY) prior to intracameral injections. Once the mouse was
fully sedated, it was secured in place with the assistance of a head-holder (Model 923-B; Kopf In-
struments, CA, USA) and placed on a warm-water place mat. Liquid around the eye was removed
using a Kimwipe (Fisher Scientific, Loughborough, UK) before cannulation. Eyes were cannulated
with a pulled glass micro-needle (100 µm tip) positioned parallel to the iris and above the limbus
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to remove a portion of the aqueous humor in the anterior chamber by capillary action. This helps
reduce the amount of reflux during intracameral injections. Intracameral injections were then carried
out with a pulled glass micro-needle (100 µm tip) filled with 1.5 µL of yellow-green tracers in dH2O
connected to a 10 µL glass syringe (Gastight; Hamilton, Reno, NV). The tracers filled glass micro-
needle was then inserted into the same cannulation site with the assistance of a micro-manipulator,
and the tracers were slowly delivered to the anterior chamber of the eye. Topical antibiotic ointment
(1% w/w Fucithalmic; LEO Pharma, Denmark) was then applied to the cannulation site followed by
removing the needle slowly from the eye to reduce reflux. After the procedures, the mice were given
1.5 mg/kg of Antisedan® via intraperitoneal injection and placed in a heated chamber (maintained
at 28°C) to allow for faster recovery from anesthesia. To better distinguish the orientation of each
eye, the right eye (OD) was cannulated in the inferior quadrant and the left eye (OS) was cannulated
in the superior quadrant. The mice were allowed to recover for 48 hrs post-surgery for the cornea to
fully heal then euthanized via an overdose of Pentobarbital (150 µL; Euthatal, Merial, UK). Once the
mice have been euthanized, the eyes were enucleated and fixed in 4% PFA overnight at 4°C ready
for further processing.
5.3.4 Embedding Protocol of Enucleated Mouse Eyes
Enucleated eyes obtained from eNOS-GFP and WT mice were washed in PBS several times
to remove any fixative remaining on the eyes. Eyes were then cleaned of their surrounding extraoc-
ular muscles and the conjunctiva, to expose the limbal region of the eye for OPT imaging for both
segmental tracer distribution and eNOS-GFP signal from the limbal vasculature. The sample was
then processed for OPT imaging either via the standard agarose/BABB protocol established by
Sharpe et al. [198,199] or by the newly developed PDMS embedding protocol (Figure 5.1).
For the standard agarose/BABB processing protocol (as shown in Figure 5.1A), the fixed
tissue was first washed in distilled water several times to remove trace amounts of salts, which could
crystalize during the dehydration and BABB clearing process. Followed by the embedding of the
eye in a 1% solution of low-melting-point agarose in a 50-mm Petri dish, with the eye positioned
horizontally in the middle of the dish at medium depth. The agarose gel was left to set at room
temperature for 10 min or set overnight at 4°C. Once the agarose gel has completely set, the sample
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was carefully removed from the Petri dish and trimmed to obtain an octagonal-shaped block, such
that the long axis of the sample is aligned with the axis of rotation. The trimming of the specimen
block minimizes the optical influence of 90°corners during image acquisition. The sample was then
dehydrated for 24 h in a glass vial containing 100% methanol and covered with aluminum foil to
protect the fluorescence signal from light. After dehydrating the sample, methanol was replaced
with BABB solution to clear the agarose gel and the embedded tissue for an additional 24 h. After
clearing the sample, the block was removed from the BABB solution and glued to a magnetic mount
then attached to the rotating assembly of the OPT scanner. The sample was then immersed in a
transparent cuvette filled with BABB solution to match the refractive index (n=1.55) for OPT imaging.
For long-term storage, the samples were kept in BABB solution in an amber glass vial at room
temperature.
For the PDMS embedding protocol (as shown in Figure 5.1B), PDMS was prepared by mix-
ing the pre-polymer and cross-linker at a 10:1 ratio (w/w) and poured into an hollow acrylic cylinder
of 25 mm x 8 mm (length and inner diameter, respectively) on a 50-mm Petri dish. The casting of the
silicone elastomer in a cylindrical container eliminates the optical influence of corners, whilst also
possessing good optical properties for OPT imaging. PDMS was then degassed in a desiccator to
remove air bubbles, then semi-cured for 15 min at 65°C. During this time, the fixed sample was
washed in PBS several times to remove residual PFA, and pre-incubated for 5 min in a 50-mm Petri
dish filled with degassed PDMS to coat the surface of the sample to minimize the presence of an
transition interface between the sample and the PDMS. After 15 min of curing the PDMS, the PDMS-
incubated sample was carefully placed inside the semi-cured PDMS filled cylinder and positioned
longitudinally, such that the long axis is aligned with the axis of rotation. The sample embedded in
PDMS was then fully-cured for an additional 45 min at 65°C. After curing, the sample was left to
cool at room temperature for 1 h then removed from the cylindrical mold and glued to a magnetic
mount ready for OPT imaging. The sample was immersed in a transparent cuvette filled with 95%
ethanol, which was used as an intermediate refractive index (n=1.36) between air and the sample.
For long-term storage, the samples were kept in PBS solution in an amber glass vial and stored at
4°C and protected from light.
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Figure 5.1: Schematic representation of tissue embedding protocol for OPT imaging. (A) Standard agarose embedding
and clearing protocol for OPT imaging. The tissue sample was washed in distilled water several times to remove trace
amounts of salts to prevent the formation of salt crystals during dehydration and clearing steps. The tissue sample was
then embedded in 1% agarose gel and left to set at room temperature or 4°C overnight. The sample was then trimmed to
an octagonal-shape and dehydrated in 100% methanol for 24 h. This was followed by clearing of the sample with BABB
solution for an additional 24 h. The sample was then mounted onto a magnetic stub and attached to the rotating assembly
of the OPT scanner. (B) PDMS embedding protocol for OPT imaging. The tissue sample was pre-incubated with PDMS
for 5 min at room temperature. Cylindrical containers were used to cast the degassed PDMS, then semi-cured for 15
min at 65°C. The pre-incubated sample was then carefully placed and centered in the cylinder. The sample embedded
in PDMS was then fully-cured for an additional 45 min at 65°C. The casted sample was allowed to cool for 1 h at room
temperature before removing it from the cylinders and mounted for OPT imaging.
5.3.5 Image Acquisition with OPT
A custom-built OPT scanner was used to acquire both bright-field and fluorescent images
from the tissue sample (Figure 5.2). For each sample, 400 projections were acquired with angular
steps of 0.9  between projections over the full 360  rotation. For fluorescence imaging, the sample
was illuminated with a xenon arc lamp (HPLS-30-04; Thorlabs Inc, UK) combined with an excitation
filter to detect the fluorescence signal. The emitted light was then detected with a back illuminated
CCD camera (sCMOS camera; Zyla, Andor, UK). The excitation filters used for this study consisted
of the GFP(470ex/525em) and Texas Red(560ex/630em) channels, which acted as band-pass filters for flu-
orescence imaging and separation of fluorescence signals. The GFP channel was used to detect
the GFP signal from the eNOS-GFP expression in the transgenic mice, in addition to the fluorescent
tracers (yellow-green) injected into WT mice. The Texas Red channel was used to detect the fluo-
rescent tracers in eNOS-GFP mice. Raw images were imported into FIJI (NIH, MD, USA) for further
analysis and processing.
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Figure 5.2: Schematic of the fluorescence OPT imaging setup. The sample is supported in a transparent material (such
as agarose gel or PDMS) and rotated through a series of angular positions to acquire projections over 360°T˙he sample is
illuminated by a xenon arc lamp combined with an excitation filter (Ex) and detected with an emission filter (Em) connected
to a CCD camera. L: Lens, TL: Tube lens, OL: Objective lens.
5.3.6 Segmental Tracer Distribution Analysis
To quantify whether segmental outflow patterns tend to preferentially drain towards certain
quadrants of the eye, we measured the fluorescent tracer intensities along the entire circumference
of the eye and examined the tracer patterns in relation to the quadrants of the eye. Additionally
we examined whether the tracer patterns observed in ex vivo eyes are representative of the flow
patterns in eyes obtained from a living WT mice. Here, we utilized the segmented line tool (FIJI,
NIH), a piecewise linear ROI was drawn along the limbus of the eye, extending 150 µm above
and below the limbus to capture the fluorescent tracers enmeshed in the TM (dashed lines; Figure
5.5A). The tracer intensity profiles was then measured along the ROI (averaged across the width of
the segmented line) using the plot profile tool (FIJI). This returned an array of fluorescence intensity
values for the tracers as a function of distance along the limbus.
Due to the technical challenges of in vivo anterior chamber injections, it is difficult to ensure
the entire bolus of tracers remained in the eye once the glass needle was removed due to reflux of
perfusate. Additionally, in ex vivo tracer perfused eyes, the amount of tracers delivered to each eye
may vary depending on the outflow resistance. Therefore, to account for possible variations in tracer
intensities that may arise between individual eyes, the fluorescence intensities of the tracers were
normalized by dividing the averaged fluorescence intensity along the selected ROI by the maximum
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intensity value to preserve the tracer patterns. The fundamental assumption here is that only the
intensity was affected and not the spatial distribution of the tracer patterns, thus we only analyze the
tracer patterns instead of the raw intensity values.
5.3.7 Image Processing of Limbal Vasculature
To improve the resolution of the acquired OPT images, image processing algorithms were
implemented to enhance the anatomical structures of the limbal vascular network. Due to the sim-
ilarities between OPT and single-photon emission computed tomography (SPECT/CT), image pro-
cessing algorithms commonly used in SPECT/CT to improve image resolution may also be adopted
for OPT images. Filtered back-projection algorithms are commonly used with ramp-based filters
to emphasize the high spatial-frequencies[168], which typically coincides with the finer anatomical
structures of the limbal vasculature, such as the corneal arcades and perilimbal vessels (Figure
5.4). However, in the spatial-frequency domain the highest frequencies are dominated by noise.
Therefore, the ramp-based filter was combined with a low-pass window to de-emphasize the high-
est frequencies and reduce the noise but still preserve the signals of interest. For the OPT images
acquired, we combined the ramp-based filter with a flat-top window to obtain the micro-vasculature
in post-trabecular outflow pathway.
5.4 Results
5.4.1 Comparison of PDMS Protocol vs. Standard BABB Protocol
To determine whether the newly developed PDMS embedding protocol was compatible with
fluorescence OPT imaging, eyes obtained from eNOS-GFP mice were processed either by (a) the
standard agarose/BABB protocol or (b) the PDMS protocol, in order to compare the suitability of
the protocols on preserving the fluorescence signals of interest in the tissue. Additionally, these
eyes were also perfused with fluorescent tracers to label the segmental outflow pathways in the
TM, whereby the tracers served as a secondary fluorescence signal of interest. The OPT imaging
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showed that eyes processed with the standard agarose/BABB protocol, resulted in the quenching of
both the endogenous GFP and fluorescent tracer signals after the BABB clearing step (Figure 5.3;
left panel). After 24 h of incubation with BABB, the GFP signal was mostly quenched leaving only
a faint band of fluorescence surrounding the limbus, but not clear enough to resolve any anatomical
structures, such as the limbal vasculature. Furthermore, the perfused fluorescent tracers were
completely quenched, rendering the agarose/BABB protocol unsuitable for most segmental outflow
tracer studies used in eye research[42,102,123,143,231]. In contrast, eyes processed with the PDMS
embedding protocol showed clear GFP fluorescence and tracer signals surrounding the limbus of
the eye (Figure 5.3; right panel). With the PDMS embedding protocol, the fluorescence signals were
preserved and eNOS-GFP labeled anatomical structures were clearly visualized with OPT imaging.
Additionally, the PDMS embedding protocol was able to reduce the sample preparation time from
a 3-day protocol to a half-day protocol. This indicates that the PDMS embedding protocol could be
used as an alternative to the standard agarose/BABB protocol for fluorescence OPT imaging.
limbus
cannulation site
EOM
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Agarose/BABB Protocol PDMS Protocol
limbus
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Figure 5.3: Comparison of sample preparation protocols used for fluorescence OPT imaging of eNOS-GFP mouse eyes.
(Left) eNOS-GFP eye perfused with fluorescent tracers were processed for OPT imaging using the standard agarose
embedding and BABB tissue clearing protocol. (Right) eNOS-GFP eye perfused with fluorescent tracers were processed
for OPT imaging using the PDMS embedding protocol. EOM: Extraocular muscles.
5.4.2 Visualization of the Limbal Vasculature in eNOS-GFP Mice
Once the PDMS embedding protocol has been established to be compatible with fluores-
cence OPT imaging, we continued to acquire high resolution images of the limbal vascular network
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of the eNOS-GFP mice. Figure 5.4 showed that the GFP signal was preserved with the newly de-
veloped PDMS embedding protocol, and the fluorescence signal is localized to the vascular-derived
endothelial cells that line the limbal vasculature, which includes the SC endothelium, episcleral ves-
sels (EV) and blood vessels in the extraocular muscles (EOM). At higher magnifications, we were
able to resolve fine anatomical structures such as corneal arcades (CA) and perilimbal vessels
(PLV), which are on the order of several microns wide (⇠ 10 – 20 µm) surrounding the limbus of
the eye. The perilimbal vessels was the most prominent vascular structure visualized in the super-
ficial limbus, and often revolved around the whole circumference of the eye which connects to the
downstream episcleral veins (Figure 5.4B-C). The episcleral veins extends posteriorly, often towards
regions where the extraocular muscles were located which reconnects to the circulatory system for
aqueous humor drainage (Figure 5.4D). In addition to the superficial vascular network along the
limbus, we were also able to visualize the SC as shown by a "band of fluorescence" underlying
the superficial limbal vasculature (Figure 5.4B-C). The Schlemm’s canal was presented as a "hazy
canal-like" structure, which is likely due to the limited depth of focus of the OPT imaging modality.
These micro-anatomical features of the post-trabecular pathway have also been previously identified
with confocal microscopy and confirms our observations[228].
5.4.3 360°View of Tracer Distribution
Fluorescence OPT imaging revealed a segmental tracer distribution in the TM/JCT of all
the perfused mouse eyes (n=3), which was consistent with previous works carried out by epifluo-
rescence and confocal microscopy in both human and animal models[42,102,123,143,231]. Segmental
tracer distribution was observed over the entire circumference of the eye, as shown by four angular
representative views separated by 90°rotation (Figure 5.5). The use of multichannel fluorescence
OPT has provided a non-invasive imaging modality that can map the segmental tracer distribution,
in relation to the limbal vasculature of the post-trabecular outflow pathway over the entire circum-
ference of the eye. The perfused fluorescent tracers (red) were co-visualized with the endogenous
GFP signal (grey ) from the eNOS-GFP mice, which allows for potential colocalization analysis of
the two fluorescent labels. Regions of higher tracer labeling (arrowheads) tends to coincide with re-
gions of the limbal vascular network that are closely situated to downstream episcleral veins, which
tend to feed into nearby extraocular muscles (Figure 5.5B,C,D). Whilst regions of lower tracer label-
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Figure 5.4: Visualization of the limbal vascular network of eNOS-GFP mouse eyes imaged with fluorescence OPT. (A)
Fluorescence OPT image of the entire mouse eye, which also includes the optic nerve and it’s surrounding blood vessels
(BV). GFP fluorescence was also detected surrounding the limbal region, where the Schlemm’s canal (SC), perilimbal
vessels (PLV) and downstream episcleral vessels (EV) reside. (B) GFP fluorescence images of the anterior segment of
the eNOS-GFP mice. Clear visualization of anatomical structures from the post-trabecular outflow pathway. (C) Higher
magnification of region of interest showing the GFP signal in the Schlemm’s canal (SC), which is defined as a "band of
fluorescence" running along the limbus of the eye. (D) Higher magnification of region of interest showing the GFP signal
in the Schlemm’s canal connecting to the episcleral veins that drains the aqueous humor back to the vascular circulation.
Collector channels (CC) could also be visualized with fluorescence OPT as "ring-like" structures. S: Blind-ending lymphatic
sprouts, CA: Corneal arcades, EOM: Extraocular muscles.
ing (asterisks) tends to be located in the midway point between downstream episcleral veins that
extend into the extraocular muscles (Figure 5.5E). Additionally, from the 360° tracer intensity pro-
file along the entire circumference of the eye, more tracer labeling was found to be located in the
nasal-superior quadrants (Figure 5.5F), which is consistent with previous findings in human eyes[42].
These findings were consistent across all three samples obtained from separate experiments. Inter-
estingly, when analyzing the segmental outflow patterns in living mice, we observed a similar trend
in tracer distribution over the circumference of the eye. Here, we typically found more tracer labeling
in the nasal-superior quadrants compared to other quadrants of the eye (Figure 5.6). This suggests
that tracer patterns observed in ex vivo eyes are comparable to the tracer patterns observed in
living WT mice, and additionally, aqueous humor outflow tends to preferentially drain towards the
121
nasal-superior quadrants of the eye.
By processing the enucleated eyes with the newly developed PDMS embedding protocol, it
allows for researchers to visualize the segmental outflow patterns in a global context and identify
regions of high and low flow, which can later be isolated for further analysis. Hence, OPT imaging
can add another dimension to tracer flow studies that compliments existing imaging techniques such
as confocal microscopy and electron microscopy.
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Figure 5.5: 360°view of tracer distribution in ex vivo mouse eyes. (A) Representative fluorescence OPT image of eNOS-
GFP mouse eye visualized with the GFP channel, whilst the perfused fluorescent tracers were visualized with the Texas
red channel (n=3). The tracer distribution in the conventional outflow pathway shows non-uniform labeling or segmental
outflow. (B-E) Regions of high tracer labeling (arrowheads) and low tracer labeling (asterisks) are shown in relation to
the anatomical structures of the post-trabecular outflow pathway as the whole eye is rotated over 360°. (F) Normalized
tracer intensity profile over the entire circumference of the eye plotted as a function of length along the limbus to illustrate
changes in segmental tracer distribution. CA: Corneal arcades, EV: Episcleral vessels, EOM: Extraocular muscles, PLV:
Perilimbal vessels.
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Figure 5.6: Segmental outflow patterns of living WT mice. (A) Representative mouse eye (OD) injected with a bolus of
fluorescent tracers (1.5 µl; ⇠1x105 particles/eye) to label the segmental outflow patterns imaged with bright-field OPT.
Region of interest along the limbus of the eye where the TM/JCT resides is indicated by the red dashed lines. Tracer
injection (yellow-green) was cannulated in the inferior quadrant of the eye indicated by the arrowhead. (B) Representative
fluorescence OPT images obtained from tracer injection into the anterior chamber of the eye. (C) Normalized tracer
intensity profile of each tracer (averaged across the ROI thickness; 300 µm) plotted as a function of length along the
limbus to illustrate the segmental tracer distribution. Asterisks = regions of low tracer labeling.
5.4.4 Image Processed Limbal Vasculature
To obtain better resolution of the limbal vascular network, OPT acquired images were image
processed with a ramp-based filter combined with a low-pass window to de-emphasise the highest
spatial-frequencies, typically dominated by noise. Hence, we applied a flat-top window to enhance
the visualisation of the micro-vasculature surrounding the limbus of the eye and reduce the noise of
the raw OPT image. Figure 5.7 shows a side-by-side comparison of the raw fluorescence OPT image
(left panel) against the flat-top filtered OPT image (right panel). The flat-top filtered image clearly
enhances the micro-vascular network along the limbus, especially the finer anatomical structures
such as the corneal arcades and perilimbal vessels when compared against the raw fluorescence
OPT image. Although by applying the flat-top filter to the OPT image, other anatomical structures
such as the SC becomes de-emphasized. Thus, depending on the anatomical features of interest,
different low-pass windows combined with the ramp-based filter can be applied to the images.
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Figure 5.7: Enhancement of fluorescence OPT acquired images of the limbal vasculature. (A) Raw fluorescence OPT
image of the limbal vasculature. (Inset) Higher magnification of the limbal vasculature before image processing enhance-
ment. (B) Flat top-filtered fluorescence OPT image of the limbal vasculature. (Inset) Higher magnification of the limbal
vasculature post-image processing enhancement. Flat top-filtering of OPT image has enhanced anatomical structures
such as the corneal arcades (CA) and perilimbal vessels (PLV), but has reduced the GFP signal in the Schlemm’s canal
(SC).
5.5 Potential Pitfalls and Trouble Shooting
5.5.1 In Vivo Tracer Injections
During intracameral injections in living WT mice, in some eyes the cornea and lens started
to exhibit acute reversible opacity under anesthesia. To reduce eye opacity we employed several
methods: 1) eyes were kept moist with periodic drops of artificial tears, 2) the body temperature was
maintained by using a custom-made water heating pad, and 3) the cannulation time was typically
limited to ⇠ 5 min per eye.
To minimize the amount of reflux during the delivery of tracers, the following steps were
carried out: 1) use a glass micro-needle to initially cannulate the cornea to remove some aqueous
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humor via capillary action, 2) use a micro-manipulator for the insertion of the tracer-loaded glass
micro-needle and maintain it in the anterior chamber for ⇠15 seconds to allow for the eye to slightly
acclimatize, and 3) place a topical antibiotic ointment drop over the cannulation site followed by the
slow removal of the needle. Note: the topical ointment has a higher viscosity than the perfusate,
thus helps "partially" seal the insertion site.
5.5.2 PDMS Embedding and Positioning of Eyes
Several potential pitfalls may arise from embedding the eyes in PDMS, such as 1) the pres-
ence of micro-bubbles which interferes with the OPT imaging, 2) the formation of an "interface"
between the surface of the eye and the PDMS (referred to as "halo effect"), and 3) off-centered
positioning of the eye. To reduce the formation of micro-bubbles the PDMS was first poured into the
casting cylinders then degassed in a dessicator for⇠15 min. This eliminates micro-bubble formation
introduced from pouring the PDMS into the cylinders. Prior to positioning and embedding the eyes in
the casting cylinders, the eyes should be transferred to a piece of Kimwipe to absorb any moisture on
the surface of the eye, followed by pre-incubating the eye in a Petri dish filled with degassed PDMS
for 5 min. Removing the residual PBS from the surface of the eye and pre-incubating in PDMS so-
lution helps reduce the halo effect. The degassed PDMS-filled cylinders should be partially casted
to increase the viscosity of the solution. This typically took ⇠15 min in the oven at 65°C, although
this pre-casting time needs to be refined by the user. To position the eye use a pair of fine forceps
to hold the optic nerve and slowly lower the eye into the PDMS-filled cylinder. Make sure that the
optic nerve is centered along the axis of rotation to ensure good OPT projections. Cure the eyes for
another 45 min at 65°C. Note: check that the eye maintains in the middle of the casting cylinder, if
the eye has moved, this indicates the pre-casting time needs to be extended. To remove the casted
PDMS from the cylindrical molds, 70% ethanol was used to dislodge the sample.
125
5.6 Conclusion and Potential Applications
In this study, we developed a novel embedding protocol for imaging segmental outflow pat-
terns in enucleated mouse eyes that is compatible with fluorescence OPT. This protocol enables
researchers to visualize segmental outflow patterns in relation to the post-trabecular limbal vascula-
ture, in particular, the aqueous veins and episcleral veins which play an important role in determining
the distal resistances of the outflow pathway[188,203,245]. Tissues can now be imaged without being
physically dissected into smaller wedges then reconstructed, therefore preserving the anatomical
structures of the eye allowing for a global visualization of the interconnectivity of the outflow pathway
with minimal disruption to the flow patterns. Additionally, with the PDMS embedding protocol, we
can now bypass the tissue clarification step with toxic chemicals such as BABB, that often resulted in
the quenching of fluorescent labels and thus the loss of tracer distribution information. By changing
the embedding and tissue processing protocol, we have effectively reduced both the processing time
from 72h to 6h preparation for OPT imaging, and the imaging time from 2-3h to less than 15 min per
sample when compared against confocal microscopy. Furthermore, after OPT image acquisition,
the tissue can be extracted from the PDMS cast and processed for other analytical or morphometric
studies.
From this study, with the newly developed protocol, we were able to visualize the segmen-
tal outflow patterns in a global context and identify regions of high and low flow in relation to the
post-trabecular limbal vasculature and extraocular muscles. Interestingly, regions of high tracer la-
beling tends to coincide with regions of the limbal vascular network that are closely situated with
downstream aqueous veins and episcleral veins. Moreover, regions of higher tracer labeling tends
to coincide with the nasal and superior quadrants of the eye (Figure 5.5). Previous studies have
shown that in both bovine[17] and human[42,102] eyes, tracer patterns tend to coincide with the dis-
tribution of collector channel ostias, which coincidentally are also found more abundant in the nasal
and superior quadrants of the eye[90,101]. These results suggest that segmental outflow is a multi-
scale problem influenced by multiple aspects: from the distal resistance sites and the distribution of
collector channels[17,42,102] at the tissue level; to the regional variations in extracellular matrix (ECM)
proteins[123,218] and non-uniform distribution of pores along the inner wall of SC[29] at the cellular
level; to the regional variations in ECM gene expression[231] at the molecular level.
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Alternatively, with the PDMS embedding protocol, we can also potentially examine the ef-
fects of outflow enhancing drugs such as pilocarpine on segmental outflow patterns. Previous stud-
ies have shown that only a fraction of the TM is considered filtration-active at any given time[42,231].
Therefore, with our PDMS embedding protocol in conjunction with previously established two-color
tracer technique[42], we can potentially visualize and compare the efficacy of drugs that target the
filtration-inactive regions of the meshwork by comparing changes in filtration patterns. The use of
OPT in conjunction with the two-color tracer technique can provide an visual assessment on whether
drugs are targeting the filtration-inactive regions of the TM. With OPT imaging, along with other
functional studies that can be carried out in ex vivo perfusions, this could lead to the development of
better targeted anti-glaucoma therapeutics that aim to lower IOP. In conclusion, we have shown that
fluorescence OPT to be a valuable imaging tool that compliments established imaging techniques,
by providing a global view of how segmental outflow is distributed over the circumference of the eye
in relation to the downstream resistance sites situated in the post-trabecular limbal vasculature.
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Chapter 6
Targeted Delivery of Nitric Oxide to the
Trabecular Outflow Pathway via Enzyme
Loaded Nanoparticles
This chapter consists of a paper in preparation to be submitted to Proceedings of the National
Academy of Science.
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6.1 Introduction
Aqueous humor outflow is regulated by the resistance generated within the conventional
or trabecular outflow pathway, which comprises of the trabecular meshwork (TM), juxtacanalicular
connective tissue (JCT) and the inner wall endothelium of the Schlemm’s canal (SC)[117,166]. In-
creased outflow resistance is responsible for elevated intraocular pressure (IOP) – a characteristic
feature and primary risk factor associated with the development of glaucoma[210]. Reducing IOP is
the only means to prevent further vision loss[3]. However the mechanism(s) responsible for modulat-
ing these resistance sites still remain largely unknown. Nitric oxide (NO), a key signaling molecule
responsible for mediating various physiological functions, has been shown to regulate aqueous hu-
mor outflow by relaxing the TM cells [61,236,237], and modulating endothelial permeability of the inner
wall of SC[44,57,65]. Both of these mechanisms have previously been shown to decrease outflow
resistance and IOP in various animal and human models[24,43,62,65,111,191,233]. Recent efforts have
resulted in the development of several NO-donating compounds[24,113,130], including latanoprostene
bunod (LBN), a NO-donating prostaglandin F2↵ receptor agonist that has been shown to be more
efficacious than latanoprost at reducing elevated IOP in ocular hypertensive patients[233]. Thus, sug-
gesting that the improved IOP reduction is likely attributed to the effects of the NO-donating moiety
targeting the TM/SC cells to enhance aqueous humor outflow.
However, NO has been shown to play a multifaceted role within the trabecular outflow path-
way. Therefore, depending on the site at which NO is delivered, the physiological response elicited
may in fact be counterproductive and result in an increase in IOP, rather than the desired IOP-
lowering effect. For instance, NO can affect the contractility of the ciliary muscle[18,84,89,236], which
can regulate the outflow resistance through the tendinous connections to the JCT and inner wall of
SC[165,186,187,222]. Furthermore, NO can also lead to an increase in episcleral venous pressure[245],
which can also result in an increase in IOP. Hence, the use of NO as a potential therapeutic treat-
ment for ocular hypertension requires NO to be delivered on-site to the trabecular meshwork where
the bulk of outflow resistance is generated to achieve the optimal therapeutic effect.
Here, we developed a targeted NO delivery platform that liberates NO within the trabecular
meshwork to modulate the outflow resistance sites to increase aqueous humor outflow[43,62,65,158,191,211].
We demonstrate a proof-of-concept for localized NO synthesis within the outflow pathway through
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the use of an enzyme prodrug therapy (EPT), whereby,  -galactosidase (enzyme; catalyst) catalyzes
 -gal-NONOate (substrate; NO donor) to liberate NO on-site to potentially enhance aqueous humor
outflow (Figure 6.1). To ensure on-site NO synthesis, the enzyme is encapsulated in micron-sized
poly(methacrylic acid) (PMA) capsules that get enmeshed within the TM, which "localizes" the cat-
alyst within the tissue. The NO donor, is then encapsulated in liposomes that can be delivered to
the outflow pathway to elicit the NO-mediated response when the substrate is slowly released at the
outflow resistance sites, thus achieving a targeted on-site NO delivery platform.
This chapter provides preliminary data to support our hypothesis that targeted and local-
ized NO synthesis in the TM will provide enhanced therapeutic effect of NO-mediated increases in
aqueous humor outflow in the eye, compared to non-targeted delivery of NO.
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Figure 6.1: Schematic representation of targeted delivery of NO via enzymatic biocatalysis. (Left) Anterior segment of
the mouse eye showing the direction of aqueous humor outflow in blue. (Center) Enlargement of the iridocorneal angle
(boxed region in left panel) showing the trabecular outflow pathway. (Right) Schematic of localized NO synthesis within
the juxtacanalicular connective tissue (JCT) region and inner wall of Schlemm’s canal endothelium (SC). TM: trabecular
meshwork, CM: ciliary muscle, CC: collector channels, PLV: perilimbal vessels
6.2 Materials and Methods
6.2.1 Materials
Poly(N-vinyl pyrrolidone) (PVP, Mw 10,000 Da),  -galactosidase, sodium acetate (NaOAc),
and 2,2’-dithiopyridine were purchased from Sigma-Aldrich.  -Gal-NONOate was obtained from
Cayman Chemical. Poly(methacrylic acid) (PMA, Mw 15,000 Da) was obtained from Polysciences
(Eppelheim, Germany). 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was purchased
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from Avanti Polar Lipids. Amine-functionalized SiO2 particles (1 µm diameter) were obtained from
Microparticles GmbH (Berlin, Germany). Alexa Fluor 488 succinimidyl ester was purchased from
Invitrogen.
6.2.2 Experimental Design
This study consists of a two-step experimental protocol: (1) the delivery of the enzyme-
encapsulated in crosslinked PMA capsules via intracameral injections in living mice, and (2) the
delivery of the substrate-encapsulated in liposomes via ex vivo perfusions 48 h post-intracameral
injections. All experiments were performed in wild-type (WT) mice using paired eyes, where the ex-
perimental eye received both enzyme-encapsulated PMA capsules and substrate-encapsulated lipo-
somes, whilst the contralateral control eye received empty PMA capsules and substrate-encapsulated
liposomes.
6.2.3 PMA Capsule Assembly
Firstly, PMASH capsules were synthesized and functionalized with 14 mol% of thiol groups
as previously reported[246]. This was followed by the PMA capsule assembly procedure and encap-
sulation of the enzyme. SiO2 particles (5 wt%) were washed with three centrifugation/redispersion
cycles (1,200 g, 30 s) in Tris-EDTA buffer (10 mM, pH 7.5).  -galactosidase (1 mg/ml in Tris-EDTA
buffer) was added to the particle solution and adsorption was allowed to proceed for 1 hour with
constant shaking. The resulting particles were washed twice with Tris-EDTA buffer and twice with
NaOAc buffer (20 mM, pH 4). Assembly of polymer multilayers was achieved by alternately incu-
bating the particles with PMASH (1 mg/ml, 15 min) and PVP (1 mg/ml, 15 min) in NaOAc buffer
with constant shaking. The particles were washed with three centrifugation/redispersion cycles in
NaOAc buffer between layers and the process was repeated until four bilayers of PMASH/PVP were
assembled. The thiols within the polymer layers were crosslinked with 2,2’-dithiopyridine (0.5 mg/ml,
15 h) in NaOAc buffer. Hollow capsules were obtained by dissolving the silica core using a 2 M
hydrofluoric acid (HF)/8 M ammonium fluoride (NH4F) solution for 2 min, followed by multiple cen-
trifugation/washing cycles (4500 g, 3 min). Caution! HF and NH4F are highly toxic. Care should
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be taken when handling HF and NH4F solutions and only small quantities should be prepared.
6.2.4 Preparation of Alexa Fluor 488-labeled  -galactosidase
A solution of 10 mg/ml  -galactosidase (5 mg) in carbonate buffer (100 mM, pH 8.3) was
incubated with 100 µl of Alexa Fluor 488 succinimidyl ester (1 mg/ml in DMSO). The reaction was
allowed to proceed overnight, followed by purification via size-exclusion chromatography (SEC).
6.2.5 Liposome Formation
POPC (5 mg) was dissolved in chloroform and dried by evaporation of the chloroform under
nitrogen for 1 h. The dry lipid film was hydrated with 1 ml of 500 µM  -gal-NONOate in DBG solution
(Dulbecco’s PBS including divalent cations and 5.5 mM D-glucose). Liposomes were obtained by
extruding the lipid solution through 1 µm filters (31 times). Non-encapsulated  -gal-NONOate was
removed from the liposome suspension by SEC.
6.2.6 Characterization of  -galactosidase Mediated Release of NO
NO release kinetics from both non-encapsulated and encapsulated  -galactosidase/ -gal-
NONOate enzymatic hydrolysis was determined with a NO-sensitive electrode (ISO-NOS II, WPI,
Hertfordshire, UK) following previously described protocol [43]. Briefly, the NO-electrode was placed
in a solution containing 0.1 M H2SO4 and 0.1 M KI to polarize the sensor and obtain a baseline
current. To determine the standard curve, changes in current were measured in response to incre-
mental volumes of 50 µM NaNO2 added to the H2SO4/KI solution within a glass vial. Conversion
of NaNO2 to NO occurs rapidly and follows 1:1 stoichiometry, such that the NO concentration is
dictated by the added concentration of NaNO2.
Once the standard curve was generated, we first examined NO synthesis from non-encapsulated
 -galactosidase and  -gal-NONOate enzymatic reaction. The NO-sensitive electrode was first equi-
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librated in a 5 ml DBG solution supplemented with  -galactosidase (0.1 mg/ml) in a glass vial and
left to stabilize for 2 hr at 37°C. To determine the standard curve for the NO synthesis from the en-
zymatic reaction, incremental volumes of  -gal-NONOate (25–150 µl, at 50 µM) was added to the
glass vial and changes in current were measured. Secondly, we examined the NO release from  -
galactosidase encapsulated PMA capsules and  -gal-NONOate encapsulated liposomes. The NO-
sensitive electrode was again immersed in a 5 ml DBG solution supplemented with  -galactosidase
encapsulated PMA capsules (400 µl; at 1 mg/ml) and left to stabilize for 2 hr at 37°C. NO release
kinetics were determined for three different concentrations of  -gal-NONOate encapsulated lipo-
somes (25, 50 and 75 µM). All NO measurements were performed in mock-aqueous humor solution
typically used for ex vivo perfusions (DBG solution) at 37°C with continuous mixing from a magnetic
stir bar.
6.2.7 Animal Husbandry
All experiments were conducted in compliance with the Association for Research in Vision
and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research under UK
Home Office Project License approval for research at Imperial College London. This study used
C57BL/6 male wild-type (WT) mice subjected to in vivo intracameral injections followed by ex vivo
eye perfusions. WT mice were 10 – 12 wk of age. Mice were housed in individually ventilated cages,
fed ad libitum, and maintained at 21°C with a 12:12-h light-dark cycle, with lights on from 6 AM to 6
PM.
6.2.8 In Vivo Delivery of  -galactosidase Encapsulated PMA Capsules
For this portion of the experiment, WT mice were delivered with a bolus of  -galactosidase
encapsulated PMA capsules into the anterior chamber of the eye via intracameral injections; this
allows for the PMA capsules to be enmeshed within the JCT region of the TM via the preferential
drainage routes in the trabecular outflow pathway. Before the delivery of the PMA capsules, WT
mice were first anesthetized with ketamine (66.6 mg/kg, Fort Dodge Animal Health, Fort Dodge,
IA) and Dormitor® (medetomidine hydrochloride; 0.66 mg/kg, Orion Pharma) via intraperitoneal
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(i.p.) injection. Each mouse received dilation drops (phenylephrine hydrochloride (2.5% w/v) and
tropicamide (1% w/v); Bausch & Lomb, Rochester, NY) to both eyes to minimize potential damage
to the iris during cannulation of the glass needle. This was followed by a subcutaneous injection with
enrofloxacin antimicrobial (5 mg/kg, Baytril; Bayer Healthcare, Leverkusen, Germany), additionally
their eyes were kept moist with artificial tears (Vidisic®; Bausch & Laumb, Rochester, NY) prior to
intracameral injections.
For the intracameral injections, the mouse was secured in place with the assistance of a
head-holder (Model 923-B; Kopf Instruments, CA, USA) and placed on a warm-water place mat.
Eyes were cannulated with a pulled glass micro-needle (100 µm tip) positioned parallel to the iris
and above the limbus to remove a portion of the aqueous humor in the anterior chamber by cap-
illary action. Intracameral injections were then carried out with a pulled glass micro-needle (100
µm tip) filled with 1.5 µL of either empty PMA capsules (vehicle-control eyes; ⇠106 particles/µl)
or  -galactosidase encapsulated PMA capsules (treated eyes; ⇠106 particles/µl) suspended in
dH2O (UltraTM DNase/RNase free water; Invitrogen) connected to a 10 µL glass syringe (Gastight;
Hamilton, Reno, NV) then inserted into the same cannulation site with the assistance of a micro-
manipulator, and delivered to the anterior chamber of the eye. Topical antibiotic ointment (1% w/w
Fucithalmic; LEO Pharma, Denmark) was then applied to the cannulation site followed by remov-
ing the needle slowly from the eye to reduce reflux. After the procedures, the mice were given 1.5
mg/kg of Antisedan® (atipamezole hydrochloride; 1.5 mg/kg, Orion Pharma, Berkshire, UK) via i.p.
injection and placed in a heated chamber (maintained at 28°C) to allow for faster recovery from
anesthesia. The mice were allowed to recover for 48 hrs post-intracameral injections before the
mice were euthanized by overdose of Pentobarbital (150 µL; Euthatal, Merial, UK) and the eyes
were enucleated for ex vivo perfusions.
6.2.9 Ex Vivo Delivery of  -gal-NONOate Encapsulated Liposomes via Mouse Eye
Perfusions
Eyes obtained from WT mice (post-intracameral delivery of PMA capsules) were perfused
with  -gal-NONOate encapsulated liposomes to determine the effect of localized synthesis of NO
within the JCT region of the outflow tract. Eyes were enucleated within 10 minutes of death by
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cervical dislocation and stored in PBS at room temperature until perfusion, typically within 15 min.
Experiments used paired contralateral eyes, which were perfused simultaneously on two identical
iPerfusion systems[200] under identical experimental conditions.
Our perfusion method follows previously described techniques[25,27,43,134,211]. Briefly, the
eye was affixed to a support using cyanoacrylate glue to stabilize the eye and submerged in PBS
in a thermo-regulated bath at 35°C. A 33-gauge beveled needle (Nanofil; World Precision Instru-
ments, Europe; Hitchin, UK) was used to cannulate the eye, with the tip of the needle positioned
in the anterior chamber using a micro-manipulator. The pressure and flow rate inside the eye were
measured using a wet-wet differential pressure transducer (PX409, Omegadyne, US) and a flow
sensor (SLG64-0075, Sensirion, Switzerland), respectively. The enucleated eyes were perfused
with DBG supplemented with  -gal-NONOate encapsulated liposomes (⇠109 particles/µl). Both the
experimental and control eyes were pressurized from a reservoir at 9 mmHg for 45 mins to allow
the eyes to acclimatize to the pressure and temperature environment. During this acclimatisation
period, the anterior chamber is filled with liposomes which flows toward the filtration-active regions
of the JCT, where the PMA capsules are enmeshed. After the acclimatisation period, eyes were
perfused at sequential pressure steps, which consisted of the following applied pressures: 6, 7.5, 9,
10.5, 12, 13.5 and 15 mmHg. For each pressure step, steady state was reached when the rate of
change in facility was less than 0.1 nl/min/mmHg over a 6 minute time period. Data points that did
not reach stable facility for a given pressure step were not included in the analysis. Perfusions that
had less than 4 pressure steps were excluded from the study. After each perfusion the eyes were
fixed in 4% paraformaldehyde (PFA) overnight at 4°C ready for further processing.
For each eye, the last 4 minutes of steady state pressure-flow data was plotted. The steady
flow rate into the eye (Q) exhibits a power-law dependence on perfusion pressure (P ), consistent
with a pressure-dependent outflow facility. As the standard linear fitting does not capture this non-
linear Q–P relationship, we therefore defined C as Q/P at 8 mmHg, corresponding to the effective
total facility at a physiological pressure drop across the outflow pathway, and we used a power-law
fitting to obtain the best estimate and confidence intervals on C at 8 mmHg. Moreover, according
to Sherwood et al. [200], in enucleated eyes there is negligible flow at zero pressure, therefore the
power-law fitting was forced through a zero-zero intercept. Additionally, based upon the population
distribution of the measured outflow facility, data was more accurately represented by a lognormal
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distribution, therefore outflow facility values are expressed as C */ 95% confidence intervals.
6.3 Results
6.3.1 In Vitro Release of NO via Enzymatic Catalysis
To characterize the NO release kinetics from the enzymatic reaction between non-encapsulated
 -galactosidase and  -gal-NONOate, we used a NO-sensitive electrode to measure changes in cur-
rent in response to increasing volumes of  -gal-NONOate (50 µM) when added to a glass vial of
well-mixed DBG solution supplemented with  -galactosidase (400 µl; at 1 mg/ml) (Figure 6.2). NO
synthesis from the  -gal-NONOate after being hydrolyzed by  -galactosidase responded in a dose-
dependent manner with increasing concentrations of substrate (Figure 6.2A). The release kinetics
show a sharp rise in NO release followed by a decline back to the original baseline signal. The av-
erage half-life (t1/2) of the NO-donor was ⇠5 mins at physiological pH (7.4) and 37°C. Interestingly,
with increasing volumes of  -gal-NONOate added to the solution in the presence of  -galactosidase,
the peak NO concentration followed the predicted 1:2 stoichiometry, suggesting that the substrate
was instantaneously metabolized by the enzyme and exhibited a linear relationship (Figure 6.2B).
6.3.2 Enzyme-Mediated NO Release from Encapsulated  -gal-NONOate In Vitro
In order to extend the NO release kinetics, we proceeded to encapsulate the enzyme and
substrate in separate carrier vehicles (PMA capsules and liposomes, respectively) to allow for the
gradual release of the NO donor to be hydrolyzed by the enzyme, resulting in an extended NO
half-life. Firstly, to demonstrate successful enzyme encapsulation within the PMA capsules, we
fluorescently-labeled the enzyme with Alexa Fluor 488, followed by visualization with fluorescence
microscopy (Olympus IX73). The fluorescent images showed an uniform fluorescence signal from
each PMA capsule, indicating that the enzymes were evenly encapsulated across the PMA capsules
(Figure 6.3A), whilst unloaded PMA capsules had negligible fluorescence.
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Figure 6.2: Characterization of NO synthesis resulting from  -galactosidase-mediated hydrolysis of  -gal-NONOate. (A)
Representative dose response curve of NO release from enzymatic hydrolysis between  -galactosidase (0.1 mg/ml) and
increasing boluses of  -gal-NONOate (50 µM) in DBG solution [Dulbecco’s PBS including divalent cations and 5.5 mM
D-glucose]. NO release was measured using a NO-sensitive probe (ISO-NOS II). (B) Relationship between NO release
and increasing volume of non-encapsulated  -gal-NONOate when hydrolyzed by  -galactosidase (n=3; bars are SD).
We then proceeded to characterize the NO release kinetics for the encapsulated enzyme
and substrate, using the same detection setup as the non-encapsulated enzymatic reaction de-
scribed previously. The  -galactosidase enzymes were encapsulated in hollow PMA capsules,
whilst  -gal-NONOate were encapsulated in liposomes to allow for the gradual release of the NO
donor to be hydrolyzed by the enzyme. Here, we measured the change in current in response to
 -gal-NONOate loaded liposomes (200 µl; at 50 µM) when added to a glass vial of well-mixed DBG
solution supplemented with  -galactosidase encapsulated PMA capsules (400 µl; at 1mg/ml). After
the liposomes were introduced to the solution, we saw an initial increase in NO release followed by
a gradual decay over 6h, returning back to the initial baseline signal (Figure 6.3A). We further tested
two additional  -gal-NONOate concentrations encapsulated in liposomes (25 and 75 µM; Figure
6.3B). These results showed a dose-dependent increase in NO release as a function of increasing
concentration of  -gal-NONOate encapsulated inside the liposomes. Interestingly, by encapsulating
the enzyme and substrate in separate carriers the duration of NO release were increased signifi-
cantly, extending the t1/2 from ⇠5 min for the non-encapsulated enzyme and substrate to t1/2 ⇠2.15
h.
In addition to the prolonged and continuous delivery of NO in vitro, we went on to investigate
the possibility of re-dosing the  -galactosidase encapsulated PMA capsules with  -gal-NONOate
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Figure 6.3: NO synthesis from  -galactosidase encapsulated PMA capsules and  -gal-NONOate encapsulated lipo-
somes. (A) Representative NO decay curve from encapsulated and non-encapsulated  -galactosidase and  -gal-
NONOate. The enzymatic hydrolysis between  -galactosidase encapsulated PMA capsules (1 mg/ml; ⇠106 particles/µl)
and  -gal-NONOate encapsulated liposomes (50 µM; ⇠109 particles/µl) are shown by the black tracing. Non-
encapsulated  -galactosidase (0.1 mg/ml) and  -gal-NONOate (200 µl; at 50 µM) are shown by the red tracing. (B)
NO release as a function of increasing loading concentration of  -gal-NONOate encapsulated inside the liposomes (n=3
for each concentration; bars are SD). (Inset) Fluorescence microscopy images of PMA capsules loaded with Alexa Fluor
488 labeled  -galactosidase to illustrate the successful encapsulation of the enzyme. Scale bar,10µm.
containing liposomes to provide additional doses of NO treatment over extended periods of time.
Figure 6.4 shows that the encapsulated enzyme can be reused to hydrolyze the  -gal-NONOate
to release NO over a ⇠42 h period, indicating that the enzymes remain active and the therapeutic
treatment can be achieved over long periods of time.
6.3.3 Targeted Delivery of NO Synthesis to the Trabecular Meshwork
To simulate the effects of this targeted delivery of NO synthesis in vivo, WT mice were
anesthetized and subjected to intracameral injections to deliver the PMA capsules. Paired eyes
were used for all experiments, where the experimental eye received  -galactosidase encapsulated
PMA capsules (⇠106 particles/µl), whilst the contralateral control eye received empty PMA capsules
(⇠106 particles/µl). The PMA capsules were delivered 48h prior to ex vivo mouse eye perfusions,
to allow for sufficient recovery time and for the PMA capsules to be enmeshed within the outflow
pathway. Eyes were enucleated for ex vivo mouse eye perfusions, where the perfusate consisted of
DBG solution supplemented with liposomes containing  -gal-NONOate (50 µM), to determine the
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Figure 6.4: Cyclic NO synthesis from  -galactosidase encapsulated PMA capsules and  -gal-NONOate encapsulated
liposomes. Representative NO release from cyclic additions of liposomes containing  -gal-NONOate (75 µM) over ⇠42
h period. Each dose consisted of 200 µl of liposomes added to the DBG solution supplemented with PMA capsules
containing  -galactosidase (1 mg/ml).
effect of localized NO synthesis on outflow facility.
Our preliminary data showed that the delivery of liposomes to the eye, resulted in an increase
in trabecular outflow facility relative to the contralateral vehicle controls (Figure 6.5). Two indepen-
dent experiments were carried out, the first pair showed a⇠3-fold increase in outflow facility between
the experimental and control eye (8.6 */ 1.1 nl/min/mmHg vs. 2.6 */ 1.1 nl/min/mmHg, respectively),
whilst the second pair showed a ⇠1.5-fold increase in outflow facility between the experimental and
control eye (5.8 */ 1.3 nl/min/mmHg vs. 4.0 */ 1.1 nl/min/mmHg, respectively). These results are con-
sistent with previous studies, showing that exogenous delivery of NO-donors increases conventional
outflow facility in various animal and human models[24,43,62,65,111,191]. In particular, when compared
against the non-targeted delivery of NO-donor, S-nitroso-N-acetylpenicillamine (SNAP), outflow fa-
cility in ex vivo mouse perfusions only increased by 62% when compared against vehicle-control
from a previous study[43]. Taken together, from our preliminary data, we show that the targeted and
localized NO synthesis in the TM, proves to be a more efficacious treatment for decreasing outflow
resistance and increasing outflow facility compared to non-targeted NO release in mice.
Currently, we are planning on obtaining more paired eye data to ensure the localized NO
synthesis in the TM and outflow facility effect is reproducible and consistent across a larger cohort
of mice.
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Figure 6.5: Effects of targeted delivery of NO synthesis on conventional outflow facility in eyes obtained from wild-type
(WT) mice. Paired eyes were injected with either  -galactosidase containing PMA capsules (red circles; experimental) or
empty PMA capsules (black circles; control) 48 h prior to ex vivo mouse eye perfusions. Enucleated eyes were perfused
with  -gal-NONOate encapsulated liposomes to determine the pressure-flow relationships for paired eyes. Pressure-flow
relationships are shown for two pairs of eyes. Solid line represents the power law fitting of the data set. Shaded region
represents the 95% confidence bounds on the fitting. Error bars represents the 95% confidence bounds for the flow values
at each pressure step.
6.4 Discussion
Exogenously delivered NO typically leads to an increase in outflow facility and a reduction in
IOP. The precise mechanism(s) that NO mediates its physiological effects within the trabecular out-
flow pathway remains unclear, but most likely involves the modulation of cellular contractility of TM
cells [61,236,237] and/or endothelial permeability of the SC cells [44,57] to enhance aqueous humor out-
flow. However, NO has also been shown to induce relaxation of the ciliary muscle[18,84,89,236], which
tends to oppose the effects of TM relaxation through the extensive tendinous connections that exist
between these two tissue structures[165,186,187,222]. Alternatively, NO may also affect aqueous humor
dynamics by decreasing aqueous humor inflow[197], increasing episcleral venous pressure[245], or
affecting choroidal blood volume[125]. Therefore, depending on the site of NO release within the
anterior chamber, the physiological response may be counterproductive and result in increased IOP,
rather than the desired IOP lowering effect. Furthermore, the reactive nature of NO and its typically
short half-life (order of seconds[154,155,167]) makes the on-site delivery of NO to the outflow resistance
sites challenging, which could result in limited efficacy on lowering IOP. Hence, the targeted deliv-
ery of NO to the outflow resistance sites would potentially achieve the optimal therapeutic benefit,
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resulting in decreased outflow resistance and increased outflow facility.
Targeted delivery of  -galactosidase encapsulated PMA and  -gal-NONOate encapsulated
liposomes to the site of outflow resistance within the TM, results in a 1.5–3-fold increase in outflow
facility compared to control treated eyes, presumably through the localized synthesis of NO targeting
the cellular mechanisms in the TM/SC cells. NO is capable of freely diffusing across cell membranes
and between cells to trigger various signaling cascades and affect the biological activity of several
proteins and enzymes. Most notably, the activation of sGC/cGMP/PKG signaling pathway, responsi-
ble for inducing smooth muscle relaxation by regulating intracellular Ca2+ levels, myosin light chain
phosphorylation and BKCa channels[81]. Interestingly, in the trabecular outflow pathway, the ciliary
muscle, TM and downstream collector channels all possess similar contractile properties to vascular
smooth muscle cells, expressing common contractile proteins such as ↵-smooth muscle actin and
smooth muscle myosin[54,79,236]. In human TM cells, NO has also been shown to not only induce re-
laxation of TM cells [61], but also decrease TM cell volume through the activation of BKCa channel [60].
Alternatively, NO can also mediate endothelial permeability of the inner wall of SC by disrupting the
adherens junctions[44,57] or by altering the SC cell volume by activating the BKCa channel [65]. These
results suggest that NO can mediate the cellular contractility of TM cells and the permeability of the
SC endothelium, which in part regulate the outflow resistance by affecting the dimensions of inner
wall pores or flow pathways to increase outflow facility.
Our preliminary data shows that the targeted delivery of NO to the trabecular outflow path-
way, leads to increased outflow facility, consistent with previous studies conducted with non-targeted
delivery of NO donors[24,43,62,65,111,191]. Here, we have developed a potential platform for delivering
NO to the targeted outflow resistance sites within the JCT/SC region, utilizing the strategy of on-site
NO synthesis to enhance aqueous humor outflow and potentially help compensate for the impaired
NO-regulatory machinery[121,141,174] within the trabecular outflow pathway that contributes towards
the pathogenesis of glaucoma.
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Chapter 7
Conclusions
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In this thesis, we examined the hypothesis that the conventional outflow pathway functions
as a dynamic mechano-regulatory feedback system that regulates the outflow resistance sites
through NO production to maintain IOP homeostasis. Within the outflow tract, the resistance sites
consists of the TM/JCT, basement membrane and inner wall endothelium of SC, which work together
synergistically as "controller(s)" of the endogenous feedback system. The inner wall experiences a
basal-to-apical directed flow (QT ) as aqueous humor crosses the outflow pathway. Increases in
outflow resistance leads to elevated IOP, which in turn increases the mechanical load on the tissues
of the outflow pathway, leading to morphological changes to the JCT and inner wall of SC. As
IOP increases, the JCT expands and pushes the inner wall into the lumen. The collapse of SC
lumen increases the hydrodynamic shear stress acting on the SC endothelial cells exerted from
the circumferential flow (QC ) along the canal (Figure 7.1A). The SC cells function as a "barostat"
or "mechano-sensors" within this endogenous feedback loop by detecting IOP-induced changes in
shear stress. In the presence of elevated shear stress, SC cells secrete NO[11,135], similar to vascular
endothelial cells [44,45] through the up-regulation of eNOS expression and activity. NO acts as a key
signaling molecule within this endogenous feedback loop to modulate the outflow resistance sites to
enhance aqueous humor outflow and restore physiological IOP.
Firstly, in Chapter 2, we demonstrated that NO plays a crucial physiological role in regulat-
ing aqueous humor outflow in mice, whereby the exogenous delivery of NO, via SNAP (NO-donor),
results in an increase in outflow facility by mediating the outflow resistance sites within the conven-
tional outflow pathway. More importantly, we demonstrated that the inhibition of endogenous NOS
activity leads to a reduction in outflow facility, suggesting a basal tone of endogenous NO is involved
in the regulation of outflow facility. In particular, the selective inhibition of eNOS accounted for the
majority of reduction in outflow facility, thus suggesting that eNOS is the primary isoform involved in
the regulation of aqueous humor outflow. Therefore, impaired eNOS activity and NO signaling could
potentially "short-circuit" this endogenous regulatory feedback mechanism and lead to elevated IOP
– characteristic of primary open angle glaucoma. Interestingly, these results are consistent with prior
studies indicating that reduced NOS activity [157] in the outflow pathway and polymorphisms in the
NOS3 gene (that encodes eNOS) are linked to the pathogenesis of glaucoma[121,141,174].
In Chapters 3 and 4, we examined the central hypothesis of the mechano-regulatory feed-
back mechanism that resides in the conventional outflow pathway. Here, we investigated whether
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local eNOS expression and activity within the SC leads to local increase in hydraulic conductiv-
ity, which in turn may affect the segmental outflow patterns in the TM. Additionally, we also tested
whether increases in IOP results in up-regulation of eNOS activity and NO production, lead pre-
sumably through increased hydrodynamic shear stress acting on SC cells. Firstly, we developed a
NO-sensitive biosensor that can detect local changes in NO production in both in vitro and in situ
models. This NO-biosensor exploits the peroxynitrite-mediated nitration process of tyrosine residues
derived from nitration-prone proteins, a selective oxidation process that results in a post-translational
modification of tyrosine residues to form 3-nitrotyrosine[19,184]. The conversion of tyrosine into 3-
nitrotyrosine serves as a biological footprint for local changes in NO levels. We then validated our
NO-biosensor in an in vitro shear stress model lined with HUVECs exposed to different levels of
shear stress, showing that the biosensor was capable of detecting and distinguishing between low
and high shear-induced NO production by living cells. The NO-biosensor achieved greater sensitiv-
ity over the standard Griess assay, commonly used for detection of nitrite from biological solutions.
Furthermore, we showed that in enucleated eNOS-GFP mouse eyes, segmental outflow patterns in
the TM correlates with the spatial distribution of eNOS-GFP expression within the SC, suggesting
that regions of higher eNOS expression and activity colocalizes with regions of higher outflow. Ad-
ditionally, with the newly developed NO-biosensors, we detected higher NO production at elevated
IOP compared to physiological IOP. Here we demonstrated for the first time that increases in IOP
lead to increased shear-induced NO production by the SC cells, which can then feed back into the
outflow pathway as an autocrine/paracrine signaling molecule to modulate local outflow resistance
sites to enhance outflow facility (as shown in Figure 7.1).
In Chapter 5, we examined the relationship between the post-trabecular outflow pathway and
segmental filtration patterns in the TM of eNOS-GFP mice. Here, we developed a novel embedding
protocol (with PDMS) for imaging segmental outflow patterns in enucleated mouse eyes with the use
of fluorescence OPT. With this new protocol, we have overcome several technical challenges that
have previously limited the use of OPT for imaging mouse eyes, such as the use of tissue clarifying
chemicals (i.e. BABB) which are toxic and often result in the quenching of fluorophores. With OPT
imaging, we now have the ability to visualize and map segmental outflow patterns in a "global"
context, relating post-trabecular limbal vasculature and extraocular muscles to regions of high and
low flow in the TM. Moreover, by embedding the tissue in PDMS it allows for a multi-scale analysis,
whereby the tissue can be retrieved post-OPT imaging and be processed for further analysis, such
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as examining morphological changes with electron microscopy or changes in gene expression in
low and high flow regions in the outflow pathway.
Finally, in Chapter 6, we developed a targeted NO-based therapeutic that liberates NO within
the trabecular meshwork, where the majority of the outflow resistance is generated within the con-
ventional outflow pathway. Previous studies have shown that non-targeted delivery of NO donors has
resulted in varied success in decreasing IOP and enhancing outflow facility [24,43,62,65,111,191,193,197,236,245].
Depending on the site of NO release within the anterior chamber, the physiological response may
be counterproductive and result in increased IOP, rather than the desired IOP lowering effect. Here,
we encapsulated  -galactosidase (enzyme; catalyst) in micron-sized PMA capsules which are de-
livered intracamerally to localize the polymers within the TM. This was followed by the delivery of
 -gal-NONOate (substrate; NO donor) encapsulated in liposomes that gets delivered via ex vivo
perfusions. Once the substrate is released from the liposomes, the NO donor gets catalyzed by
the enzyme resulting in localized release of NO at the site of outflow resistance. Therefore, our tar-
geted approach of localized NO synthesis within the TM/JCT through the use of an enzyme prodrug
therapy (EPT) proves to be a more promising therapeutic approach for treating ocular hyperten-
sion and potentially glaucoma, where the endogenous NO-machinery has been suggested to be
impaired[157].
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Figure 7.1: Mechano-regulatory feedback system via shear-induced eNOS activity and NO production. (A) Schematic
representation of mechano-regulatory feedback system. As IOP increases, the TM/JCT expands and pushes the inner
wall into the SC, partially collapsing the SC lumen. The collapse of SC effectively reduces the cross-sectional area of
the lumen, and leads to an increase in shear stress acting on the SC endothelial cells exerted from the circumferential
flow (QC ) along the canal. Increased shear stress up-regulates eNOS expression and activity, resulting in increased NO
production. NO acts as an autocrine/paracrine signaling molecule to modulate the various outflow resistance sites within
the outflow pathway via retrograde diffusion and/or advection along the canal. (B) In vivo representation of regulatory
feedback mechanism. Here, the regulatory feedback mechanism is driven by a constant-flow source, aqueous humor
secreted by the ciliary processes resulting in transendothelial flow (QT ) through the meshwork. Increases in IOP leads to
increased shear stress and NO production. NO secreted by the SC cells feeds back into the outflow pathway to regulate
outflow resistance sites to restore IOP homeostasis. (C) Ex vivo representation of positive feedforward mechanism. Here,
in the ex vivo model, we use a constant-pressure system (P) as aqueous humor production is not present in the enucleated
eye. Increases in IOP leads to increased shear stress and NO production. NO feeds back into the outflow pathway to
decrease outflow resistance. As pressure is kept constant, the SC remains collapsed leading to sustained shear stress
and NO production. This creates a "feedforward" mechanism resulting in increased outflow.
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7.1 Future Work
This thesis has developed our understanding of the role of NO in the regulation of conven-
tional outflow physiology. We have gained insights on the endogenous regulatory feedback mecha-
nism that helps regulate the outflow resistance sites and maintain IOP homeostasis in vivo. In this
section, we highlight several areas that would benefit from further investigation to build upon the
results obtained thus far in this thesis.
7.1.1 Effect of Selective-Inhibition of eNOS on Segmental Outflow Distribution
In Chapter 4, we showed that segmental outflow in the TM is partially regulated by the en-
dogenous NO-regulatory mechanism within the outflow tract. Our data strongly suggests that eNOS
is the primary isoform involved in the regulation of aqueous humor outflow, although several studies
have also indicated that both nNOS and iNOS are expressed in the TM region. Thus endogenous
NO production may not be limited to eNOS activity. Here, we propose to use an eNOS-selective
inhibitor, such as cavtratin (50 µM), in these eNOS-GFP mice to examine whether the disruption
of endogenous NO signaling leads to altered segmental outflow patterns in the TM. These studies
will shed light on whether eNOS is in fact the primary isoform responsible for regulating aqueous
humor outflow, especially at elevated IOP where increased shear stress has been shown to trigger
the NO signaling cascade. Hence, by disrupting the endogenous NOS activity, we can directly test
the causality effect of eNOS within the endogenous mechano-regulatory feedback loop.
7.1.2 Targeted NO Synthesis within the Conventional Outflow Pathway
In Chapter 6, we have provided preliminary data suggesting that targeted and localized syn-
thesis of NO within the trabecular meshwork, would lead to increased outflow facility with greater
efficacy over non-targeted delivery of NO. Here, we propose to carry out more replicates to increase
our statistical power and to show that the data we observed is in fact representative and repeat-
able. Moreover, we want to confirm that the PMA capsules loaded with  -galactosidase are in fact
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enmeshed in the TM and that the enzymes are active, compared to the empty PMA. This would
be done with standard  -gal staining on cryosectioned eyes co-stained with CD31 to identify where
the SC lumen is located. Positive  -gal staining would confirm that the catalysis of the NO donor
( -gal-NONOate) is in fact due to the active enzyme encapsulated in the PMA capsules. Addition-
ally, the enzymes activity should also be characterized to help understand the feasibility of utilizing
these enzymes over extended periods of timescales. To fully validate the therapeutic potential of
this enzyme prodrug therapy on lowering IOP, these PMA capsules and liposomes should also be
tested in vivo in ocular hypertensive mice. Long-term IOP monitoring in these ocular hypertensive
mice, would allow us to understand whether this NO-based therapeutic is a viable treatment option
for lowering IOP.
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